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ABSTRACT
Extracellular Matrix Mediated Cartilage Regeneration:
A Novel Three-Dimensional In Vitro Microenvironment to Facilitate Cell
Expansion and Chondrogenesis
Fan He
Joint articular cartilage is vulnerable for degenerative disease after trauma due to the limited
self-healing ability. Mesenchymal stem cells (MSCs) are considered a promising source for
cartilage repair and regenerative medicine because of their excellent capacities of
self-renewal and multipotent differentiation. Conventional in vitro expansion system, however,
limits the utilization of MSCs for cartilage regeneration because in monolayer culture MSCs
rapidly lose their self-renewal ability and differentiation potential. The lack of proper
microenvironment in the current two-dimensional expansion system is attributed to the loss of
self-renewal and multipotent differentiation in MSCs. Three-dimensional (3D) cell-deposited
extracellular matrix (ECM) provides a novel strategy for in vitro MSC expansion, not only
promoting cell proliferative rate but also improving chondrogenic potential. We generated 3D
ECM deposited by synovium-derived stem cells (SDSCs) to reconstruct an in vitro 3D stem
cell niche. First, MSCs were expanded on 3D ECM including SDSCs, adipose-derived stem
cells (ADSCs) and bone marrow stem cells (BMSCs). The cell morphology of MSCs cultured
on ECM changed to a thin and spindle-like shape and cell migration was directional along the
fibrils of ECM. A dramatic increase in cell number and a greatly enhanced chondrogenic
potential were observed, though surprisingly the ECM-treated MSCs did not display
concomitantly improved adipogenic or osteogenic potentials. 3D ECM was also adopted to
expand terminally differentiated cells including articular chondrocytes and nucleus pulposus
(NP) cells, in order to improve the technique of autologous cell transplantation for cartilage
repair and intervertebral disc regeneration. We found that ECM not only improved
chondrocyte or NP cell expansion but also delayed dedifferentiation. Chondrocytes or NP
cells expanded on ECM also acquired a strong redifferentiation capacity, particularly when
treated with TGF-β1 in a pellet culture system. Further, we compared the activity of several
key signaling kinases and integrin expression in BMSCs cultured on ECM and conventional
plastic flasks. 3D ECM increased the expression of SSEA-4, integrin α 2 , α 4 and β 5 , and
induced sustained activation of Src kinase, ERK1/2 and cyclin D1. Not only the expression
but also the responsiveness of TGF-β type II receptor was enhanced by 3D ECM in BMSCs.
These observations suggested that 3D cell-deposited ECM promoted BMSC proliferative
capacity through integrin/Src/ERK1/2 signaling pathway and enhanced chondrogenic
potential by improving the responsiveness of TGF-β receptors. Finally we generated two
distinct types of ECM separately deposited by SDSCs and articular chondrocytes.
SDSC-deposited ECM (S-ECM) contained fibrillar type I collagen, whereas
chondrocyte-deposited ECM (C-ECM) is composed of fibrillar type I and II collagen with
proteoglycans. S-ECM showed a superior influence on SDSCs to C-ECM in cell self-renewal
and chondrogenic potential. The proliferative and chondrogenic abilities of chondrocytes
were comparable on S-ECM and C-ECM. SDSC-deposited ECM was superior to

chondrocyte-deposited ECM and functioned as a universal expansion system in vitro for
MSCs and terminally differentiated cells to promote cell proliferative and chondrogenic
potentials. In conclusion, we demonstrated that 3D cell-deposited ECM provides a proper
microenvironment for in vitro expansion of MSCs and terminally differentiated cells, not only
promoting self-renewal ability but also improving chondrogenic potential, and the novel 3D
expansion system greatly improves cell-based cartilage and intervertebral disc regeneration.
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SPECIFIC AIMS

Articular cartilage is a unique, hypocellular and avascular tissue, mostly made of extracellular
collagens and proteoglycans (PGs), supporting frictionless movements and loading-bearing
capacity of articulation.1 Articular cartilage has a limited ability to heal after trauma and
cartilage lesions often progress to cartilage degeneration if untreated. Mesenchymal stem
cells (MSCs) are considered an attractive source for cell therapy and regenerative medicine
because of their excellent self-renewal and differentiation potentials to multiply lineages.2
Conventional monolayer expansion system in vitro limits the utilization of MSCs for
regeneration of cartilage defects and intervertebral disc, because MSCs rapidly lose their
self-renewal ability and multipotent differentiation capacity.3;4 The lack of a proper
microenvironment in current two-dimensional (2D) expansion system is proposed to be
responsible for the loss of multipotential differentiation in MSCs.5 We hypothesize that a
nature three-dimensional (3D) cell-deposited extracellular matrix (ECM) can provide a
proper microenvironment to improve MSC self-renewal and multipotent differentiation.

Natural ECM provides a structural scaffold to resist tensile and compressive stress and
functions as a tight connection to cytoskeleton of cells through cell-surface receptors,
enabling cells to sense and respond to mechanical and chemical signals.6 Compared to
traditional 2D ECM, this natural 3D ECM is composed of multiple matrix proteins such as
collagens, fibronectin and proteoglycans.7 In the structure, 3D ECM is more pliable than 2D
ECM, has more fibrillar matrix and contains the space originally occupied by the cells
generating matrix. The native cell-deposited ECM not only provides a proper niche to
maintain MSC self-renewal and differentiation potential but also establishes a model to mimic
the interaction in vivo between cells and ECM.8

Our long term goal is to develop a strategy that can maintain MSCs self-renewal and
promote the chondrogenic potential in the in vitro culture system, to improve the current
therapy of autologous cell transplantation and to investigate the interaction between cells and
ECM. The objectives of this dissertation are: (1) compare the effects of 3D ECM and 2D
xvi

conventional plastic culture on MSCs; (2) improve the culture conditions of terminally
differentiated cells by adopting 3D ECM; (3) investigate the interaction between MSCs and
ECM; (4) compared extracellular matrices deposited by two distinct types of cells.
The central hypothesis is that natural cell-deposited ECM serves as an in vitro 3D stem cell
niche to maintain self-renewal and enhance the chondrogenic potential.

Specific Aims:

Specific aim 1: Compare the proliferative rate and chondrogenic potential of MSCs on
3D cell-deposited ECM and the conventional plastic culture.

1.1 Generate and characterize 3D ECM deposited by synovium-derived stem cells (SDSCs).

1.2 Expand SDSCs on 3D ECM and conventional plastic culture and compare the
chondrogenic potentials.

1.3 Expand and compare adipose-derived stem cells (ADSCs) on SDSC-deposited ECM,
ADSC-deposited ECM and conventional plastic culture.

Hypothesis 1: We hypothesize that 3D ECM will improve SDSCs and ADSCs self-renewal
ability and enhance chondrogenic potential. More specifically, we believe that SDSCs and
ADSCs expanded on ECM will show a higher proliferative rate than the cells cultured on
conventional plastic surface. In a pellet culture system, SDSCs and ADSCs will exhibited a
higher chondrogenic gene expression and cartilage-specific proteins and matrix.

Specific aim 2: Use SDSC-deposited ECM to improve in vitro culture of terminally
differentiated cells such as articular chondrocytes and nucleus pulposus cells.

2.1 Expand articular chondrocytes on 3D SDSC-deposited ECM and conventional plastic
flasks and investigate the changes of cell proliferative rate, immunophenotype profile and the
xvii

level of dedifferentiation.

2.2 Induce articular chondrocytes expanded on ECM and plastic flasks toward
redifferentiation by incubation of TGF-β-containing medium or serum-containing medium.

2.3 Expand and compare cell proliferative and redifferentiation potentials of nucleus pulposus
cells on 3D ECM and conventional plastic flask.

Hypothesis 2: We hypothesize that 3D SDSC-deposited ECM will promote the proliferation
of articular chondrocytes and nucleus pulposus cells, delay the process of dedifferentiation
and enhance the effect of redifferentiation.

Specific aim 3: Investigate the interaction between ECM and bone marrow stem cells
(BMSCs) and the potential mechanism of the enhanced chondrogenic differentiation
after expansion on ECM.

3.1 Investigate BMSCs expanded on ECM including proliferative rate, immunophenotype
profile, intracellular oxygen reactive species and apoptotic response.

3.2 Explore integrin system and intracellular signaling pathways that affect BMSC
self-renewal.

3.3 Induce BMSCs toward chondrogenic differentiation and elucidate the mechanism for the
improved chondrogenic potential.

Hypothesis 3: We hypothesize that 3D ECM interacts cells through integrin system to
activate Src/ERK signaling pathway. Phosphorylated ERK1/2 will increase the expression
and activation of cyclin D1 to promote cell cycle from G1 to S phase. The elevated cyclin D1
will be responsible for the improved cell self-renewal. Meanwhile, 3D ECM will increase the
responsiveness of TGF-β receptors to enhance chondrogenic differentiation.
xviii

Specific aim 4: Compare two different extracellular matrices separately deposited by
SDSCs and articular chondrocytes on the effects of cell proliferation and
chondrogenic potential.

4.1 Obtain ECMs from SDSCs and chondrocytes and compare the components in the two
types of ECM.

4.2 Expand SDSCs and chondrocytes separately on conventional

plastic

flaks,

SDSC-deposited ECM and chondrocyte-deposited ECM.

4.3 Compare chondrogenic differentiation of SDSCs and chondrocytes expanded under the
three different conditions.

Hypothesis 4: We hypothesized that ECM from tissue-specific sources will improve the
proliferation and chondrogenic potential differently. More specifically, we believe that SDSCs
cultured on SDSC-deposited ECM will have a superior effect on self-renewal and
chondrogenesis to those on chondrocyte-deposited ECM. We also believe that chondrocyte
cultured on chondrocyte-deposited ECM will have a better result in cell proliferation and
redifferentiation than those on SDSC-deposited ECM.
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Chapter 1:
Literature Review

1

1.1 Articular Cartilage Biology

Cartilage is a unique tissue in articulated joints covering long bones and provides frictionless
movement and a mechanical loading-bearing surface. Cartilage transfers the force generated
by underlying bones and supports a large range of joint motion with lubrication and stability.1-3
The structure of cartilage can be divided into four zones: superficial zone, middle zone, deep
zone and calcified cartilage zone shown in Table 1.1 and Figure 1.1.2-5

Zones

Thickness

Composition

Superficial zone

200 μm
10-20% of the cartilage thickness

Tangentially oriented collagen fibers

Middle zone

1 mm
60% of the cartilage thickness

Randomly oriented collagen fibers

Deep zone

600 μm
30% of the cartilage thickness

Perpendicularly oriented collagen
fibers

Calcified zone

Interface with the bone

Large bundled collagen fibers
anchored within subchondral bone

Table 1.1 Four zones in articular cartilage

Cartilage is composed of 1% chondrocytes and 99% the matrix.4;6 There are two major
functions of chondrocytes: 1) to produce sufficient collagens and proteoglycans to form
mature cartilage tissue in the developmental stage; and 2) to release enzymes to break down
aging components and replace with newly generated matrix.4;6;7 The size, morphology and
arrangement of chondrocytes vary with the depth of cartilage. From the surface of cartilage to
the deeper level, chondrocytes change from flatter to rounder and from a scattered to an
organized arrangement. The major compositions of cartilage include water (70%), type II
collagen (15%) and proteoglycans (15%). The function of each component in cartilage is
demonstrated in Table 1.2 and Figure 1.2.4;6;8;9

Component

Percentage

Function
2

Chondrocytes

1%

Produce extracellular matrix and enzymes
to break down aging contents

Collagen (major Type II)

15%

Provides cartilage with its tensile strength
and stiffness

Proteoglycans

15%

Provide resiliency to compression and
elasticity

Water

70%

Provides suitable environment for
chondrocyte survival and matrix function

Table 1.2 Major components in articular cartilage

Cartilage functions to transfer force and bear loads, and the biomechanical properties of
human articular cartilage have been extensively studied. Cartilage provides resiliency not
only to tensile loads but also to compressive forces depending on different matrix
compositions. Cartilage has a relatively low compressive stiffness (E = 0.1 - 2.0 MPa),
Poisson’s ratio (ν = 0.2) and permeability.10;11 Table 1.3 shows other biomechanical properties
of normal and aged human cartilage; the mechanical properties of cartilage decrease with
aging.12;13

Mechanical Parameter

Normal Cartilage

Aged Cartilage

Young’s modulus (MPa)

122

76

Elastic energy (kJ/m3)

141

83

Viscoelastic energy (kJ/m3)

42.5

22.9

Table 1.3 Biomechanical properties of normal and aged human cartilage

1.2 Cartilage defects and degenerative diseases

1.2.1 Three cartilage defects
Three typical cartilage defects occur in clinical practice, including subchondral, full-thickness
and osteochondral defects (Figure 1.3).14 Subchondral defect is typically a focal lesion limited
to the superficial or middle zone of cartilage. Full-thickness defect extends to subchondral
3

bony plate but stays intact. Osteochondral defect includes damage to cartilage and
subchondral bone tissue.15-17

1.2.2 Trauma
Young patients usually suffer cartilage-related diseases caused by trauma. Clinical focal
lesions after trauma are usually very small (< 1 cm2) and happen only on the articular
cartilage surface.14-17 Due to the limited self-healing ability of articular cartilage, focal lesions if
untreated may progess to degenerative disease.18

1.2.3 Osteoarthritis
Osteoarthritis (OA) is one of the oldest and most common diseases in human history; it is
defined as a degenerative disease of joints affecting not only articular cartilage but also
menisci and bone tissue. The symptoms of OA include steady or intermittent pain in joints,
stiffness after a period of inactivity such as sleeping and sitting, swelling or tenderness in one
or more joints, reduced range of motion and cracking in joints.3

Besides trauma, several risk factors may lead to OA. Age is a main risk; it is reported that
most people over the age of 60 have OA of some severity and 72% of OA patients are over
40-years old.3 Gender is another factor related to OA; women are more likely to be affected
than men. OA is more common in men before age 45 and in women after age 45.17;19
Hereditary gene defects result in damaged collagen components in cartilage and obesity
leading to joint overload.17 Other risk factors include metabolic problems such as diabetes or
alcohol abuse.19

Four grades of macroscopic changes in osteoarthritic articular cartilage were proposed by
Outerbridge. In grade 1, cartilage becomes soften in some areas. In grade 2, there is
fragmentation a half inch or less in diameter. In grade 3, the fragmented area enlarges to
more than half an inch, and in grade 4, the injuries develop to full-thickness defects or to
subchondral bone tissue (Figure 1.4).20
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Articular cartilage becomes soften, fibrillated, and eroded down to the subchondral bone in
OA. At the microscopic level, OA results in chondrocyte cell death and the degradation of
cartilage matrix.21;22 Since chondrocytes are the only cellular components in articular cartilage,
they are able to respond to cartilage damage caused by OA, firstly by clustering and
proliferating. Moreover, OA increases the production and activity of cytokines, chemokines
and other inflammatory mediators from immune cells, synovial cells and chondrocytes.
Inflammatory mediators include interleukins such as IL-1, IL-6, IL-7, IL-17 and IL-18; reactive
oxygen species such as hydrogen peroxide, superoxide and nitric oxide; and lipid-derived
mediators such as prostaglandins.23-25 The mediators induce chondrocyte apoptosis,
proteolysis and cell death. In OA, proteolytic enzymes destroy cartilage matrix by cleaving
type II collagen without degrading type IX or type XI collagen.21;24

Recently the Centers for Disease Control and Prevention (CDC) reported that 27 million
Americans suffered from OA and that females were more likely to be affected than males. By
the year 2030, 25% of adult U.S. citizens, nearly 67 million people, will have arthritis and
other cartilage degenerative diseases. A study conducted by the researchers in Stony Brook
(NY) showed that about 0.8% of women and 0.3% of men nationwide had OA. The annual
medical care expended on OA is about $185.5 billion and work absence due to OA costs
employers over $10 billion per year in U.S.26;27

1.3 Intervertebral disc degeneration
Intervertebral discs (IVD) are between two vertebrae in human spine. The total number of
discs in spine is twenty-three. IVD composes 20% to 30% of the length of spine and the size
of discs increases from cervical to lumbar regions. IVD degeneration is the primary cause of
low back pain. It is reported that, in US, approximately 5.7 million people suffer with IVD
degeneration and most of them are in the 45 to 64 year old range.28-30

Intervertebral discs have the following functions: 1) manage the movement of fluid within the
nucleus that allows vertebrae to rock back and forth and increases flexibility; 2) serve as
shock absorbers; 3) act as pads to maintain the space between the 24 movable vertebrae; 4)
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allow extension and flexion.31;32

The structure of IVD contains three avascular tissues: annulus fibrosus (AF), nucleus
pulposus (NP) and cartilage endplates (Figure 1.5A).33 NP, located at the center of IVD, acts
as a spongy tissue and is composed of a large amount of water, proteoglycans and collagens
to resist compression. Chondrocyte-like cells are found in NP tissue; the cell density is 4 ×
106 cells/cm3 at maturity.28;31;32 Outside NP is annulus fibrosus that is made of a series of
lamellae. The concentric collagen fibers that compose AF tissue orient at various angles and
bear the upper body weight due to the swelling effect of NP. Fibroblast-like cells are found in
AF with a relatively higher cell density of 9 × 106 cells/cm3. The cell density in NP and AF is
much less compared to that in articular cartilage of 1.4 × 107 cells/cm3. Cartilage endplates, a
thin horizontal layer, are on the superior and inferior faces of IVD and function to regulate the
diffusion of nutrients.28-30

In normal IVD, the compositions of AF and NP include a network of collagens including type I,
II, III, V, VI, IX, XI, XII, and XIV, a variety of proteoglycans that mainly contains aggrecan,
versican, decorin, biglycan and fibromodulin, and other matrix proteins such as fibronectin
and elastin.28-30 However, the proportion of matrix components varies from NP to AF and the
inner to the outer part of AF. The outermost layers of AF are composed of mostly type I
collagen and NP contains type II collagen. From the outer to the inner AF, type I collagen
decreases and type II collagen increases.Type X collagen is also found in NP and inner AF
layers. Aggrecan is a major component of matrix proteoglycans in AF and NP. In NP the
proportion of aggrecan and water content is about 50% to 80% of the wet weight but, in AF, it
only holds 20% to 70% from the outer to inner part.29-31;34

IVD degeneration progresses with age or after trauma due to the poor self-repair mechanism
similar to articular cartilage. Loss of proteoglycans is the most significant change in IVD
degeneration and aggrecan degrades from large molecules to small fragments (Figure
1.5B).30 The degeneration progresses steadily in NP since aggrecan composes most of the
matrix and the loss of aggrecan results in dysfunction in loading-bearing and back pain.29-31
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The network of collagen matrix also undergoes degeneration but not as obvious as that of
proteoglycans. The types and distribution of collagens alter in NP during IVD degeneration;
type II collagen becomes denatured and more type I collagen is synthesized. Except the
significant decrease in matrix components, some enzyme production and activity increases,
such as matrix metalloproteinases (MMPs), cathepsins and aggrecanases.28-32 The activity of
these enzymes is higher in degenerated IVD than in normal IVD to enhance further matrix
degradation.34-36

During the process of IVD degeneration, NP cells are stimulated to proliferate and the cell
density increases.36;37 However, the level of cell death and cell senescence increases
simultaneously. Shortening telomeres when cells undergo repeated division and an increased
generation of reactive oxygen species and cytokines would be the reason for cell death and
senescence.38-40 The phenotype of NP cells in IVD degeneration also changes caused by
synthesizing different matrix proteins from NP cells, secretion of growth factors, an increase
in the level of inflammatory factors and enhanced enzymatic activity.35;41

1.4 Current therapy tragedies for articular cartilage repair and IVD degeneration

1.4.1 Intrinsic self-repair of articular cartilage
Articular cartilage has very limited self-healing ability once trauma or degeneration occurs
because the avascular structure prevents mesenchymal stem cells in bone marrow or
chondrocyte progenitors from migrating to damaged areas. Some animal studies showed that
spontaneous healing was observed when minor lesions were on the surface of cartilage or
subchondral defects were less than 3 mm in diameter.17;19 However, articular cartilage fails to
repair the large defects that extend to osteochondral tissue and the damages ultimately lead
to cartilage degeneration. The most important issue in cartilage self-repair is that the repaired
chondral tissue is fibrocartilagenous in which the ratio of type I collagen is much higher than
type II collagen with fewer proteoglycans. This fibrocartilagenous tissue fails to have normal
biomechanical functions or withstand load-bearing like hyaline cartilage tissue. Eventually the
fibrocartilagenous tissue leads to degradation and loss of cartilage tissue.19;22;42;43
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1.4.2 Conservative treatments and surgical procedures
Steroidal and non-steroid anti-inflammatory drugs are commonly used to treat cartilage
defects but those medicines are mainly for pain relief. Hyaluronic acid can be injected into the
joints to reduce pain. At present D-glucosaminesulphate and chondroitinsulphate are proven
to improve articular cartilage healing. Overall, the effectiveness of drug treatments is minor
and none of them can fully heal cartilage defects.19;42

Surgical procedures are used to stimulate the intrinsic repair in articular cartilage by drilling or
microfracturing subchondral bones. The purpose of these procedures is to release the
mesenchymal stem cells in blood and bone marrow to recruit into the defects. However,
fibrocartilagenous or scar tissue is formed and therefore is susceptible to degradation.14;19;42;44

Transplantation of periosteum and perichondrium was used in cartilage repair; the tissue
covered articular cartilage defects. The procedure provided a fast reconstruction of the
cartilage surface but resulted in calcification and eventually degeneration in the defect area.
The transplantation of pure periosteum and perichondrium is no longer recommended in
clinical use.14;19;45

Osteochondral transplantation is the procedure in which osteochondral plugs are harvested
from less used load-bearing areas in joints and transferred into cartilage defects. The
technique can be used to repair large defects and provides rapid bone healing to fix the
osteochondral plugs into the implant site. The disadvantages of the procedure include donor
site morbidity, increased cell death of chondrocytes and formation of fibrocartilagenous tissue
which leads to further cartilage degeneration.8;14;46-49

1.4.3 Autologous chondrocyte transplantation
Autologous chondrocyte transplantation (ACT) has been used in clinical practice since 1994
and has been proven more effective than other surgical procedures.50 In the first step of ACT,
a small amount of cartilage tissue is taken by arthroscopy from a non-weight bearing area
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(150 - 300 mg). In the second step, chondrocytes are released from biopsy by enzymatic
digestion and expanded in vitro to reach an adequate cell number for intra-articular injections.
In the third step, cultivated chondrocytes are injected into articular cartilage damage sites,
covered with a periosteal graft and sutured to prevent water leak (Figure 1.6).43;43;50;51

The first generation of ACT relied on cultured chondrocytes and injecting cells beneath a
periosteal graft. It has several disadvantages including surgical damage in cartilage biopsy,
cell-phenotype change in the process of chondrocyte expansion in vitro (also called
dedifferentiation), leakage of chondrocytes from the defects and periosteal complications
such as hypertrophy and detachment from the injection site.8;42;43;51

The second generation of ACT uses a bi-layer collagen membrane instead of periosteal graft.
The collagen membrane is sutured onto the cartilage defects and expanded chondrocytes
are injected underneath. The replacement of collagen membrane to periosteal graft simplifies
the surgical procedure, reduces the risk in periosteal surgery and decreases the number of
incisions in patients.8;42;43;51

The third generation of ACT is also called the “all-in-one” procedure; it uses
three-dimensional biocompatible scaffolds where chondrocytes are seeded and differentiate
to generate cartilage-specific matrix. The newly generated cartilage repair graft is designed to
fit the size of defects and fibrin glue is used as sealant to fix the graft.8;42;43;51

The clinical outcomes of ACT are successful because hyaline-like cartilage tissues are
observed and reach 90% of native cartilage stiffness. Different from fibrocartilagenous tissues,
the hyaline repaired cartilage does not lead to further degeneration and have normal
biomechanical functions.14;42;43;51;52

However, the disadvantages of ACT are obvious including the limited expandability of
chondrocytes and the rapid dedifferentiation in the process of in vitro expansion over several
passages. In dedifferentiation, chondrocytes lose their round morphology and change to a
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spindle-shaped, fibroblast-like phenotype. Type I collagen is synthesized in dedifferentiated
chondrocytes instead of type II collagen and aggrecan. Another common complication of ACT
is periosteal hypertrophy that results in pain in the repaired joints and detachment of
periosteal graft leading to the failure of ACT. The ACT procedure includes cartilage biopsy
from the patients’ healthy joints that might cause surgical defects in cartilage even it is not
load-bearing.42;43;51;53-56

1.4.4 Autologous or allogeneic cell transplantation for nucleus pulposus repair
Mature nucleus pulposus (NP) contains chondrocyte-like cells with a low cell density and
limited self-healing. The NP environment is harsh because of high stress, low oxygen tension,
low pH and limited nutrients due to an avascular structure. Intervertebral discs (IVD) face the
risk of degeneration with aging and, due to the limited self-repair, the degeneration process is
irreversible.57

Similar to autologous chondrocyte transplantation (ACT), autologous or allogeneic NP cell
transplantation has been used in animal studies. NP cells are first obtained from a healthy
IVD and expanded in vitro to reach an adequate cell number, then injected into the
degenerated IVD. The injected NP cells are able to synthesize new matrix contents such as
aggrecan and type II collagen. The implanted NP cells effectively improve disc conditions
without a major immune response.58

Worse than articular cartilage, the cell density is much lower in NP and NP cells have less
expandability than chondrocytes. It is reported that the cell viability was improved when NP
cells were co-cultured with AF cells.59 A new co-culture system with MSCs was adopted to
increase NP cells’ proliferative ability.60 Growth factors, such as transforming growth factor β
and insulin-like growth factor, were supplemented to stimulate NP cell proliferation.60
However, the poor expandability of NP cells limits the application of autologous or allogeneic
cell transplantation to repair IVD degeneration.

Because the matrix components in articular cartilage are similar to those in IVD,
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transplantation of articular chondrocytes into degenerative IVD was tested and this method
effectively reduced the loss of proteoglycans in the injured IVD.57;61 Even though aggrecan
and type II collagen are found both in articular cartilage and NP tissue, the ratio of aggrecan
to collagen is different. In NP, the ratio of aggrecan to collagen is significantly higher
(approximately 27:1) than that in articular cartilage (2:1),62 indicating that chondrocyte
transplantation for IVD is still risky.

1.5 Adult mesenchymal stem cells

1.5.1 Embryonic stem cells and induced pluripotent stem cells
Embryonic stem cells (ESCs) are identified by the properties of unlimited self-renewal,
immortality and pluripotent differentiation to multiple tissues and organs. The study of ESCs
began in the 1950s and the culturing system was adopted in 1981 using a fibroblast feeder
layer and serum.63;64 Thomson et al. in 1998 first created several human embryonic stem cell
lines (hESCs).65 Human embryonic stem cells are typically isolated from the inner cell mass
of the blastocytes and expanded on a feeder cell layer to maintain hESC in an
undifferentiated state. After removing hESCs from the feeder cell layer, they are cultured in
suspension where embryoid bodies containing differentiated and undifferentiated cell
aggregate. Embryoid bodies can be cultured on monolayer later and spontaneously
differentiate to three germ lineages. Theoretically, ESCs can differentiate into any desired
lineage through stimulation of specific growth factors or under proper protocols.66-69

Levenberg et al.70 cultured hESCs on a three-dimensional (3D) scaffold to promote cell
proliferation and differentiation. A 3D vessel-like structure was observed, characterized by
neural tissue, cartilage and liver.70 ESCs are a potential candidate for cartilage and bone
tissue repair. Jukes et al. developed cartilage tissue-engineered constructs using mouse
ESCs on a 3D scaffold in vitro and, after transplantation in vivo, the cartilage construct was
ossificated and ultimately replaced by bone tissue.71 However, the disadvantages of using
hESCs are obvious. The use of hESCs involves the destruction of in vitro human fertilized
eggs to obtain blastocytes, which is unacceptable by some people in certain religions and
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countries. A major immune rejection or response can occur when hESCs are implanted into
patients. The risk of hESCs forming tumor tissue in vivo is still large.72-76

Recently the generation of induced pluripotent stem (iPS) cells provides a novel method and
potentially exciting approach for stem cell research, drug testing and tissue engineering. iPS
cells are the pluripotent stem cells transferred from terminally differentiated adult somatic
cells by induction of several key transcription factors. Takahashi et al. in 2006 successfully
developed the first iPS mouse cells by inserting four transcription factors [Sox2, Oct-3, c-Myc
and Klf4 (Krueppel-like factor 4)] to reprogram fibroblasts to ES-like cells.77 Yu et al. also
reprogrammed iPS cells using Oct3-4, Sox2, Nanog and Lin28 by lentivirus transfection78. In
2008 iPS cells were generated by using adenovirus79;80 and, in 2009, the first iPS cells were
reported using only recombinant proteins.81-83 The use of adenovirus and recombinant
proteins can significantly reduce the risk of tumor formation since they do not affect the
targeted host genes. Although iPS cells overcome some disadvantages of hESCs, there are
still some drawbacks to limit their use. The reprogramming of iPS cells involves viral
integration, even though recombinant proteins are in use but with low efficiency. The
generation of iPS cells faces the disadvantages of low efficiency and high cost, because the
typical efficiency of iPS cell generation is less than 1%; the efficiency can increase to 28% if
using hematopoietic stem cells or mesenchymal stem cells.66;82;84

1.5.2 Adult stem cells
A well-known adult stem cell is hematopoietic stem cell (HSC) that can be collected from
bone marrow and umbilical cord blood. Hematopoietic stem cells (HSCs) are characterized
by cell surface markers, which are positive for CD34, CD133, CD177, CD59 and CXCR4, but
negative for lineage-specific antigen, CD38, and CD73 etc. The ability of HSC differentiation
into non-hematopoietic lineage tissues is possibly artifact, because mesenchymal stem cells
locate or migrate into hematopoietic organs.85-89

Mesenchymal stem cells (MSCs) are another type of adult stem cells, characterized by a
strong self-renewal ability and multipotent capacity to differentiate into multiple lineages,
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including bone, cartilage, adipose tissue, muscle, tendon, stromal cells and connective tissue.
MSCs are characterized by surface markers positive for CD73, CD90 and CD105, but
negative for CD45, DC34, CD14, CD11b, CD79a, CD19 or HLA-DR. Three typical MSCs,
which are frequently studied in stem cell research and cartilage tissue engineering, will be
introduced, including bone marrow stem cells, synovium-derived stem cells and
adipose-derived stem cells.73;90-92

Ideal MSCs for regenerative medicine include the following criteria: 1) they should have a
large cell number for clinical therapy; 2) they should have a minimally invasive procedure to
collect or harvest tissue for MSCs; 3) they should have multiple differentiation potentials; 4)
they should have safe transplantation for autologous and allogeneic MSCs to avoid immune
rejection.93

MSCs provide a great potential for regenerative medicine and cartilage tissue engineering.
MSCs have several advantages over ESCs and iPS cells. Even though MSCs have a weaker
proliferative rate than ESCs, they can be collected from various tissue sources and still
provide adequate cells for therapy if culture conditions and protocols are improved94;95. The
multipotential differentiation to multiple lineage tissues of MSCs can benefit bone and
cartilage tissue regeneration, tendon and skeletal muscle repair and cardiac tissue
engineering.19;96;97 MSCs can be collected directly from patients to avoid any immune
rejection. Meanwhile, the results of various immunoassays on MSCs suggest that MSCs
have a strong immunosuppressive effect by inhibiting T-cell recognition and suppressing the
production of TNF-α or INF-γ. The immunosuppressive effect enables the use of allogeneic
MSCs with minimal immune reaction.91;98-100 MSCs are not subject to the ethical dilemmas
and forming teratocarcinoma that are associated with ESCs.101-104

1.5.3 Bone marrow stem cells
Bone marrow stem cells (BMSCs) were first reported by Friedenstein et al.91;105-107 The
fibroblast-like cells in bone marrow were found through attachment to tissue culture plates
and the cells exhibited osteogenic differentiation ability. Since their discovery, BMSCs have
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been studied in depth and found to differentiate into not only osteoblasts108 but also
chondrocytes,109 adipocytes,110 myoblasts111 and early progenitors of neural cells.112

The BMSC population in bone marrow is scant and represents 0.001% to 0.01% of the
nucleated cells, which is only 1/10 of the proportion of HSCs. BMSCs, however, show a
strong proliferation ability in monolayer expansion in vitro.91;107;113 The expansion conditions
were improved to increase BMSC cell yield and to maintain their differentiation potentials. In
the process of in vitro expansion, BMSCs with different cell morphologies are harvested,
including thin and spindle-shaped cells and wider cells. It was found that small, thin BMSCs
self-renewed rapidly and had a greater potential for multipotential differentiation. In repeated
passages, low seeding density can help BMSCs increase their proliferative rate and maintain
their differentiation capacity.114-116

The immunophenotype profile of BMSCs is similar to other mesenchymal stem cells. BMSCs
are positive for CD105, CD73 and CD90 but negative for CD34, CD 45 CD11a CD19 and
HLA-DR. Table 1.4 lists the cell surface markers to characterize BMSCs and other
MSCs.91;103;117;118

Positive markers

Negative markers

CD9. CD10. CD13, CD29, CD44, CD49a,

CD45, CD34, CD14, CD11A, CD19, CD86;

CD49c, CD49e, CD51, CD54, CD58, CD61,

CD80/CD40, CD15, CD18, CD25, CD31,

CD71, CD73, CD90, CD102, CD104, CD105, CD50, CD62E, CD62P, CD117
CD106, CD119, CD120a, CD120b, CD121,
CD127, CD140a,, CD166, CCR1, CCR4,
CCR7, CXCR5, CCR10, VCAM-1, CD166,
AL-CAM, ICAM-1, STRO-1, CD340, SSEA-4.
W8B2, W3D5, W4A5, W5C4, W5C5, W7C6,
9A3, 58B1, HEK-3D6
Table 1.4 Cell surface markers to characterize BMSCs
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BMSCs have been successfully used in animal studies and clinical practices. The injection of
BMSCs was used to repair fresh bone fractures and osteochondral defects. The injected cells
shortened healing period, enhanced the repair effect in bone fracture treatment, and reduced
the chance of future bone fracture.119;120 BMSCs were used to repair full-thickness defects in
articular cartilage using various scaffolds. The repair effectiveness of BMSC transplantation
was better than those not treated with BMSCs.102;121;122 However, BMSC injection therapy
failed to significantly improve osteoarthritis possibly due to the serious inflammatory reaction
caused by arthritis.123 Since BMSCs can differentiate to skeletal, smooth and cardiac muscle
cells, cardiac regeneration is the focus of current research. In animal studies, autologous
BMSCs were used to treat myocardial infarction and improved cardiac function and
angiogenesis,96;124;125 indicating that BMSC can be useful in cardiomyocyte regeneration.

1.5.4 Adipose-derived stem cells
Adipose-derived stem cells (ADSCs), termed “pre-adipocytes” historically, are another
promising candidate for regenerative medicine.126;127 ADSCs can be digested enzymatically
from adipose tissue and separated from adipocytes by centrifugation. ADSCs share
similarities with BMSCs such as an extensive proliferative ability and multipotential
differentiation capacity to osteoblasts, adipocytes, chondrocytes, myoblasts and neural
cells.128-132 Compared to BMSCs, ADSCs have several advantages including easy
accessibility, abundant adipose tissue source, higher yield of cell numbers and superior
proliferative rate. It is reported that approximately 400,000 liposuction surgeries are
preformed in U.S. every year and yield about 100 mL to 3 L of lipoaspirate tissue that is
discarded. ADSCs can be collected safely and conveniently from those abundant lipoaspirate
tissues.132-134 Surgery risk is reduced by using autologous ADSCs because fat tissue is more
easily accessible than bone marrow. Furthermore, 5 × 103 cells can be collected from 1 g of
adipose tissue; that is 500-fold greater than the number of BMSCs from the same weight of
bone marrow.135-137 Adipose tissue is considered a rich and safe source for ADSCs.

The cell surface marker expression of ADSCs is similar to that of BMSCs, positive for MSC
markers and negative for HSC markers.138 Particularly, CD49d is positive and CD106 is
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negative in ADSCs. ADSCs also show increased expression of CD54 (ICAM-1) compared to
BMSCs.138-140 The proliferative rate of ADSCs in vitro expansion is not different from that of
BMSCs,140 but the colony forming rate of ADSCs is higher (50 - 100 times more) than
BMSCs.141

It is not surprising that ADSCs exhibit excellent adipogenic potential when induced in
adipogenic differentiation medium.128;138;142 Under osteogenic stimulation, ADSCs are able to
express osteoblast-specific genes and bone tissue matrix that are compatible with
BMSCs.138;142-144 In a murine calvarial defect model, ADSCs were transplanted to repair bone
defects and the newly generated bone tissue had biological and biomechanical functions.145
In chondrogenic differentiation, ADSCs are able to express chondrogenic-specific genes
such as Sox9, aggrecan and type II collagen and generate cartilage-related extracellular
matrix of sulfated glycosaminoglycans and type I and II collagens.138;142;146 However,
compared to BMSCs, ADSCs showed no difference in chondrogenic ability in
two-dimensional culture but were much weaker in a three-dimensional system.147

1.5.5 Synovium-derived stem cells
Synovium-derived stem cells (SDSCs) are from “synovial fibroblasts” that are considered
tissue-specific cells for regeneration medicine and cartilage repair.92;148;149 Compared to
BMSCs, ADSCs and other MSCs, synovial membrane is located near articular cartilage and
provides suitable MSCs to migrate into subchondral defects. SDSCs have several
advantages over BMSCs and ADSCs including higher proliferative rate, regardless of donor
age, and a stronger chondrogenic potential with minimal hypertrophy risk.

Synovial membrane can be harvested by arthroscopy with minimal invasiveness and less risk
to donors because of its strong regenerative capacity. SDSCs can be released by enzyme
digestion. Approximately 21,000 cells can be harvested from 1 mg of synovium tissue which
provides a sufficient cell number for animal studies and clinical practices.92 The expandability
of SDSCs is identical to BMSCs and superior to ADSCs; SDSCs can be expanded over 10
passages without cell senescence (cell morphology changes to flattened and larger and then
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the cells stop proliferating). When seeding at a low cell density, SDSCs show a more rapid
proliferative rate than other MSCs.150;151 The colony forming ability of SDSC is about 100-fold
greater than that of BMSCs and comparable to ADSCs.141 With regard to adipogenesis and
osteogenesis, SDSCs are identical to BMSCs and ADSCs.140;141;152 SDSCs exhibited superior
chondrogenic potential compared to BMSCs and ADSCs. With the induction of transforming
growth factor-β1 (TGF-β1), both BMSCs and SDSCs generated cartilage-specific genes and
matrix that were stronger than ADSCs.152 Using the combination of transforming growth
factor-β3 (TGF-β3) and bone morphogenic protein - 2 (BMP-2), SDSCs produced 2.5-fold
more sulfated glycosaminoglycans and 50% more collagen than BMSCs.150 The superior
chondrogenic capacity of SDSCs was also confirmed by other studies.153;154

There are two major cell types in synovial tissue, where the round nucleated cells are called
“macrophage-like” or “type A” cells and the spindle type cells are named “fibroblast-like” or
“type B” cells. Our laboratory developed a “negative isolation” procedure to improve SDSCs’
proliferative and chondrogenic capacities. Cells from digested synovial tissue are suspended
and incubated with Dynabeads® M-450 conjugated with CD14 antibody specific for
macrophages; then the conjugated cells are removed by using the Dynal Magnetic Particle
Concentrator® and unconjugated cells are presumed “type B” cells (SDSCs). Figure 1.7
shows the negative isolation procedure in synovial cells.155 The negatively isolated SDSCs
show improved proliferation and a higher level of matrix generation than untreated synovial
cells.149;155

1.6 Chondrogenesis of mesenchymal stem cells
MSC chondrogenesis is the process where multipotent MSCs differentiate into articular
chondrocytes and generate cartilage-specific extracellular matrix, induced by growth factors
and nonproteinaceous chemical molecules, in a serum-free medium and under optimal
culture conditions such as hypoxia. In the process of chondrogenesis, MSCs continue to
express type I and II collagen and aggrecan (chondrogenic markers), and type X collagen
(hypertrophic marker) in the late stage.109;149;156-158 The first chondrogenesis of MSCs was
reported by Ashton et al.156 and a pellet culture system was developed by Johnstone et al. to
17

enhance chondrogenic effect.109 The pellet culture system is widely used to evaluate
chondrogenic potential of MSCs in vitro.109;149;157;159 The following introduction will focus on
growth factors, optimal chondrogenic media and culture conditions and the hypertrophic
markers

of

chondrogenesis.

Chondrogenic

differentiation

signaling

pathways

and

transcription factors induced by TGF-β growth factor will be discussed.

1.6.1 Growth factors in chondrogenesis
The transforming growth factor-β (TGF-β) superfamily is the most commonly used to induce
chondrogenesis of MSCs; the family includes TGF-β, bone morphogenetic proteins (BMPs),
activins and inhibins.160

TGF-β1, 2, and 3 promote the synthesis of proteoglycans and type II collagen in MSCs in
vitro.159;161 TGF-β1 in vivo stimulates skeletal tissue development and induces MSC
chondrogenic differentiation to repair cartilage defects.19;159;162 TGF-β3 is proposed to have a
stronger effect in MSC chondrogenesis than TGF-β1, but our study using SDSCs suggested
that there was no difference in chondrogenic effect between these two TGF-β factors. From
histology and immunohistochemistry, both TGF-β1 and TGF-β3 can induce SDSCs to
generate a large amount of sulfated GAGs and type II collagen. The quantification of
chondrogenic index induced by TGF-β1 and TGF-β3 shows no statistical difference. (Figure
1.8)

Bone morphogenetic proteins (BMPs) are important members of the TGF-β superfamily that
contain a sub-class of 20 polypeptides. Several BMPs can promote MSC chondrogenesis
and cartilage formation by increasing the expression of aggrecan and collagens, such as
BMP-2, -4, -6, -7, -13 and -14. Interestingly, BMP-3 inhibits MSC chondrogenesis and
osteogenesis by inhibiting BMP-2 activity.163;164 The combination of TGF-β and BMPs can
enhance MSC chondrogenic differentiation, proven by previous studies165 and our research
on ADSCs (Chapter 3).

The insulin-like growth factor (IGF) family including IGF-I and IGF-II is also investigated in
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MSC chondrogenic differentiation. The binding of IGF to receptors induces activation of
different intracellular downstreams and subcutaneously enhances the expression of
chondrogenic genes and proteins.159;166 In articular cartilage, IGF-I is produced to maintain
chondrocyte morphology and induce cell migration to repair defects. It has been proven that
IGF-I plays an important role in embryonic development and that the mutation of IGF-I results
in serious developmental defects in various musculoskeletal tissues.159;166;167

The fibroblast growth factor (FGF) family is also used to improve MSC chondrogenesis and
includes 22 sub-class proteins binding to receptors.168 The intracellular signaling pathway of
FGF is characterized to Ras–MAPK (mitogen activated protein kinase) pathway.169 The most
well-known member of the FGF family is FGF-2, which functions to promote the proliferation
of MSCs and chondrocytes and to enhance chondrogenic differentiation with other TGF-β
factors.170 The knock-out FGF-/- mice had serious issues in cartilage and bone
development.159;168 In the adult rabbit model, the induction of FGF-2 improved the repair of
cartilage defects.171

1.6.2 Optimal chondrogenic conditions
In addition to protein-based growth factors, several nonproteinaceous chemical compounds
are used as supplements in the induction of MSC in vitro chondrogenesis. Dexamethasone is
a synthetic glucocorticoid that can enhance MSC chondrogenesis. The normal concentration
of dexamethasone is 10-7 M and the combination with TGF-β can induce a greater generation
of aggrecan and type II collagen.109;172 Ascorbic acid (vitamin C) is demonstrated to have a
stimulatory effect on chondrogenic differentiation in adult MSCs and in embryonic limb
development.173;174 Insulin is also added to promote in vitro chondrogenesis of MSCs and
chondrocytes and is used at a higher level than that in normal human serum.175;176

Hypoxia, a low oxygen tension (1% - 5%), can improve MSC chondrogenesis demonstrated
by several studies. The improvement of chondrogenic differentiation in hypoxia is related to
an elevated expression of hypoxia-inducible factors (HIFs), specifically HIF-1α, and
chondrogenic transcription factor Sox-9. Thus, protein downstream affects MSCs to generate
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an increased level of cartilage-specific matrix.177-180 Hypoxia is also demonstrated to inhibit
the formation of fibrous cartilage by decreasing the marker genes of type I and III collagen,181
and to induce dedifferentiated chondrocytes in primary culture towards redifferentiation.182;183

1.6.3 Hypertrophy
Hypertrophy is the terminal stage in chondrogenesis where ossification occurs in cartilage
matrix and chondrocytes change their morphology to fibroblast-like cells and eventually
differentiate into osteoblasts and form endochondral bone tissue. Typical hypertrophic
markers include type X collagen, matrix metalloproteinase 13 (MMP13), alkaline
phosphatase (ALP), bone sialoprotein type II (IBSP), secreted phosphoprotein type 1 (SPP1,
or osteopontin) and Runt domain transcription factor (Runx2).184;185 The fate of hypertrophic
chondrocytes is either to differentiate to osteoblasts or to undergo apoptosis, and this will
jeopardize the effect of MSC-generated cartilage tissue.186;187

BMP-2 and BMP-4 not only stimulate MSCs toward chondrogenesis but also induce the
expression of hypertrophic marker genes.188 However, TGF-β can suppress hypertrophy in
chondrocytes.189 Intracellular reactive oxygen species (ROS) play an important role in
chondrogenesis and hypertrophy. An elevated level of ROS is found in hypertrophic
chondrocytes and antioxidant treatment can reverse the excessive hypertrophy. Morita et al.
demonstrated that increased ROS can inhibit proliferation and initiate hypertrophic changes
in chondrocytes.187 Type X collagen is the only well-accepted marker for chondrocyte
hypertrophy that is regulated by Runx2, a transcription factor in osteogenesis, and the
suppression of Runx2 in chondrogenic differentiation inhibit the expression of hypertrophic
genes.190

Hypertrophy is one of the major concerns in MSC-derived cartilage tissue engineering, not
only ossification but also vascularization. Articular chondrocytes show no signs of
hypertrophy including negative expression of type X collagen and resistance to calcification,
but MSC-derived chondrocytes have the potential to mineralize and develop vascular
invasion after transplantation in vivo.184;185 Parathyroid hormone-like peptide (PTHrP) is
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proposed as an inhibitor to hypertrophy in in vitro MSC chondrogenesis.191 A recent study
showed that the coculture of articular chondrocytes and MSCs can significantly suppress
MSC hypertrophy during chondrogenesis because of PTHrP secreted by articular
chondrocytes.192 In future, the mechanism of hypertrophy in MSC chondrogenesis needs to
be studied to improve cartilage tissue engineering.

1.6.4 Chondrogenesis of SDSC induced by the combination of TGF-β1, IGF-I and FGF-2
Our previous study investigated SDSC chondrogenesis and improved chondrogenic
differentiation by growth factor cocktail: TGF-β1, IGF-I and FGF-2.149

Following negative isolation, SDSCs were centrifuged into pellets and cultured in serum-free
chondrogenic medium. The SDSC pellets were divided into five groups. All five groups were
treated with 50 ng/mL of FGF-2 for three days and then induced to chondrogenesis by the
growth factor cocktail (10 ng/mL of TGF-β1 and 500 ng/mL of IGF-I) for 15 days. The detail
experiment schedule is shown in Figure 1.9A. Group D1 was treated only with 10 ng/mL of
TGF-β1. Group D2 was treated with 10 ng/mL of TGF-β1 for 11 days and switched to the
cocktail for 4 days. Group D3 was treated with TGF-β1 for 7 days and the cocktail for 8 days.
Group D4 was treated with TGF-β1 for 4 days and the cocktail for 11 days. Group D5 was
treated with the cocktail for 15 days (Figure 1.9A).

Histology and immunohistochemistry showed that, with the cocktail treatment of TGF-β1 and
IGF-I, SDSC pellets had the strongest potential of chondrogenesis. Group D5 had the
extensive expression of sulfated GAGs and type II collagen. Type I collagen was positive in
all the groups but type X collagen was negative (Figure 1.9B). Biochemistry and real-time
PCR also showed that the combination of TGF-β1 and IGF-I can maximally induce the
expression of chondrogenic matrix and genes. This study suggested a new strategy to induce
chondrogenesis of MSCs by the sequential combination of growth factors.

1.6.5 Intracellular signaling pathways of TGF-β induced chondrogenesis
Members of the TGF-β superfamily bind to type II and type I TGF-β receptors. Both type II
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and type I receptors contain serine/threonine kinase domains in the intracellular parts. In the
process of binding TGF-β to type II receptor, type I receptor is recruited and phosphorylated.
Following the phosphorylation, type I receptor phosphorylates and activates intracellular
signaling pathways, including Smad, mitogen-activated protein kinase (MAPK)/extracellular
signal regulated kinase (ERK), JNK/p38 signaling, Wnt and Noggle. Therefore, type I
receptor functions as a downstream of type II receptor.193-197

Smad proteins, named from mothers against DPP homologs, are the major signaling
mediators in the TGF-β superfamily induced chondrogenesis. There are three types of Smad
proteins: receptor-regulated Smads (R-Smads), common-partner Smads (Co-Smads) and
inhibitory Smads (I-Smads). In the TGF-β induced signaling pathway, phosphorylated type I
receptor activates R-Smads, Smad2 and Smad3 specifically. Samd2/3 associate with
Co-Smad (Smad4) and the complex transfers to the nucleus to regulate the expression of
target genes in cooperation with transcription factors. In BMP signaling pathway, type I
receptor activates Smad1/5/8 and links to Smad4. The compound of Samd1/5/8/4 moves to
the nucleus and starts the target gene expression (Figure 1.10).193-195;198-200

TGF-β also induces the MAPK/ERK signaling pathway. In this pathway, binding of TGF-β to
type II receptor induces the activation of type I receptor. This results in phosphorylation of
numerous kinases, such as Src (v-src sarcoma (Schmidt-Ruppin A-2) viral oncogene
homolog) and Grb2 (growth factor receptor binding protein 2). The phosphorylation of Src or
Grb2 activates Ras by catalyzing the exchange of GDP to GTP. Ras then binds to Raf and
activates the MAPK cascade including MEK and ERK1/2 (Figure 1.11).201-204 However, the
function of ERK1/2 in chondrogenesis is controversial. Yamada et al. demonstrated that
activation of ERK1/2 was crucial in regulation of aggrecan gene expression induced by
TGF-β,205 but recent studies suggested that inhibition of ERK1/2 can improve the MSC
chondrogenic differentiation.206-208 One possible explanation is that activation of ERK1/2 is
essential to chondrogenesis induced by TGF-β in the early stage up to 120 minutes, but in a
long culture period like 14 days, the activity of ERK1/2 is suppressed to give way to other
signaling pathways.
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TGF-β can induce JNK and p38 MAPK signaling cascades. TGF-β activates JNK through
MKK4 (MAP kinase kinase 4) and p38 MAPK through MKK3/6. Activated JNK and p38 MAPK
move to the nucleus and initiate the expression of target genes with transcription factors
(Figure 1.12).204;209-213 More importantly, the signaling pathway of JNK and p38 is independent
of Smad signaling, proven by sustained activation of JNK and p38 in a Smad3- and
Smad4-deficient model.214;215

TGF-β can induce the PI3K/Akt signaling pathway. PI3K is activated by TGF-β and then
phosphorylates the downstream Akt that is independent of Smad activation 216. PI3K plays an
important role in cell adhesion, migration and TGF-β-induced actin filament reorganization
(Figure 1.13).204;217 However, the PI3K/Akt signaling was reported to antagonize
Smad-mediated effects. The activated Akt can interact with Smad3 and hence prevent the
translocation of Smad2/3 to the nucleus. The interaction of Akt and Smad3 can delay
chondrogenic differentiation induced by TGF-β.218-221

TGF-β can activate Rho-like GTPase, including RhoA, Rac and Cdc42 to modulate cell
adhesion, proliferation and survival.204;222;223 The activation of RhoA and Cdc42 by TGF-β is
independent of the Smads signaling pathway, indicated by the unaffected activation of
p21-activated kinase (PAK) in the inhibition of Smad2/3 phosphorylation.224;225 However,
Smad7 is associated with the activation of Cdc42 (Figure 1.14).226;227

In MSC chondrogenic differentiation, Sox9 (Sry-related high-mobility-group box 9) is the key
transcriptional factor to initiate the expression of chondrogenic-specific genes and inhibits
chondrocyte hypertrophy. After the activation of Smad2/3 by TGF-β, the Sox9 and Smad2/3/4
complex translocate to the nucleus. Cooperating with other transcription factors, such as
Barx2 and c-Maf, chondrogenic genes like type II collagen and aggrecan are activated to
express.228-230 In vivo Sox9 plays an important role in the development of musculoskeletal
tissues and organs, proven by the failure of mutant Sox9-/- mice to develop normal bone and
cartilage.231-236
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1.7 MSC-based cartilage tissue engineering

1.7.1 Definition of cartilage tissue engineering
Tissue engineering (TE) is defined as the utilization of biomaterials, cells, factors and other
biochemical and biophysical stimulations to regenerate, repair or restore live tissues that
have not only physiological but also biomechanical functions.237 Cells used in TE can be
autologous, allogeneic and xenogeneic. Biochemical factors, such as signaling molecules
and biophysical stimulation like compression or shear force, induce cells toward desired
lineage tissues. Biomaterials like scaffolds function to provide support for cells and
mechanical properties such as suitable stiffness and elasticity. The general procedure of TE
includes the following steps. MSCs or autologous cells are harvested from patients and
expanded in vitro to acquire adequate cell numbers. The expanded cells are seeded into
biocompatible scaffolds and cultured in the presence of growth factor combination to induce
cell proliferation and differentiation. The immature constructs containing the scaffolds and
cells are cultured in a bioreactor that mimics the in vivo condition or presses suitable physical
stimulations. The mature constructs (also called engineered tissue) are transplanted into
patients to repair catilage defects or damaged tissues.237;238 The cells used in cartilage tissue
engineering include chondrocytes, ESCs and adult MSCs that were discussed previously.
The growth factors in TE are the same as those used to induce chondrogenesis. Next we will
focus on biocompatible scaffolds and bioreactors.

1.7.2 Biocompatible scaffolds
The primary function of scaffolds is to provide a temporary structure for implanted cells until
new extracellular matrix is generated. The criteria for scaffolds include biocompatibility,
biodegradability, mechanical stability and a porous structure that is three-dimensional and
permissive for biological growth factors.

Fibrous scaffolds are the most commonly used in cartilage tissue engineering including poly
glycolic acid (PGA), poly lactic acid (PLA) and the copolymer poly lactic-co-glycolic acid
24

(PLGA). They have been approved by US Food and Drug Administration (FDA) for clinical
use. The fibrous scaffolds have a three-dimensional structure for cell attachment, migration
and proliferation. They can be degraded by hydrolysis and the degradation time is
controllable. Several in vitro and in vivo studies showed that MSCs or chondrocytes seeded
in scaffolds generated extracellular matrix that is identical to native hyaline cartilage. Those
constructs were implanted to repair partial-thickness or full-thickness defects in articular
cartilage and achieved better results than control groups.155;239-244 Fibrous scaffolds are
modified and improved by using nano-technology. Due to the morphological similarities of
nanofibers to natural extracellular matrix, MSCs and chondrocytes can be improved to higher
proliferative rate and better generation of matrix.245-247 Composite scaffolds are developed to
enhance cell attachment and chondrogenesis, such as the synthesis of PLA, chitosan and
hyaluronan.248-250

Hydrogel scaffolds are also commonly used in cartilage tissue engineering that can absorb
water and signaling factors, keep cell morphology and be injected into defect areas. The
types of hydrogels include type I and III collagen, hyaluronan, chondroitin sulfate and poly
ethylene glycol (PEG).251-254 MSCs and chondrocytes are seeded in hydrogels and
successfully generate cartilage-specific matrix. The hydrogels are improved to incorporate
signaling molecules such as growth factors that can spontaneously deliver TGF-β1 to induce
cell chondrogenesis and be removed by cellular enzymes.255;256

1.7.3 Bioreactors
Hydrodynamic bioreactor is the most commonly used equipment in tissue engineering and is
also called a rotating wall vessel (RWV). Cell-scaffold constructs are placed in the
hydrodynamic bioreactor filled with medium and growth factor supplements, and gas
exchange occurs through a permeable core. With rotation, constructs can be cultured with
sufficient nutrients and subjected to a low-level shear force.257-259 Our laboratory used the
hydrodynamic bioreactor to induce SDSCs into hyaline cartilage-like tissue.155 Dynamic
compression bioreactor is designed to increase construct mechanical properties by
enhancing cartilage-specific matrix generation. It is reported that chondrocytes seeded in
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hydrogel increased matrix synthesis though daily compressive stimulation.260;261 The
hydrostatic pressure bioreactor is made to mimic the contact stress in joints and increase the
generation of cartilage-like matrix.262

1.7.4 Cartilage tissue engineering using synovium-derived stem cells
Our laboratory successfully generated tissue constructs identical to native hyaline cartilage
using porcine SDSCs.155 SDSCs were collected from two young pigs and negative isolation
was undertaken using CD14 specific antibody conjugated Dynabeads® or conventional
expansion. SDSCs were seeded in PGA scaffold with fibrin glue and cultured in a cocktail of
10 ng/mL TGF-β1, 50 ng/mL FGF-2 and 500 ng/mL IGF-I for 3 days. After that, the constructs
containing SDSCs and PGA were transferred to a hydrodynamic bioreactor filled with
chondrogenic medium supplemented with 10 ng/mL TGF-β1 and 500 ng/mL IGF-I for one
month.

Histology and immunohistochemistry showed that the SDSC constructs strongly expressed
sulfated glycosaminoglycans and type II collagen. The hypertrophic marker, type X collagen
was negative. Mechanical analysis suggested that the SDSC constructs had similar
equilibrium modulus to natural hyaline cartilage. SDSC constructs with negative isolation
generated 50% more GAG and had two-fold equilibrium modulus than the constructs with
conventional expansion. Immunohistochemistry confirmed that macrophage cells existed in
the conventionally expanded synovial cells, but were completely removed after negative
isolation (Figure 1.15).

Rabbit SDSC constructs were engineered following the same protocol above and
transplanted into full-thickness femoral condyle cartilage defects in New Zealand white
rabbits. After six months, cartilage morphology and histology analysis showed that the
cartilage defects were filled with newly generated constructs, strongly expressing
proteoglycans and type II collagen but had negative expression of type I collagen. In the
control group, fibrocartilagenous tissues were found in the defects that were positive for type I
collagen. Mechanical analysis showed that the defect areas repaired with SDSC constructs
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had an equilibrium modulus that was identical to the surrounding undamaged cartilage tissue
and were higher than that in the control group (Figure 1.16). The engineered constructs using
SDSCs successfully repaired full-thickness defects in articular cartilage.263

1.8 Extracellular matrix
Extracellular matrix (ECM) provides an essential microenvironment for mesenchymal stem
cells and plays an important role in cell adhesion, survival, migration, proliferation,
differentiation and matrix remodeling.174;264;265 Natural ECM provides a structural scaffold to
resist tensile and compressive stress, and functions as a tight connection to the cytoskeleton
of cells through cell-surface receptors to enable cells to sense and respond to mechanical
and chemical signals. Stromal cells and MSCs usually reside within a specific extracellular
regulatory microenvironment containing a complex mixture of ECM signals to direct cell
self-renewal or differentiation. The extracellular signaling includes soluble cytokines and
growth factors, components of ECM such as collagen and mineralized materials and the
interaction between neighboring cells through cell surface receptors.266-268

Bone marrow, the microenvironment for osteoblasts, BMSCs and HSCs, is composed of
calcified bone matrix, type I, III, IV, V and VI collagen, fibronectin, laminin, connecting
proteins and large molecular weight proteoglycans.265;269-271 Growth factors reside in bone
marrow (such as TGF-β, IGF, BMPs) and ECM acts as a reservoir to pass signals to cells
through interaction with cell surface receptors.272-275 In bone marrow, the sustainability of
BMSC self-renewal and the induction of differentiation are supported by the influence of
factors secreted by osteoblasts, the adhesion to ECM and the connections between MSCs
and osteoblasts, HSCs and stromal cells.276;277

In articular cartilage ECM not only provides structural integrity but also has physiological
functions to maintain chondrocyte morphology, direct chondrocyte migration and influence
immune cytokines.8;21;45;159 The components of articular cartilage include type II collagen,
proteoglycans (primarily aggrecan), hyaluronan and other matrix proteins. Cartilage ECM
plays an important role in influencing the microenvironment of chondrocytes through
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cell-matrix receptors.4;278;279

1.8.1 Integrin system and signaling mechanism
Extracellular matrix has a profound influence on cell adhesion, survival, proliferation and
differentiation. The interaction between cells and ECM are mainly dependent on integrins and
other surface receptors.280-282 Here we focus on the integrins of mesenchymal stem cells and
the integrin-dependent intracellular signaling mechanism.

Integrin receptors have a transmembrane structure and are composed of heterodimeric
molecules including α and β subunits. The extracellular domains have contact with ECM and
the cytoplasmic domains associate with cell actin cytoskeleton and protein kinases. Currently
at least 16 α and 8 β subunits of integrins have been identified that can generate 22 distinct
αβ heterodimeric receptors.280;281;283;284 Table 1.5 shows the major integrin heterodimeric
receptors and their protein ligands.281

Integrin subunits

ligands

β 1 α1

Collagens, Laminins

α2

Collagens, Laminins

α3

Collagens, Laminins, Fibronectin, Entacin

α4

Fibronectin, VCAM-1

α5

Fibronectin

α6

Laminins

α7

Laminins

α8

Vitronectin, Fibronectin, Tenascin

α9

Vitronectin, Fibronectin, Tenascin

α10

Collagens

α11

Collagens

αV

Vitronectin, Fibronectin

β 2 αL

ICAM-1. ICAM-2, ICAM-3
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αM

IC3b, Fibronectin, ICAM-1

αX

IC3b, Fibronectin

αD

ICAM-3

β3 αIIβ

Fibronectin, Fibrinogen, von Willebrand factor,
Vitroectin, Thrombospondin, Tenasin

αV

Fibronectin, Fibrinogen, von Willebrand factor,
Vitroectin, Thrombospondin, Osteopontin, Collagens

β 4 α6

Laminins

β 5 αV

Vitronectin, Fibronectin

β 6 αV

Tenasin, Fibronectin

β 7 α4

Fibronectin, VCAM-1

αE
β 8 αV

E-cadherin
Vitroectin

Table 1.5 Integrin receptors and the protein ligands281

Due to the short structure and lack of enzymatic function of the cytoplasmic domains of
integrins, extracellular signaling transduction must be accompanied by cytoskeletal actins,
cytoplasmic kinases and transmembrane growth factor receptors. After contacting with ECM,
integrins cluster in cell membrane, become a signaling complex and associate with
cytoskeletal actin filaments. The reorganized actin filaments in turn accelerate the clustering
of integrin with a positive feedback mechanism. Finally, ECM, integrins and the cytoskeletal
actins aggregate into a large complex through cell membrane to transduce extracellular
signals into cells.281;282;285

Integrins activate several tyrosine kinase; one of those, focal adhesion kinase (FAK), has
been studied in depth. After integrin clustering, the β subunit activated FAK directly or through
cytoskeletal proteins such as talin and paxillin. FAK autophosphorylates Tyr397 and creates a
binding site for Src homology 2 (SH2) domain of Src or Fyn. Src then phosphorylates FAK at
Tyr925 and activates Grb2 and Ras. Phosphorylated FAK eventually activates MAPK
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cascades and modifies cytoskeletal actin filaments.281;282;286 Activation of MAPK cascades
can also be FAK-independent, in which the activation is initiated by integrin α5β1, αVβ3, α2β1,
αVβ6 and α6β4 respectively, when cells adhere to ECM proteins such as fibronectin, collagens,
laminins, virtonectin and tenascin. It is believed that FAK-related proteins such as CAKβ and
PYK2/RAFTK may compensate for FAK to activate the MAPK signaling pathway.280;282;287;288

1.8.2 Typical ECM proteins and their integrin receptors
Fibronectin is one of the major ECM proteins in bone marrow and articular cartilage, and it is
most commonly used as a substrate in MSC expansion in vitro.289-291 Two different integrins,
α5β1 and αVβ3, are identified as the receptors to fibronectin, which recognize a short motif
composed by three amino acid residues (RGD: arginine, glysine and aspartic acid) in
fibronectin.292-295 In addition, integrins of αIIbβ3, αVβ5, αVβ8, αVβ6 and αVβ1 are shown to contact
fibronectin by binding to the RGD motif. α4β1 and α4β7 integrins recognize fibronectin through
an RGD-independent motif but LDV or REDV motif.296-298 The binding of integrins to
fibronectin induces FAK phosphorylation and activation of the MAPK cascade.292;293
Interestingly many proteoglycans and glycosaminoglycans bind to fibronectin and the
interaction between integrins and proteoglycans are associated with syndecans. Syndecans
1, 2 and 3 are only found in specific tissues whereas syndencan 4 is ubiquitous. Integrin
heterodimers bind to proteoglycans with the cooperation of syndecans and syndecans
activate intracellular signaling transduction and induce focal adhesion.292;299-303

Collagen is a main component in bone and cartilage that is recognized by several receptors.
Four collagen receptors of integrin heterodimers are identified including α1β1, α2β1, α10β1 and
α11β1.293;299;300;304 Integrin α1β1, expressed in MSCs, is considered the receptor to type IV
collagen and has a high affinity to non-fibrillar collagens.305-307 Integrin α2β1 is widely
expressed and binds to collagen fibrils and fibrillar collagens.308-310 Integrin α10β1 is found in
cartilage chondrocytes311 and integrin α11β1 plays an important role in tooth development.312
Integrin collagen receptors can recognize proteoglycans with an association with syndecans
that is similar to fibronectin receptors.313;314 In addition to integrin collagen receptors, discoidin
domain receptors (DDRs) and glycoprotein (GP) VI can also bind to collagens and activate
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intracellular signaling pathways.315-317

Laminins are important components of the basement membrane together with type IV
collagen. Four integrin heterodimers are the receptors including α3β1, α6β1, α6β4 and α7β1.293
Integrin α3β1 is essential in the development of kidneys, lungs and skin.318;319 Integrin α7β1 is
found in muscle tissue and is important to muscle development320. Integrin α6β4 is found in
epithelial cells and binds to the basement membranes.321;322 Besides integrin receptors,
α-dystroglycan functions as a laminin receptor that is also known as 67kD laminin receptor
due to its molecular weight.292;323;324

1.8.3 3D vs. 2D ECM and distinct cellular response
The current understanding of interaction between cells and ECM is based on studies of focal
and fibrillar adhesions. Research on cell adhesion, migration, proliferation and differentiation
is primarily derived from in vitro two-dimensional (2D) tissue culture substrate. However, in
vivo three-dimensional (3D) ECM provides a different support to cells and induces distinct
intracellular signaling transductions to influence cell adhesion, motility and proliferation. The
studies of 3D ECM and the induced cell response can improve MSC-based tissue
regeneration including MSC in vitro expansion, tissue-specific differentiation and the design
of novel scaffolds.264;325;326

A novel cell-deposited 3D ECM provides a new approach to study the interaction between
cells and ECM.94;95;325 Traditional 2D ECM involves the deposition of soluble matrix proteins
such as fibronectin, collagen and laminins on culture surface. Compared to traditional 2D
ECM, this natural 3D ECM composes multiple matrix proteins such as type I and III collagen,
fibronectin, heparin sulfate proteoglycans, elastin, laminins and decorin etc. In the structure,
3D ECM is more pliable than 2D ECM, has higher fibrillar matrix and contains the space
originally occupied by the feeder cells generating matrix.325;327;328

An assay using human fibroblasts grown on 3D and 2D ECM showed that the cells attached
to 3D ECM six-fold faster compared to the substrates of fibronectin, collagen, laminin or 3D
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collagen gel.264 In 2D culture, cells adhere to ECM primarily on focal adhesion involving
integrin αVβ3 and fibrillar adhesion depending on integrin α5β1. On 3D ECM, cells adhesion
involves integrin α5β1 and α2β1 and the absence of integrin αVβ3. The focal adhesion is
completely associated with fibronectin-containing fibrils that can be independent of fibronectin
in 2D culture.264;325;326 Meanwhile, phosphorylation of FAK decreases when cells are cultured
on 3D ECM but the activity of Src and ERK1/2 increases, indicating that cell adhesion and
protein kinase activity are different between the 3D and 2D environments.329

The cell proliferation rate on 3D ECM increases at least two-fold in human fibroblasts325 and
12-fold in porcine SDSCs95 compared to cells in 2D culture. The cell migration on 3D ECM is
directional rather than the random migration on 2D culture. Rac is considered to control cell
migration and Rac activity was proven to decrease on 3D ECM. The lower activity of Rac
induced more directional migration.264;325;326 Another reason for the directional movement is
that 3D ECM is more pliable and contains more space than 2D ECM; cells can sense the
rigidity of ECM and move to areas with higher rigidity.264;325;330;331 However, the work on 3D
ECM and cell response is just beginning. Using 3D ECM is a new approach to study cell
behavior, cancer mechanisms, drug delivery and to improve MSC-based tissue regeneration.

1.9 Challenges in cartilage tissue regeneration
Mesenchymal stem cells provide a promising cell source for cartilage tissue regeneration due
to their self-renewal ability and multipotential differentiation capacity. However, there are
several challenges facing the current application of MSC-based cartilage regeneration.

The lack of a unique MSC surface marker makes it difficult to identify and isolate MSCs from
cell pools. Even though it is reported that MSCs must show positive for CD90, CD105 and
CD73 but negative for CD45, CD11b, CD14 or HLA-DR, the percentage of positive surface
markers changes in different MSCs from different tissue sources.332 SSEA-4 is demonstrated
as a positive surface marker in MSCs and the sorting of SSEA-4+ cells indeed enhanced
differentiation including osteogenesis, adipogenesis and chondrogenesis.333 The SSEA-4
positive isolation method is mainly limited to BMSCs, so future work will concentrate on
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testing different tissue-source MSCs. Our negative isolation method using Dynabeads
conjugated with CD14 antibody is an indirect way to purify SDSCs.148;155 This negative
isolation has some drawbacks including the removal of excessive cells up to 50% of the total
population and unbound cells that are a mixed population of SDSCs and synovial fibroblasts.
In future, it is important to identify unique cell surface markers for MSCs and develop a new
isolation method to purify MSCs from other fibroblasts and immune cells.

Self-renewal, the process by which MSCs proliferate and create more cells, is one of the
important properties of MSCs. Maintaining self-renewal ability in vitro is crucial to MSCs as
that it provides sufficient cells for tissue regeneration in vivo. Conventional MSC in vitro
culture requires weekly passaging to retain proliferation rate and preserve future
differentiation potential. However, the late passages of MSCs not only fail to
proliferate140;152;154 but also lose multipotency except for differentiation into adipocytes.334

Another important property of MSCs is the stemness that is defined by the potentials of MSCs
to differentiate into multiple tissues. The loss of multipotency in late-passage MSCs is
possibly due to exposure to enzymes such as trypsin that damages cell surface
proteins.335-338 Another explanation is spontaneous differentiation in the expansion period
affected by serum and the 2D culture environment. Spontaneous differentiation is different
from induced differentiation which is controlled by growth factors. Cells express multiple
differentiation growth factors and cytokines in spontaneous differentiation that significantly
reduce the sensitivity and effectiveness of cells in the future induced differentiation.94;271;339
Tuan and colleagues tried to identify the signature genes that maintain MSC self-renewal and
multipotency. Five specific genes were found expressed in undifferentiated MSCs but absent
in differentiated cells, including actin filament associated protein, frizzled 7, dickkopf 3,
protein tyrosine phosphatase receptor F and RAB3B. The interference of these genes by
siRNA could affect MSC proliferative rate and multipotency.340 However, our understanding of
the stemness of MSCs is poor and it is important to improve the in vitro culture of MSCs to
improve self-renewal and multipotency.
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Figure 1.1

Figure 1.1 The structure of articular cartilage is composed by four zones: the superficial zone,
the middle zone, the deep zone and the calcified cartilage zone. Figures are from Nelson L,
Fairclough J, Archer CW. Use of stem cells in the biological repair of articular cartilage.
Expert.Opin.Biol.Ther. 2010;10:43-55.
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Figure 1.2

Figure 1.2 Histology and immunohistochemistry of hyaline cartilage tissue. Images are from
joint U-diet (A&C) and O-diet (B&D). Safranin O were used to stain sulfated GAGs (A-B) and
immunohistochemistry were probed for type II collagen (C-D). Figures are from Matthew
J.Ravosa, Elisabeth K.Lopez, Rachel A.Menegaz et al. Using ''Mighty Mouse'' to understand
masticatory plasticity: myostatin-deficient mice and musculoskeletal function. Integrative and
Comparative Biology 2008;48:345-59.
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Figure 1.3

Figure 1.3 Three typical cartilage defects were met and studied in clinics, including
subchondral defect, full-thickness defect and osteochondral defect. Figures are from Khan IM,
Gilbert SJ, Singhrao SK et al. Cartilage integration: evaluation of the reasons for failure of
integration during cartilage repair. A review. Eur.Cell Mater. 2008;16:26-39.
*
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Figure 1.4

Figure 1.4 Articular cartilage is the main tissue affected by OA, which becomes softening,
fibrillation, and erosion down to the subchondral bone. In the microscopic level OA results in
chondrocyte cell death and the degradation of cartilage matrix.
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Figure 1.5
(A)

(B)

Figure 1.5 (A) The structure of intervertebral disc contains three avascular tissues: annulus
fibrosus (AF), nucleus pulposus (NP) and the cartilage endplates; (B) the degenerative
disease of intervertebral disc changes the normal organized annulus and soften nucleus
pulposus (left) to desiccated and disorganized tissues (right). Figure 1.5(A) from Smith LJ,
Fazzalari NL. The elastic fibre network of the human lumbar anulus fibrosus: architecture,
mechanical function and potential role in the progression of intervertebral disc degeneration.
Eur.Spine J. 2009;18:439-48. Figure 1.5B from Urban JP, Roberts S. Degeneration of the
intervertebral disc. Arthritis Res.Ther. 2003;5:120-30.
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Figure 1.6

Figure 1.6 The autologous chondrocyte transplantation (ACT) technique biopsy of cartilage
tissue, release of chondrocytes and expansion in vitro, and the intraarticular injection into the
articular cartilage defect. Figure 1.6 from Marlovits S, Zeller P, Singer P et al. Cartilage repair:
generations of autologous chondrocyte transplantation. Eur.J.Radiol. 2006;57:24-31.
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Figure 1.7

Figure 1.7 The procedure of negative isolation method. Cell from the digested synovial tissue
(A) are suspended and incubated with Dynabeads® M-450 CD14 conjugated with a
monoclonal antibody specific for macrophages; then the conjugated cells are removed by
using the Dynal Magnetic Particle Concentrator® and unconjugated cells are supposed “type
B” cells (SDSCs) (B); (C) is the conventional way to isolate SDSCs by passaging.
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Figure 1.8

Figure 1.8 Chondrogenesis of SDSC separately induced by TGF-β1 or TGF-β3. (A) Alcian
blue staining and immunohistochemistry of type II collagen for SDSC pellets after 14-day
induction; (B) Quantification of chondrogenesis index (GAG/DNA) of SDSC pellets induced
by TGF-β1 or TGF-β3 (n = 5).
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Figure 1.9
(A)

(B)

Figure 1.9 Chondrogenesis of SDSC induced by the combination of TGF-β1, IGF-I and
FGF-2. (A) the detail schedule of adoption TGF-β1, IGF-I and FGF-2; (B) the treatment of the
cocktail of TGF-β1 and IGF-I, SDSC pellets had the strongest potential for chondrogenesis.
Group D5 had the extensive expression of sulfate GAGs and type II collagen.
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Figure 1.10

Figure 1.10 In the TGF-β induced signaling pathway, the phosphorylated type I receptor
actives R-Smads, Smad2 and Smad3 specifically. Samd2/3 associates with Co-Smad
(Smad4) and the complex transfers to the nucleus to regulate the expression of target genes
in cooperation with transcription factors. Figure 1.10 from Miyazawa K, Shinozaki M, Hara T
et al. Two major Smad pathways in TGF-beta superfamily signalling. Genes Cells
2002;7:1191-204.
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Figure 1.11

Figure 1.11 TGF-β can induce the activation of MAPK/ERK signaling pathway. In this pathway,
binding of TGF-β to type II receptor induces the activation of type I receptor. The
phosphorylation of Src or Grb2 activates Ras by catalyzing the exchange of GDP to GTP. Ras
then binds to Raf and activates MAPK cascade including MEK and ERK1/2. Figure 1.11 from
Zhang YE. Non-Smad pathways in TGF-beta signaling. Cell Res. 2009;19:128-39.
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Figure 1.12

Figure 1.12 TGF-β can induce JNK and p38 MAPK signaling cascades. TGF-β activate JNK
through MKK4 (MAP kinase kinase 4) and p38 MAPK through MKK3/6. The activated JNK
and p38 MAPK move to the nucleus and initiate the expression of target genes with
transcription factors Figure 1.12 from Zhang YE. Non-Smad pathways in TGF-beta signaling.
Cell Res. 2009;19:128-39.
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Figure 1.13

Figure 1.13 TGF-β can induce PI3K/Akt signaling pathway. PI3K is activated by TGF-β and
then phosphorylate the downstream Akt that is independent of Smads activation. PI3K plays
an important role in cell adhesion, migration and TGF-β-induced actin filament reorganization.
Figure 1.13 from Zhang YE. Non-Smad pathways in TGF-beta signaling. Cell Res.
2009;19:128-39.
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Figure 1.14

Figure 1.14 TGF-β can activate Rho-like GTPase, including RhoA, Rac and Cdc42 to
modulate the cell adhesion, proliferation and survival. The activation of RhoA and Cdc42 by
TGF-β is independent of Smads signaling pathway, indicated by the unaffected activation of
p21-activated kinase (PAK) in the inhibition of Smad2/3 phosphorylation Figure 1.14 from
Zhang YE. Non-Smad pathways in TGF-beta signaling. Cell Res. 2009;19:128-39.
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Figure 1.15

Figure 1.15 The engineered SDSC constructs were strongly positive for sulfated
glycosaminoglycans and type II collagen. Hypertrophic marker, type X collagen was negative.
The mechanical analysis suggested that the SDSC constructs had the similar equilibrium
modulus to the nature hyaline cartilage.
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Figure 1.16

Figure 1.16 The engineered constructs using SDSCs successfully repaired the full-thickness
defects in articular cartilage. Group A was repaired with SDSC constructs; Group B was
repaired with only cell-free scaffolds; Group C was control group with saline.
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ABSTRACT

Joint injury results in cartilage lesions that are characterized by a poor repair response. Adult
stem cells are immensely appealing for biological joint repair, such as cartilage tissue
engineering and regeneration. However, adult stem cells gradually lose their stemness once
they are removed from their in vivo niche for plating in plastic flasks. We utilized a
tissue-specific stem cell, synovium-derived stem cell (SDSC), as a model to reconstruct an in
vitro three dimensional (3D) stem cell niche. After seeding on SDSC-derived extracellular
matrix (ECM), the initially wide and flat SDSCs became thin and spindle-shaped and were
arranged in a 3D configuration with typical stem cell phenotypes. A dramatic increase in cell
number and a greatly enhanced chondrogenic capacity were observed, though surprisingly
the ECM-treated SDSCs did not display concomitantly improved adipogenic or osteogenic
potentials. Thus, we conclude that a tissue-specific stem cell can be used to prepare its own
in vitro niche for stem cell proliferation while maintaining and enhancing its lineage-specific
stemness. The ability to reconstitute the in vitro stem cell niche will greatly benefit
SDSC-based therapy for cartilage defects.

80

INTRODUCTION

Adult stem cells are immensely appealing for tissue engineering and therapeutic applications
because of their general multipotentiality and relative ease of isolation from numerous tissues;
they are currently a leading candidate for a renewable source of transplantable cells. The
effectiveness of stem cell therapy is facilitated by the ability to manipulate the signals that
determine stem cell behavior in a temporal and spatially appropriate fashion, both at the
treatment target site as well as during in vitro processing prior to transplantation. In vitro
expansion represents a formidable challenge since stem cells are thought to exist in niches
where extrinsic signals modulate the intrinsic signals that drive self-renewal and cell fate
determination.1,2 However, outside of their niche, adult stem cells lose their developmental
potential quickly3 and tend to either randomly differentiate or undergo apoptosis over time4.
Though a cocktail of growth factors can be used to increase the number of cells dramatically,
the cells do not maintain stem cell characteristics. Instead, they become more mature,
differentiated progenitor cells which eventually exhaust themselves after having divided a
specific number of times. Therefore, one of the major challenges is controlling the fate of
stem cells outside their natural environment.

In order to successfully translate human adult stem cell biology into applications in
regenerative medicine, it is important to recreate a functional stem cell niche in vitro that
consists entirely of known, xeno-free, and chemically defined factors and molecules.5 Studies
on Drosophila indicate that when germ stem cell (GSC) niches are experimentally “emptied”
of their GSCs, the remaining niches can signal incoming somatic stem cells to take up foreign
residence and at least transiently maintain some of their stem cell features6 and even reverse
the fate of already differentiating cells.7 Here we hypothesized that synovium-derived stem
cell (SDSC)-derived extracellular matrix (ECM) can serve as an in vitro three dimensional (3D)
niche, facilitating SDSC propagation and allowing restoration of stem cell stemness toward
chondrogenesis. In our previous studies, we negatively isolated SDSCs from harvested
synovial tissue8 for in vitro cartilage tissue engineering9 and in vivo tissue transplantation.10
SDSCs are reported as a tissue-specific stem cell for chondrogenesis.11-14 Using minimally
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invasive arthroscopic techniques, it is possible to harvest synovial tissue from patients from
which SDSCs can be isolated. This brings up the intriguing possibility of autologous
transplantation therapy, whereby these isolated SDSCs can be modified and retransplanted.

To date, we know of no studies that present a stem cell-derived ECM exhibiting a ‘niche
effect’ on stem cell proliferation while maintaining stemness for a tissue-specific lineage
except one study that demonstrated that ECM induced differentiation.15 Here we negatively
purified SDSCs from pig synovial cells and engineered SDSC-derived 3D ECM. Partially
differentiated SDSCs (Passage 3) were plated in plastic flasks either with or without ECM
coating for two consecutive passages. The SDSCs grown on 3D ECM exhibited more of the
properties typical of native stem cells compared with those plated on plastic flasks.
ECM-treated SDSCs also displayed a remarkably enhanced chondrogenic capacity but not
adipogenic or osteogenic potential.
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MATERIALS AND METHODS

Isolation and culture of SDSCs
Two 3-month-old pigs were collected from a local slaughterhouse and harvested to provide
synovial tissue from both knees. The synovial tissue was finely minced and digested at 37ºC
for 30 min in 0.1% trypsin (Roche) and then for 2 h in 0.1% collagenase P (Roche) to release
SDSCs. SDSCs were collected from the filtrate by centrifugation and plated in complete
medium [αMEM containing 10% fetal bovine serum (FBS), 100 U/mL penicillin, 100 µg/mL
streptomycin and 0.25 μg/ml fungizone (Invitrogen)]. Nonadherent cells were removed by
medium change every two days. For negative isolation of synovial fibroblasts from primary
cultures, cell suspension (107 cells/mL) was incubated with 5 × 107/mL Dynabeads® M-450
CD14 containing a monoclonal antibody specific for macrophages (Dynal Biotech) at 4ºC for 1
h. The conjugated cells and the unbound Dynabeads® were collected using the Dynal
Magnetic Particle Concentrator® (Dynal Biotech), and the depleted supernatant with synovial
fibroblasts (referred to as SDSCs8) was saved for further passaging.

Preparation of SDSC-derived ECM
Fibronectin (1 µg/cm2, BD Bioscience) was pre-coated on plastic flasks at 37oC for 1 h.
Passage 2 SDSCs were plated in 175-cm2 flasks at a density of 6 × 103 cells/cm2 in complete
medium for 7 days. After SDSCs reached 90% confluence, 50 µM L-ascorbic acid phosphate
(Wako) was added for an additional 8 days. To obtain cell-free ECM, ECM was incubated with
0.5% Triton X-100 (Sigma) containing 20 mM ammonium hydroxide (Sargent-Welch) in PBS
for 5 min at 37ºC. ECM was stored in D-PBS containing 100 U/mL penicillin, 100 μg/mL
streptomycin and 0.25 μg/mL fungizone at 4 ºC.

SDSCs grown on SDSC-derived ECM
Passage 3 SDSCs were plated at 3,000 cells/cm2 in plastic flasks for two passages in two
groups: ECM-coated flasks (ECM) or plain plastic flasks (Plastic). The medium was replaced
every three days. The cell number from both treatments at P4 and P5 was counted using a
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counting hemocytometer for cell proliferation rate.

Scanning Electron Microscope
Representative samples (n=2) were primarily fixed for 2 h at room temperature in 2.5%
glutaraldehyde (Sigma). Secondary fixation was completed for another 2 h in 2% osmium
tetroxide (Sigma). The samples were then dehydrated consecutively in 25%, 50%, 75%, 95%,
and 100% (twice) ethanol for 10 min each, in hexamethyldisilazane (HMDS, Sigma) at a ratio
of 1:1 with ethanol twice for one hour each time, in HMDS at a ratio of 1:2 with ethanol
overnight, and in HMDS 3 times for 4 h each time. The samples were freeze-dried for 24 h
and added with gold sputter. The images were recorded by a scanning electron microscope
(Hitachi, Model S 2400).

FACS analysis
0.5 × 106 SDSCs were incubated for 30 min on ice in PBS containing 5% FBS and 1% NaN3
(Sigma), and then for 30 min on ice with appropriately diluted mouse monoclonal antibodies
to CD29 (Abcam), CD44 (Abcam), CD45 (Abcam), CD68 (BD Pharmingen), CD90 (BD
Pharmingen), and CD105 (GeneTex Inc.) or isotype-matched IgGs [IgG1 and IgG2a
(Beckman Coulter)]. After washing with cold PBS, SDSCs were incubated with the secondary
antibody [FITC-conjugated goat anti-mouse Ig (Abcam)] for 30 min in the dark followed by
fixation in 400µL of 1% paraformaldehyde. Negative control samples received equivalent
amounts of isotype-matched pre-immune antibodies. The cells were analyzed on a BD dual
laser FACSCalibur (BD Biosciences) using the FCS Express 3 software package.

Chondrogenic differentiation of SDSCs
0.3 × 106 of SDSCs, either with or without ECM treatment, from P3 and P5 were placed in
15-ml polypropylene tubes and centrifuged at 500 g for 5 min to form pellets. The pellets were
cultured in chondrogenic medium consisting of high-glucose DMEM, 40 µg/mL proline, 100
nM dexamethasone, 100 U/mL penicillin, 100 µg/mL streptomycin, 0.1 mM ascorbic
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acid-2-phosphate and 1 × ITS™ Premix (BD Biosciences) with the supplementation of 10
ng/mL TGF-β1 (R&D) for 14 days.

Adipogenic differentiation of SDSCs
After 95% cell confluence, the culture medium was switched to adipogenic medium consisting
of growth medium (low glucose DMEM, 10% FBS, 100 U/mL penicillin, 100 µg/mL
streptomycin) supplemented with 10-6 M dexamethasone, 0.5 mM isobutyl-1-methy xanthine,
100 µM indomethacin and 10 µg/mL insulin for an additional 21 days. Adipogenic
differentiation was assessed using Oil Red O stain for adipose oil and TaqMan® real time
PCR for quantification expression of adipogenic marker genes.

Osteogenic differentiation of SDSCs
After 95% cell confluence, the culture medium was switched to calcification medium
consisting of growth medium supplemented with 10-7 M dexamethasone, 10 mM β-glycerol
phosphate, 0.2 mM ascorbate-2-phosphate, and L-glutamine for an additional 21 days.
Osteogenic differentiation was assessed using alizarin red stain for ECM calcification.
TaqMan® real time PCR was used to semi-quantitatively evaluate osteogenic marker gene
expression.

Histochemistry and immunohistochemistry
The pellets (n=3) were fixed overnight at 4ºC in 4% paraformaldehyde, followed by
dehydrating in a gradient ethanol series, clearing with xylene, and embedding in paraffin
blocks. 5-μm sections were histochemically stained with alcian blue (Sigma) and Safranin O
(Sigma). For immunohistochemical analysis, the sections were immunolabeled with primary
antibodies against collagen II (II-II6B3), collagen I (Abcam), and collagen X (Sigma), followed
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by the secondary antibody of biotinylated horse anti-mouse IgG (Vector). Immunoactivity was
detected using Vectastain ABC reagent (Vector) with 3,3’-diaminobenzidine (DAB) as a
substrate.

Biochemical analysis for DNA and GAG content
For biochemical analysis, the pellets (n=6) were digested for 4 h at 60ºC with 125 μg/mL
papain in PBE buffer (100 mmol/L phosphate, 10 mmol/L EDTA, pH 6.5) containing 10
mmol/L cysteine, by using 100 μL enzyme per sample. To quantify cell density, the amount of
DNA in the papain digestion was measured using the QuantiTTM PicoGreen® dsDNA assay kit
(Invitrogen) with a CytoFluor® Series 4000 (Applied Biosystems). GAG was measured using
dimethylmethylene blue dye and a SpectronicTM BioMateTM 3 Spectrophotometer (Thermo
Scientific) with bovine chondroitin sulfate as a standard.

Western blot
To assess non-dissolvable collagen II expression in extracellular matrix, SDSC pellets (n = 3)
were lyophilized and incubated in 4 M guanidine hydrochloride (GuHCl, Sigma) for 20 h at
4ºC, then digested with 0.6 mg/ml of pepsin (Sigma) in 0.5 M acetic acid at 4ºC for 48 h at a
ratio of 10:1 (mg/mg) dry sample to pepsin. The samples were centrifuged at 48,000 g for 1 h,
and the supernatant was lyophilized and dissolved in radioimmunoprecipitation assay (RIPA)
buffer with protease inhibitors (Pierce). To assess dissolvable collagen II expression in
cytoplasm, the pellets were homogenized and dissolved in RIPA buffer with protease
inhibitors. Total proteins were quantified using BCATM Protein Assay Kit (Pierce). 40 μg
protein from each sample was denatured and separated using NuPAGE® Novex® Bis-Tris
Mini Gels (Invitrogen) in the XCell SureLockTM Mini-Cell (Invitrogen) at 120 volts for 3 h at 4°C.
Bands were transferred onto a nitrocellulose membrane (Invitrogen) using an XCell ΙΙTM Blot
module (Invitrogen) at 15 volts overnight at 4°C. The membrane was incubated with a primary
monoclonal antibody against collagen II (II-II6B3) in 1% non-fat milk in TBST for 1 h at room
temperature (β-actin served as an internal control), followed by the secondary antibody of
HRP-conjugated goat anti-mouse (Pierce) for 40 min at room temperature and exposure
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using SuperSignal West Femto Maximum Sensitivity Substrate (Pierce) and CL-XPosure
Film (Pierce).

TaqMan® Quantitative PCR
The total RNA was extracted from samples (n=4) using an RNase-free pestle in TRIzol®
(Invitrogen). 1 µg of mRNA was used for reverse transcriptase (RT) with High-Capacity cDNA
Archive Kit at 37ºC for 120 min as recommended by the manufacturer (Applied Biosystems).
Chondrogenic marker genes (types I, II, X collagen, Sox 9, and aggrecan), adipogenic
marker genes (LPL, PPARγ, and C/EBPα), and osteogenic marker genes (OCN, SPP1, and
type I collagen) were customized by Applied Biosystems as part of the Custom Taqman®
Gene Expression Assays (Table 1). Eukaryotic 18S rRNA (Assay ID HS99999901_s1 ABI)
was carried out as the endogenous control gene. Real-time PCR was performed with the
iCycler iQTM Multi Color RT-PCR Detection and calculated by computer software
(Perkin-Elmer). Relative transcript levels were calculated as χ=2-ΔΔCt, in which ΔΔCt=ΔE-ΔC,
ΔE=Ctexp-Ct18s, and ΔC=Ctct1-Ct18s.

Statistics
The Mann-Whitney U test was used for pairwise comparison in biochemistry analysis and
real-time PCR data. All the statistical analysis was performed with SPSS 13.0 statistical
software (SPSS Inc., Chicago, IL). P values less than 0.05 are considered statistically
significant.
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RESULTS

SDSC-derived ECM serves as an in vitro 3D stem cell niche
After using SDSCs to prepare 3D ECM substrate, Passage 3 (P3) SDSCs were plated in
plastic flasks with (Figure 2.1A) or without (Figure 2.1B) ECM coating at the same initial cell
density for 10 days. At day 2, SDSCs grown on ECM were thinner and more spindle-shaped
though both groups exhibited similar cell distribution. After 4 days, SDSCs plated on plastic
flasks proliferated slowly; in contrast, SDSCs grown on ECM increased their cell number
dramatically and reached confluence at day 5 [shown by phase contrast microscope (PCM)]
and were arranged in order [shown by scanning electron microscope (SEM)]. At day 9,
SDSCs plated on plastic flasks became wider and flattened (shown by PCM and SEM); in
contrast, ECM-treated SDSCs overlapped in 3D format (shown by PCM) with tightly
organized cell distribution (shown by SEM).

To assess SDSC proliferation efficiency, P3 SDSCs were plated in plastic flasks either with
(red line) or without (blue line) ECM coating for two continuing passages (Figure 2.1C). In the
first passage (Passage 4, P4), ECM-treated SDSCs increased in cell number 17.5-fold
compared with 6.5-fold for SDSCs plated on plastic flasks. For the last passage (Passage 5,
P5), ECM-treated SDSCs increased in cell number 37.9-fold compared with 2.6-fold for
SDSCs plated on plastic flasks. In total, SDSCs grown on ECM yielded a total cell number
39.2-fold more than those incubated on plastic flasks after two-passage expansion.

The SDSC-derived cell-free ECM exhibited a nanosized 3D fibrillar structure (the diameter for
nanofibers was approximately 45.09 ± 8.83 nm) as revealed by SEM (Figure 2.1D). Once the
ECM was detached from the flasks, ECM tension switched from “stressed” to “relaxed”, which
is similar to a natural scaffold. Cartilage associated structural matrix proteins were assessed
in SDSC-derived ECM by safranin O staining for sulfated glycosaminoglycans (GAGs) and
immunostaining for collagens I, II, and X (Figure 2.1E), suggesting that the ECM was
predominantly composed of collagen I.
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SDSCs grown on SDSC-derived ECM regain stem cell phenotypes
We assessed the phenotype expression profiles from SDSCs with or without ECM treatment,
including mesenchymal stem cell (MSC) surface markers (CD29, CD44, CD90, and CD105,
Figure 2.2A) and a hematopoietic stem cell (HSC) marker (CD45) as well as a
monocyte/macrophage marker (CD68) (Figure 2.2B). There was no CD45 or CD68
detectable in SDSCs (Figure 2.2B), probably due to monocytes and macrophages having
been removed by negative selection (8, 9). The percentage of CD90-positive-SDSCs at P3
was 13.32% and increased dramatically to 66.15% at P4 and 79.87% at P5 when SDSCs
were propagated on SDSC-derived ECM. When SDSCs were incubated on plastic flasks,
however, only a small increase was observed (13.32% at P3 versus 18.03% at P4 versus
28.15% at P5) (Figure 2.2C). CD90 percentage data were also consistent with CD90 mean
fluorescent intensity (MFI) data, which was more intense in ECM-treated SDSCs than SDSCs
plated on plastic flasks (30.46 versus 15.47 at P5) (Figure 2.2D). An important indicator of
chondrogenic potential16, the CD90 data suggested that ECM-treated SDSCs may regain
their capacity for differentiating toward chondrogenesis. Surprisingly, the percentage of
CD29-positive-SDSCs was lower in treatment with ECM than that plated on plastic flasks
(81.89% versus 96.52%) at P5 (Figure 2.2C), which was consistent with CD29 MFI tendency
(29.48 versus 57.13) (Figure 2.2D). There was no obvious difference between the two
treatments in CD105-positive-SDSCs (18.78% for ECM versus 19.71% for Plastic) and
CD44-positive-SDSCs (99.31% for ECM versus 99.19% for Plastic) at P5 (Figure 2.2C).

SDSCs propagated on ECM enhance their capacity toward chondrogenesis
To define the potentially protective effects of SDSC-derived ECM on SDSC determination,
pellets from passage 3 SDSCs grown on plastic flasks (P3.Plastic), passage 5 SDSCs grown
on plastic flasks (P5.Plastic), or passage 5 SDSCs grown on ECM (P5.ECM) were incubated
in chondrogenic medium for 14 days. Histochemical and immunohistochemical staining
showed that SDSCs propagated on ECM displayed greatly enhanced chondrogenic potential
(Figure 2.3A). At day 0, there was no detectable positive staining in pellets from all three
groups. At day 7, sulfated GAGs were intensely stained in P5.ECM pellets compared with
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much less staining in P3.Plastic pellets and were almost non-detectable in P5.Plastic pellets.
At day 14, the staining trend for sulfated GAGs became more obvious with the most intense
expression in P5.ECM pellets and the least expression in P5.Plastic pellets. Another key
marker, collagen II, displayed a similar staining profile as sulfated GAGs. As an early marker
of chondrogenesis, collagen I expression became weaker at days 7 and 14 in P5.ECM pellets
in contrast with being more intense at day 14 in pellets from SDSCs plated on plastic flasks,
suggesting that P5.ECM pellets undergo chondrogenic differentiation much earlier than those
from either P5.Plastic or P3.Plastic. Interestingly, compared with SDSCs plated on plastic
flasks, at day 14, ECM-treated SDSCs formed pellets surrounded with a unique “false
membrane”, which stained positively for collagen II instead of sulfated GAGs and collagen I.
There was no type X collagen detectable in pellets from any of the three groups.

To quantify stem cell proliferation and chondrogenic differentiation at the protein level in a
pellet culture system, we performed biochemical analyses for DNA content per pellet and
ratio of GAG to DNA (chondrogenic index) as well as western blot for collagen II expression in
cytoplasm (immature type) and extracellular matrix (mature type). After incubation in
chondrogenic medium, DNA contents (Figure 2.3C) from both SDSC pellets at P5 were
shown to decrease with time. However, after day 14, DNA content in pellets from SDSCs
grown on ECM was maintained until day 14 (1.31 ± 0.07 µg per pellet) compared with a
continuing drop in pellets from SDSCs plated on plastic flasks (1.03 ± 0.06 µg per pellet). The
chondrogenic index (Figure 2.3D) increased in pellets from all three groups with time, except
for P5.Plastic pellets between day 0 and day 7. At day 14, P5.ECM SDSCs yielded pellets
with the highest chondrogenic index (39.37 ± 3.05) compared with P3.Plastic SDSCs (12.77 ±
1.21), and P5.Plastic SDSCs yielded pellets that had the lowest chondrogenic index (5.19 ±
1.11). At day 0, however, P5.Plastic SDSCs formed pellets with the highest chondrogenic
index (1.05 ± 0.29) compared with P3.Plastic SDSCs (0.47 ± 0.11), while P5.ECM SDSCs
formed pellets with the lowest chondrogenic index (0.21 ± 0.39), suggesting that SDSCs
grown on ECM displayed not only less differentiation and highly proliferative stem cells but
also tremendously enhanced chondrogenic potential. Our western blot data (Figure 2.3B)
showed that collagen II protein was detectable in both cytoplasm and extracellular matrix of
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P5.ECM pellets at days 7 and 14; however, collagen II was detectable only in the cytoplasm
of P5.Plastic pellets at day 14, which is consistent with our above histology and biochemical
data.

We also quantitatively assessed chondrogenic marker gene expression in SDSC pellets. The
mRNA profiles for collagen II (Figure 2.3E) and aggrecan (Figure 2.3F) were similar to the
chondrogenic index at the protein level (Figure 2.3D). At day 7, collagen II mRNA in P5.ECM
pellets was 160-fold higher than those from P3.Plastic, and 330-fold higher than those from
P5.Plastic. At day 14, collagen II mRNA in P5.ECM pellets was 6-fold higher than those from
P3.Plastic, and 95-fold higher than those from P5.Plastic. Sox 9 mRNA (Figure 2.3G) in
P5.ECM pellets increased dramatically at day 7 and remained stable until day 14 compared
with that at a low level in P5.Plastic pellets, probably accounting for the high expression of
collagen II at day 7. In SDSC pellets from P5.ECM, collagen I mRNA (Figure 2.3H) transiently
increased in the early phase and dropped to the lowest expression at day 14 compared with
that in pellets of SDSCs plated on plastic flasks, indicating the maturity of ECM-treated SDSC
pellets. In the meantime, the low level of collagen X mRNA (Figure 2.3I) suggested that ECM
treatment could prevent SDSCs from hypertrophic differentiation.

ECM does not retain SDSCs’ potential for adipogenic and osteogenic differentiation
Under stimulation by the cocktail for adipogenic differentiation, P3.Plastic SDSCs exhibited
more lipid vacuoles than those from either P5.Plastic or P5.ECM (Figure 2.4A).
Adipose-specific genes, such as lipoprotein lipase (LPL, Figure 2.4B), peroxisome
proliferator-activated receptor gamma (PPARγ, Figure 2.4C), and CCAAT/enhancer binding
protein alpha (C/EBPα, Figure 2.4D) were quantified to assess their relative mRNA level.
P3.Plastic SDSCs had the highest expression in all three adipogenic marker genes. P5.ECM
SDSCs displayed higher (LPL mRNA and C/EBPα mRNA) or similar (PPARγ mRNA)
expression of adipogenic marker genes compared with P5.Plastic SDSCs. Our quantitative
PCR data indicated that adipogenic capacity was not improved with each passage even with
ECM treatment.
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Under stimulation by the cocktail for osteogenic differentiation, SDSCs underwent a change
in morphology from spindle-shaped to cuboidal, and formed large nodules, which were
observed with a PCM and were positive for Alizarin Red staining compared with negative
controls (Figure 2.5A). This process was demonstrated by a significant increase in the
expression of osteogenesis specific genes, including osteocalcin (OCN, Figure 2.5B),
secreted phosphoprotein 1 (SPP1/osteopontin, Figure 2.5C) and collagen α1 (Col I, Figure
2.5D). In all three osteogenic marker genes, P3.Plastic SDSCs had the highest expression
while SDSCs from P5.ECM SDSCs had the lowest expression, indicating SDSCs grown on
ECM exhibited decreased osteogenic capacity.
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DISCUSSION

As a tissue-specific stem cell, SDSCs are promising MSCs for cartilage tissue engineering
and regeneration. However, like other MSCs, SDSCs exhibit diminished proliferation and
differentiation capacity when they are expanded on standard plastic flasks, which presents a
number of problems in the clinical setting. In this study, we successfully engineered an in vitro
3D stem cell niche using SDSC-derived ECM for improving SDSC proliferation while
enhancing SDSC stemness toward chondrogenesis. In contrast, SDSCs grown on plastic
flasks displayed diminished replicative capacity and increased random multi-differentiation
properties. We also demonstrated that ECM-treated SDSCs do not regain their adipogenic
and osteogenic potential, suggesting that an in vitro 3D stem cell niche facilitates SDSC
propagation while allowing SDSCs to retain or even reinforce stemness for chondrogenic
differentiation.

The stem cell niche is a specialized microenvironment that helps sustain the stem cell pool
within each tissue or organ system 4. Typically, even with considerable variation in niche
design, there are three key components in the niche concept: supporting niche cells,
supporting ECM with growth-modulating factors, and the physical characteristics of the
surrounding 3D structures.17,18 Of them, niche cells are normally a heterogeneous cell
population and act to limit or control stem cell division. For instance, osteoblasts, the HSC
niche cells, maintain HSC quiescence19 by producing osteopontin, which suppresses stem cell
expansion20. Thus, in native tissue, a loss of niche cells may result in overproliferation of stem
cells. Recently, growing evidence suggests that some stem cells can create their own
microenvironments.21-23 Stem cells may play an important role in organizing and specifying
their niche, and conversely the architectural design of a niche appears to be specifically
tailored to suit the particular needs of its resident stem cells.24 Tissue-specific matrices clearly
influence developmental lineage choices, and thus whole tissue and organ formation.25 In
such a microenvironment, adult stem cells are expected to expand greatly while retaining their
stemness for a tissue-specific lineage. In our study, SDSCs were used to create their own
microenvironments without supporting niche cells. When partially differentiated SDSCs were
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seeded in such a niche, the morphological transformation accelerated from wider, flattened
cells to thinner, spindle-shaped cells, demonstrating that SDSC-derived ECM can restore
SDSCs back to the original size and shape observed in their natural niche. After the initial lag,
the cell numbers were dramatically expanded with cells growing in a 3D format. Phenotypic
characterization demonstrated that SDSCs grown on ECM retained and possibly enhanced
stem cell stemness. Differentiation data clearly indicated that SDSCs grown on SDSC-derived
ECM regained stemness specifically toward the chondrogenic lineage but not toward
adipogenic or osteogenic lineages, supporting reports that stem cell niches act to protect the
self-renewing, undifferentiated state of the cells within and regulate the rate of production of
committed, tissue-specific progenitors.26 Although the presence of niche cells in an in vivo
niche act to limit or inhibit stem cell proliferation and maintain its multi-differentiation potential,
our findings indicate that in an in vitro niche, the absence of niche cells may be associated with
restoring stem cell proliferation and enhancing tissue-specific lineage differentiation capacity.
The underlying mechanisms need further elucidation.

The geometry, composition, and stiffness of the ECM surrounding cells residing in their niche
also have major effects on cell signaling and behavior.27-29 While ECM is known to serve as a
reservoir for growth factors and cytokines,25 our study demonstrated that SDSC-derived ECM
is a 3D matrix consisting of nanostructured fibers with collagen I as one of the major structural
proteins. ECM adhering on plastic flasks through fibronectin exhibited substrate tension,
reported to up-regulate type I collagen polymerization.30 The presence of greater amounts of
type I collagen may contribute to a physical architecture that transmits different mechanical
cues to their resident cells.31 Because there is a growing body of evidence that cell
attachment, proliferation, and migration will be enhanced when cells grow in a more
physiologically similar environment as opposed to standard 2D tissue culture substrates,27,31,32
creating such an in vitro functional niche becomes a vital step to restoring the full potential of
stem cells for therapeutic applications and may also have important implications for research
regarding niche-related signal transduction. For example, signaling by morphogens,
particularly through the Wnt, Notch and Hedgehog pathways, is known to be important for the
self-renewal of many adult stem cell types.33-35 With further study in the context of stem
94

cell-derived ECM, functional in vitro niches, may implicate these signals in even more
complex roles. Although most proliferative signals seem to concurrently stimulate the
commitment to differentiation,36 our study suggests that an in vitro stem cell niche can
encourage stem cell self-renewal and prevent both undesired differentiations and exhaustion,
consequently improving the potential of the cell population as a whole. Communication within
the niche is essential for the maintenance of proper stem cell function and for determining the
rate of stem cell self-renewal. Further studies are needed to determine which of these ECM
molecules are crucial for the maintenance of the undifferentiated stem cell phenotype, the
underlying tissue-specific stem cell signalling pathways, and the mechanical interactions
between the ECM and seeded cells. This in vitro stem cell niche provides a promising and
reliable approach in re-programming stem cells for either investigational or therapeutic
purposes.
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FIGURE LEGENDS

Figure 2.1. Effect of SDSC-derived ECM on SDSC morphology and proliferation. (A)
Passage 4 SDSCs grown on SDSC-derived ECM at days 2, 5, and 9.

(B) Passage 4

SDSCs grown on plastic flasks at days 2, 5, and 9. Phase contrast microscope (PCM) and
scanning electron microscope (SEM) were used to evaluate SDSC morphology properties. (C)
Cell proliferation from Passage 3 SDSCs grown in plastic flasks either with or without ECM
coating for two consecutive passages. (D) SDSC-derived ECM attaching on plastic flasks
(“stressed” ECM) or detaching from plastic flasks (“relaxed” ECM). (E) SDSC-derived ECM
was stained with Safranin O for sulfated GAGs, and immunostained for chondrogenic matrix
(collagens I, II, and X). All scale bars are 200 μm.

Figure 2.2. Quantitative flow cytometry analysis of typical cell surface antigens (red color)
from

MSC

(CD29,

CD44,

CD90,

CD105)

(A)

and

HSC (CD45)

as

well

as

monocyte/macrophage (CD68) (B) with isotype-specific control. The percentage of positive
cells (C) and mean fluorescent intensity (MFI) (D) were also shown for MSC phenotype
changes in SDSCs grown in plastic flasks with or without ECM coating for two consecutive
passages.

Figure 2.3. Distinctively chondrogenic capacity from SDSCs grown on SDSC-derived ECM.
The pellets from P3 and P5 SDSCs were incubated in chondrogenic medium for 14 days. (A)
Alcian blue and Safranin O staining were used to detect sulfated GAGs, and immunostaining
was used to detect collagens I, II, and X. The scale bar is 800 µm. (B) Western blot was used
to detect collagen II protein either in the pellet matrix (mature type) or in cytoplasm (immature
type) of differentiated SDSCs. Three independent experiments were performed. Biochemical
analyses were used to detect DNA content per pellet (C) and ratio of GAG to DNA (D).
TaqMan real time PCR was used to quantitatively assess chondrogenic markers [collagen II
(E), aggrecan (F), Sox 9 (G), collagen I (H), and collagen X (I)] at the mRNA level. Significant
differences are indicated as follows: * = p < 0.05;

**

= p < 0.01; and

***

= p < 0.001. Data are

shown as average ± SD for n = 6 in biochemical analyses and n = 5 in real time PCR.
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Figure 2.4. Adipogenic differentiation of SDSCs. The SDSCs from P3.Plastic, P5.Plastic or
P5.ECM were incubated in adipogenic induction medium for 14 days. PCM was used to
detect adipose vacuoles, which was also confirmed by Oil Red O staining (A). The SDSCs
incubated in DMEM with 10% FBS served as a control and are referred to as either a control
for PCM (“P”-Control) or a control for Oil Red O (“O”-Control). All scale bars are 200 μm.
TaqMan real time PCR was also used to quantitatively assess relative gene expression of
adipogenic markers [LPL (B), PPARγ (C), and C/EBPα (D)]. Significant differences are
indicated as follows: * = p < 0.05 and ** = p < 0.01. Data are shown as average ± SD for n = 5
in real time PCR.

Figure 2.5. Osteogenic differentiation of SDSCs. The SDSCs from P3.Plastic, P5.Plastic or
P5.ECM were incubated in osteogenic induction medium for 14 days. PCM was used to
detect bone nodules, which was also confirmed by Alizarin Red staining (A). The SDSCs
incubated in DMEM with 10% FBS served as a control and are referred to as either a control
for PCM (“P”-Control) or a control for Alizarin Red (“A”-Control). All scale bars are 200 μm.
TaqMan real time PCR was also used to quantitatively assess relative gene expression of
osteogenic markers [OCN (B), SPP1 (C), and Collagen I (D)]. Significant differences are
indicated as follows: * = p < 0.05; ** = p < 0.01; and *** = p < 0.001. Data are shown as average
± SD for n = 5 in real time PCR.
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Table 2.1. TaqMan® Customized Porcine Marker Gene Primers and Probes

Genebank
Name

Primer/Probe

Sequence (5’-3’)
Accession

Chondrogenic markers

Aggrecan

Col I α1

Col II α1

Forward

GCCACTGTTACCGCCACTT

Reverse

CACTGGCTCTCTGCATCCA

Probe

CTGACCGGGCGACCTG

Forward

CCGTGCCCTGCCAGATC

Reverse

CAGTTCTTGATTTCGTCGCAGATC

Probe

TCGCACAACACATTGC

Forward

TCCTGGCCTCGTGGGT

Reverse

GGGATCCGGGAGAGCCA

Probe

Col X α1

Sox 9

GGCCCGGCAGGTCATC

Reverse

TGGGATGCCTTTTGGTCCTT

AF201724

NM_001005153

TCAGACCTGGTTCCCC

Forward

TGGCAAGGCTGACCTGAAG

Reverse

GCTCAGCTCGCCGATGT

Probe

AF201723

CTCCCCTGGGAAACC

Forward

Probe

X60107

AF029696

CCCCATCGACTTCCGC

Adipogenic markers

LPL

Forward

GATTCATACTTCAGCTGGTCCAACT

Reverse

CTGCCTTCACTCTGATCTTCTCAAT

Probe

CEBP/a

CCAGGGCTGCTCCACC

Forward

AAGCGGGTGGAACAACTGA

Reverse

GCAGCTGGCGGAAGATG

Probe

X62984

AF103944.1

CCGCAGCGTGTCCAG

Forward

AGGGCGATCTTGACAGGAAAG

Reverse

ATCTTCTCCCATCATTAAGGAATTCATGTC

PPARr

AF059245
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Probe

CCACAGACAAATCACC

Osteogenic markers

OCN

Forward

CCTGCTGGCCTGGCT

Reverse

CCGGGCAGGGAAGTCA

Probe

SPP1

Col I α1

CAGCACGCCCAGCTC

Forward

CCCAAGGCCATCCTCGTT

Reverse

GTCTCCTGACTGTCCTTCTCTTG

Probe

AY150038.1

CCCAGCGCCTGCACG

See chondrogenic markers
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ABSTRACT

Objective.

To improve the proliferative capacity and chondrogenic differentiation potential

of adipose stem cells (ASCs) by large-scale ex vivo expansion on either ASC- or
synovium-derived stem cell (SDSC)-derived extracellular matrix (ECM) followed by
differentiation in a serum-free chondrogenic medium.
Methods.

ASCs isolated from porcine infrapatellar fat pad were expanded in plastic flasks

coated with ECM deposited by either ASCs or SDSCs for two passages. ASCs grown in
non-coated flasks served as a control. The expanded ASCs were evaluated for cell
proliferation and intracellular reactive oxygen species (ROS). The cells were centrifuged to
form pellets and cultured in a serum-free chondrogenic medium with either 10 ng/mL
transforming growth factor beta 3 (TGF-β3) or 10 ng/mL TGF-β3 combined with 10 ng/mL
bone morphogenetic protein 6 (BMP-6) for 14 days. The expanded ASCs were also
evaluated

for

their

chondrogenic

differentiation

capacity

using

histology,

immunohistochemistry, biochemistry, and real-time PCR.
Results. The cell number yielded on ECM expansion did not show significant difference in
deposition between ASCs and SDSCs and was 6 to 10 times that grown on conventional
plastic flasks. ECM-expanded ASCs exhibited a lower ROS level compared to those grown
on non-coated flasks. Our histology data showed that typical chondrogenic markers,
including type II collagen and glycosaminoglycans, were intensively distributed in the pellets
from ECM-expanded ASCs instead of those from flask-grown cells. Our biochemical analysis
data indicated that ASCs expanded on ECM, either from ASCs or SDSCs, exhibited a similar
chondrogenic index (GAG/DNA), which was significantly higher than that from ASCs grown
on plastic flasks. The combination of TGF-β3 and BMP-6 increased 36% more in ASC
chondrogenic index than the treatment with TGF-β3 alone. Real-time PCR was consistent
with the above data. Interestingly, ECM pretreatment also decreased expanded ASC
hypertrophy (ALP and MMP13). ECM deposited by either ASCs or SDSCs did not exhibit
enhanced adipogenic differentiation of ASCs.
Conclusion.

Ex vivo expansion of ASCs on ECM, deposited by either ASCs or SDSCs, had

a dramatic increase in cell proliferation and chondrogenic differentiation capacity. The
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expanded cells did not display a similar increase in adipogenesis even on ECM deposited by
ASCs. The supplementation of BMP-6 enhanced TGF-β3-induced ASC chondrogenesis
while inhibiting concomitant hypertrophy. The sequential application of ECM for cell
expansion and combined TGF-β3 with BMP-6 for chondrogenic differentiation may be a
promising approach for ASC-based cartilage tissue engineering and regeneration.
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INTRODUCTION

Articular cartilage is an avascular tissue with limited capacity for self-repair. Current treatment
options for cartilage injuries vary greatly in success rates. Autologous chondrocyte
transplantation (ACT) has shown promising results in early clinical studies

[1]

but, recently,

randomized trials indicate little difference in the efficacy of this procedure compared with that
of inducing subchondral bone microfracture [2]. This approach has also been associated with
significant donor-site morbidity and the initiation of osteoarthritic changes in the joint

[3]

,

suggesting the need for alternative cell sources for cell-based cartilage repair.

An emerging body of literature suggests that the adult stem cell is a promising cell source for
cartilage repair due to its proliferation and multilineage differentiation capacity. Of the stem
cells, bone marrow stromal cells (BMSCs) and adipose stem cells (ASCs) are two typical
stromal populations isolated from a fatty compartment with similar properties in terms of
immunogenicity, growth kinetics, cell senescence, gene transduction efficiency, and surface
marker expression

[4-6]

. Despite a better chondrogenic potential, BMSCs also showed a

stronger propensity than ASCs toward a hypertrophic chondrocyte phenotype [7-10]. Compared
to bone marrow with one stem cell in one hundred thousand cell population, the average yield
from adipose tissue is in the range of 200,000 – 290,000 cells/g of tissue [11], making adipose
tissue an abundant and accessible source of stem cells for cell-based therapy.

Despite easy access and abundance, the chondrogenic potential of ASCs from subcutaneous
adipose tissue was much weaker than that of BMSCs

[12,13]

. In contrast, ASCs from the

infrapatellar fat pad (IPFP) exhibited higher chondrogenic capacity
protein (SZP)-producing phenotypes

[16]

. Like synovial tissue

[14,15]

and surface zone

[17]

, the IPFP also has the

potential to self-regenerate after removal from joints [18] and can be obtained arthroscopically
by the orthopaedic surgeon with minimal invasion and without causing complications at the
donor site. However, synovial tissue in patients with osteoarthritis may be heterogeneous due
to fibrotic or hemorrhagic changes or inflammation

[19]

; in contrast, inflammatory changes in

IPFP of the osteoarthritic knee were less frequent. Therefore, the IPFP may be a better cell
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source for superficial zone cartilage tissue engineering for osteoarthritic patients.

The goal of this study was to find an ex vivo expansion approach for the reprogramming of
IPFP-derived ASCs toward chondrogenesis. Our recent study suggested that extracellular
matrix (ECM) deposited by synovium-derived stem cells (SDSCs) enhanced the seeded
SDSC proliferation and chondrogenic differentiation capacity but not adipogenic and
osteogenic differentiation ability

[20]

. These results indicate that ECM deposited by a

tissue-specific stem cell can provide an in vitro 3D microenvironment for stem cell
rejuvenation toward chondrogenesis. In this study, we evaluated the efficiency of
IPFP-derived ASCs expanded by ECM, deposited either from ASCs or SDSCs, in order to
identify whether the chondrogenic capacity of ASCs will be enhanced after expansion on
ECM and whether ECM deposited by different cell types will have a different reprogramming
effect. Our study also evaluated whether or not bone morphogenetic protein 6 (BMP-6) would
enhance transforming growth factor beta3 (TGF-β3)-induced chondrogenic differentiation but
inhibit hypertrophy.
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MATERIALS AND METHODS

Isolation and culture of ASCs and SDSCs
The protocol was approved by the West Virginia University Animal Care and Use Committee.
The IPFP and synovial membrane were harvested from both knees of two 3-month-old
minipigs (Marshall BioResources, North Rose, NY) and finely minced into pieces with scapel
blades. The IPFP tissue was digested in 0.1% collagenase P (Roche, Indianapolis, IN) at 37ºC
for 1 h to release ASCs. The synovial membrane was digested at 37ºC in 0.1% trypsin (Roche)
for 30 min and then in 0.1% collagenase P (Roche) for 2 h. Both released cells were filtered
through 70-μm nylon filter (BD Falcon, Bedford, MA) and plated at 3000 cells/cm2 in complete
medium [α-minimum essential medium (α-MEM, Invitrogen, Carlsbad, CA) containing 10%
fetal bovine serum (FBS, Atlanta Biologicals, Lawrenceville, GA), 100 U/ml penicillin, 100
µg/ml streptomycin and 0.25 μg/ml fungizone (Invitrogen)] at 37ºC in humidified 5% CO2 and
21% O2 incubator. Nonadherent cells were removed by medium change every two days. For
negative isolation of SDSCs from primary cultures

[21]

, a cell suspension (107 cells/mL) was

incubated with 5 × 107/mL Dynabeads® M-450 CD14 containing a monoclonal antibody
specific for macrophages (Dynal Biotech, Oslo, Norway) at 4ºC for 1 h. The conjugated cells
and the unbound Dynabeads® were collected using the Dynal Magnetic Particle Concentrator®
(Dynal Biotech), and the depleted supernatant with SDSCs was saved for further passaging.

Preparation of ASC-ECM and SDSC-ECM
The procedure of obtaining cell-free ECM was described in our previous study

[20]

. Briefly, 75

cm 2 of plastic flasks and 6-well plates were pretreated with 0.2% gelatin solution (Sigma, St.
Louis, MO) for 1 h at 37̊C, followed by 1% glutaraldehyde (Sigma) and 1 M ethanolamine
(Sigma) sequentially for 30 min each at room temperature. Passage 3 ASCs and SDSCs
were seeded on pretreated plastic flasks and 6-well plates at 3000 cells/cm2 in complete
medium for 7 days. When cells reached 90% confluence, culture medium was supplemented
with 50 μg/mL L-ascorbic acid phosphate (Wako Chemicals USA Inc., Richmond, VA) for an
additional 8 days. The ECMs deposited by ASCs and SDSCs were incubated with 0.5%
Triton X-100 (Sigma) containing 20 mM ammonium hydroxide (Sargent-Welch, Skokie, IL) at
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37ºC for 5 min.

Culture of ASCs on Plastic and ECM
Passage 1 ASCs were cultured in complete medium for two passages in three conditions:
plastic flasks (Plastic), flasks coated with ASC-derived ECM (AECM), and flasks coated with
SDSC-derived ECM (SECM). The culture period for each passage was seven days and the
medium was changed every 3 days. At each passage, cell number was counted using a
counting hemacytometer (Hausser Scientific, Horsham, PA) for cell proliferative rate.

Measurement of intracellular reactive oxygen species (ROS)
Intracellular

ROS

generation

was

measured

with 2′,7′-dichlorofluorescein-diacetate

(DCFH-DA) (Sigma). In brief, 0.2 × 106 of the detached ASCs were washed with PBS and
incubated in 10 μM DCFH-DA at 37ºC for 10 min. After washing twice with PBS, the
fluorescence

from′,7′2

-dichlorofluorescein

(DCF)

was

analyzed

by

a

dual-laser

fluorescence-activated cell sorting (FACS) Calibur CytoFluorimeter (BD Biosciences, Bedford,
MA) using FCS Express Software Package (De Novo Software, Los Angeles, CA) and 20000
events of each sample were analyzed.

Chondrogenic differentiation of the expanded ASCs
3 × 105 of ASCs at passage 1 and passage 3 cultured on Plastic, AECM and SECM were
centrifuged at 500 g for 5 min to form a pellet in a 15-ml polypropylene tube. After 24 h of
incubation, the pellets were incubated in a serum-free chondrogenic medium [high-glucose
DMEM, 40 µg/ml proline (Sigma), 100 nM dexamethasone (Sigma), 100 U/ml penicillin, 100
µg/ml streptomycin, 0.1 mM ascorbic acid-2-phosphate and ITS™ Premix (6.25 µg/mL insulin,
6.25 µg/mL transferrin, 6.25 µg/mL selenous acid, 5.35 µg/mL linoleic acid and 1.25 µg/mL
bovine serum albumin, from BD Biosciences] with the supplementation of 10 ng/ml of TGF-β3
(PeproTech Inc., Rocky Hill, NJ) alone or 10 ng/mL of TGF-β3 combined with 10 ng/ml of
BMP-6 (PeproTech Inc). The pellets were collected at days 0, 7 and 14 for histology,
immunohistochemistry, biochemistry, and real-time PCR.

116

Adipogenic differentiation of the expanded ASCs
Passage 3 ASCs were cultured on Plastic, AECM, or SECM in 6-well plates until 95%
confluence, and the complete medium was switched to adipogenic differentiation medium
[low glucose DMEM (Invitrogen), 10% FBS, 100 U/ml penicillin, 100 µg/ml streptomycin, 10-6
M dexamethasone, 0.5 mM isobutyl-1-methy xanthine (Sigma), 100 μM indomethacin (Sigma)
and 10 μg/mL insulin (Sigma)] for an additional 14 days. The cultured cells were fixed in 4%
paraformaldehyde (Sigma), stained with Oil Red O solution (Diagnostic Biosystems,
Pleasanton, CA) and counterstained with hematoxylin (Vector Laboratories Inc., Burlingame,
CA). The expanded cells were also collected for quantitative evaluation of adipogenic gene
expression using real-time PCR.

Histology and Immunohistochemistry
The pellets (n = 2) were fixed at 4˚C in 4% paraformaldehyde, embedded in paraffin blocks
and cut into 5-μm thick sections. Safranin O solution (Sigma) was used to stain sulfated
glycosaminoglycans (GAGs). For immunohistochemical analysis, the sections were
immunolabeled with primary antibodies against collagen II (II-II6B3, DSHB, Iowa City, IA),
collagen I (Abcam, Cambridge, MA), and collagen X (Sigma), followed by the secondary
antibody of biotinylated horse anti-mouse IgG (Vector). Immunoactivity was detected using
Vectastain ABC reagent (Vector) with 3,3’-diaminobenzidine (DAB) as a substrate.

Biochemical analysis
The pellets (n = 5) were digested for 4 h at 60ºC with 125 μg/mL papain in PBE buffer (100
mmol/L phosphate, 10 mmol/L EDTA, pH 6.5) containing 10 mmol/L cysteine, by using 100 μL
enzyme per sample. DNA amount in the papain digestion was measured using the QuantiTTM
PicoGreen® dsDNA assay kit (Invitrogen) with a CytoFluor® Series 4000 (Applied Biosystems,
Foster City, CA). GAG was measured using dimethylmethylene blue dye and a SpectronicTM
BioMateTM 3 Spectrophotometer (Thermo Scientific, Milford, MA) with bovine chondroitin
sulfate (Sigma) as a standard.

Real-time polymerase chain reaction (Real-time PCR)
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The total mRNA from pellets (n = 4) was extracted using TRIzol® (Invitrogen) and 1 µg of
mRNA was converted to cDNA with a High-Capacity cDNA Archive Kit (Applied Biosystems).
Chondrogenic marker genes [aggrecan, types I and II collagen, and SRY (sex determining
region Y)-box 9 (Sox9)], hypertrophy marker genes [type X collagen and matrix
metalloproteinase 13 (MMP13)], and adipogenic marker genes [lipoprotein lipase (LPL),
peroxisome proliferator activated receptor γ (PPARγ), and CCAAT enhancer binding protein
α (C/EBPα)] were customized by Applied Biosystems as part of the Custom TaqMan® Gene
Expression Assays. Eukaryotic 18S rRNA (Assay ID HS99999901_s1 ABI) was carried out
as the endogenous control gene. Real-time PCR was performed with the iCycler iQTM Multi
Color RT-PCR Detection and calculated by computer software (Perkin-Elmer, Waltham, MA).
Relative transcript levels were calculated as χ=2-ΔΔCt, in which ΔΔCt=ΔE-ΔC, ΔE=Ctexp-Ct18s,
and ΔC=Ctct1-Ct18s.

Statistical Analysis
The Kruskal-Wallis test was used to test for significant differences among all groups and the
Mann-Whitney U test was used for pairwise comparison. All the statistical analysis was
performed with SPSS 13.0 statistical software (SPSS Inc., Chicago, IL). P values less than
0.05 were considered statistically significant.
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RESULTS

ECM expansion enhanced ASC proliferation and sustained stem cell morphology
(Figure 3.1A) Passage 1 ASCs were expanded on Plastic, AECM, or SECM for two passages.
In regard to cell morphology, ASCs grown on Plastic appeared large and flattened while
ASCs plated on ECM became smaller and spindle-like and overlapped with time in a 3D
format. Intriguingly, ASCs grown on AECM or SECM exhibited similar cell morphology and
underwent directional migration along the ECM fibrils whereas the cells on Plastic grew in a
random direction. (Figure 3.1B) During a seven-day incubation, the proliferative rate of ASCs
on Plastic dropped with each passage, with a 4.53-fold increase at passage 2 and a 7.47-fold
increase at passage 3 compared to a 15.47-fold increase at passage 1. On the contrary,
ASCs plated on AECM and SECM exhibited a robust and stable proliferative ability, with a
43.73-fold increase at passage 2 and a 44.8-fold increase at passage 3 for ASCs expanded
on AECM and a 43.73-fold increase at passage 2 and a 48.8-fold increase at passage 3 for
ASCs expanded on SECM. There was no significant difference in the cell yield number in two
different ECMs.

(Figure 3.1C) In order to determine whether ECM expansion could decrease cell stress, we
examined the intracellular levels of ROS accumulation in ASCs cultured in Plastic, AECM, or
SECM using flow cytometry. The ASCs cultured in Plastic indeed showed a higher level of
DCF fluorescence compared with those expanded in AECM or SECM. (Figure 3.1D) The
mean fluorescent intensity (MFI) of ROS in ASCs in Plastic was 148 ± 6, which was 2.4-fold
that in AECM and 3.5-fold that in SECM, indicating that ECM effectively reduced the
generation or accumulation of the intracellular ROS in ASCs.

ECM expansion enhanced ASC chondrogenic capacity
After expansion on Plastic, AECM, and SECM, ASCs were cultured in a serum-free pellet
system supplemented with 10 ng/mL of TGF-β3 to evaluate the effect of expansion approach
on ASC chondrogenic capacity. (Figure 3.2) Compared to nondetectable staining at day 0,
ASC pellets from P1.Plastic or P3.Plastic were barely positive for sulfated GAGs and type II
119

collagen at day 7 despite a gradually positive staining on the periphery of pellets at day 14.
The pellets from P3.AECM and P3.SECM, however, were intensively positive for sulfated
GAGs and type II collagen even at day 7 and dramatically improved in range and density after
incubation in chondrogenic medium for 14 days.

(Figure 3.3) At the protein level, ASCs from P3.Plastic yielded pellets with a lower
chondrogenic index (GAG/DNA) compared with that from P1.Plastic. In contrast, ASCs from
P3.AECM and P3.SECM yielded pellets with not only a sustained cell number but also a
greatly enhanced chondrogenic index. There was no significant difference in chondrogenic
index for ASCs expanded on AECM or SECM. (Figure 3.4) At the mRNA level, ASCs from
P3.AECM or P3.SECM yielded pellets with higher mRNA levels in type II collagen (at days 7
and 14), aggrecan (at days 7 and 14), and Sox9 (at day 7) than that from P1.Plastic and
P3.Plastic. Similar to protein expression, there was no significant difference in the above
chondrogenic marker genes for ASCs expanded on AECM or SECM.

BMP-6 increased TGF-β3-induced ASC chondrogenic

differentiation

but

inhibited

hypertrophy
(Figure 3.2) Compared to the expanded ASCs on ECM, the combined treatment with TGF-β3
and BMP-6 yielded pellets from Plastic-expanded ASCs with more intense sulfated GAGs
and type II collagen than the treatment with TGF-β3 alone. Intriguingly, the expanded ASCs
on ECM yielded pellets with less type I collagen stain when the pellets were treated with
TGF-β3 combined with BMP-6 than that with TGF-β3 alone. No type X collagen was
detectable in either Plastic- or ECM-expanded ASCs. (data not shown)
(Figure 3.3) The combination of TGF-β3 with BMP-6 maintained cell number in ASC pellets
compared to treatment with TGF-β3 alone, especially after a 14-day incubation. More
importantly, the combined treatment significantly increased ASC chondrogenic index in all
groups except P3.Plastic compared to treatment with TGF-β3 alone. (Figure 3.4&3.5)
Consistent with histology data, the combined treatment significantly decreased mRNA levels
of type I collagen, type X collagen, and MMP-13 compared to treatment with TGF-β3 alone.
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ECM expansion delayed the decrease of ASC adipogenic capacity
(Figure 3.6A) ASCs from P1.Plastic exhibited more Oil Red O stained spots than the other
three groups. (Figure 3.6B) As an early marker gene of adipogenesis, the level of LPL mRNA
was the highest in P1.Plastic with only 5.6% in P3.Plastic, 18.7% in P3.AECM, and 27.5% in
P3.SECM. (Figure 3.6C,D) PPARγ and C/EBPα are the transcription factors involved in
adipogenesis, both of which showed a similar tendency as LPL mRNA.
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DISCUSSION

ASCs are increasingly becoming a promising stem cell source for the treatment of cartilage
defects. However, it is still a big challenge to establish an in vitro microenvironment for
reprogramming autologous ASCs toward chondrogenic differentiation. In this study, we found
that ECM enhanced ASC proliferation, maintained stem cell morphology and lowered ASC
intracellular ROS level; ECM-expanded ASCs exhibited a decreased level of intracellular
ROS; and the expansion on ECM enhanced ASC chondrogenic differentiation capacity.
Interestingly, there was no significant difference in ASC proliferation and differentiation using
two different ECMs deposited by either ASCs or SDSCs. Our findings also suggested that
BMP-6 increased

TGF-β3-induced

ASC chondrogenic

differentiation

but

inhibited

concomitant hypertrophy. Surprisingly, we did not find that the expanded ASCs exhibited an
enhanced adipogenic capacity, regardless of expansion on ECM deposited by ASCs or
SDSCs.

Plenty of stem cells are needed for stem cell-based tissue engineering and regeneration.
Adult tissues contain unique local niches with tissue-specific stem cells; however, ex vivo
expansion on conventional plastic flasks results in stem cell senescence, indicated by the
loss of proliferation and differentiation capacity. In this study, we found that ECM expansion
could decrease ASC intracellular ROS level, indicating that ROS associated cell stress may
play a major role in monolayer culture on plastic flasks; this could be prevented by expansion
on 3D ECM. Due to the 3D growth format on ECM, expanded ASCs grew much faster and
were more orderly than 2D growth on plastic flasks. Moreover, ECM deposited by stem cells,
either SDSCs or ASCs, could maintain the expanded ASC stem cell characteristics (small
with spindle-shape). The connection between stem cell size and function is consistent with
bone marrow derived MSCs, which have also been shown to possess more “stemness” when
the MSCs are small and rapidly dividing [22]. This result is also in agreement with reports from
us and other investigators. We found ECM deposited by SDSCs could dramatically enhance
seeded SDSC proliferation

[20]

. Chen et al. demonstrated that ECM deposited by BMSCs

enhanced plated BMSC expansion

[23]

. These cell-derived matrices appear to more closely
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approximate native tissue

[24]

rather than the ‘‘reconstituted’’ matrices (such as 3D pure

collagen gels and Matrigel matrices

[25]

). As noted previously

[24,26,27]

, cells within this in

vivo-like 3D environment developed an elongated shape and had reduced lamella, confined
predominantly to one of the cell ends. In contrast, control fibroblasts grown on
fibronectin-coated surfaces had a flattened and triangular shape with an increased number of
peripheral lamellae. No significant difference was observed in ASC proliferation after
expansion on ECM deposited by either ASCs or SDSCs, indicating that the stimulatory effect
of the matrix is most probably due to its three-dimensionality, rather than to its composition, as
flattening of the matrix by mechanical force abolishes the formation of 3D matrix adhesions
and ERK-stimulated cell proliferation [24,28].

In our previous study, expanded SDSCs on SDSC-derived ECM exhibited a robust
chondrogenic differentiation potential. Since SDSCs are considered a tissue-specific stem
cell for chondrogenesis, we proposed that the chondrogenic potential of ASCs would be
improved after expansion on ECM deposited by SDSCs instead of ASCs while the adipogenic
potential of ASCs would be improved after expansion on ECM deposited by ASCs.
Surprisingly, ASCs expanded on ECM deposited from either SDSCs or ASCs developed a
similar enhanced chondrogenic differentiation capacity, indicating that 3D ECM may induce
sustained activation of the extracellular signal-activated kinase 1/2 (ERK1/2) via Src/Ras/Raf
[26]

signaling pathway

and the high level of phosphorylated ERK1/2 could be responsible for

the improved chondrogenic differentiation potential of ASCs. This signal transduction
pathway needs to be further demonstrated.

Our study also found that supplementation of BMP-6 enhanced TGF-β-induced ASC
chondrogenesis but inhibit hypertrophy, which is in agreement with reports from other
investigators

. Although TGF-β can inhibit chondrocyte hypertrophy

[29,30]

[31]

, perhaps the

chondrogenic differentiation potential of ASCs treated by ECM was very robust, and the level
of TGF-β3 used in this study was insufficient to completely stop further development into
hypertrophy.

Despite

the

fact

that

BMP-6

combined

hypertrophy/endochondral ossification pathway in BMSCs
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with

[32,33,34]

TGF-β

results

in

, BMP-6 alone is a strong

chondrogenic inducer and also acts as a hypertrophy inhibitor in ASCs

[29]

. This was in

agreement with our results that supplementation of BMP-6 enhanced ASC chondrogenic but
inhibited hypertrophic differentiation. The underlying mechanism may be associated with the
reduced expression of BMP-2, -4, and -6 mRNA and no expression of TGF-β-receptor-1
protein in ASCs, which BMSCs have. BMP-6 treatment induced TGFβ-receptor-1 expression
and combined application of TGF-β and BMP-6 eliminated the reduced chondrogenic
potential of ASCs inducing a gene expression profile similar to differentiated BMSCs. [30]

The decreased adipogenic and osteogenic differentiation (data not shown) of ASCs culturing
on ASC- and SDSC-derived ECMs could be correlated with the effect of suppressing
“spontaneous” differentiation. ECM was proven to modulate the activity of growth factors,
interact with cell surface receptors to prevent activation, and absorb growth factors from
serum

[23,35-37]

. Expansion of MSCs on ECM not only increased the proliferative rate but also

suppressed “spontaneous” differentiation and maintained stem cell properties. However, the
molecular mechanism that ECM used to interact with cells and improve the proliferation and
chondrogenic potential still needs to be investigated.

In summary, our study proved that the utilization of ECM on ASC ex vivo expansion was able
to dramatically increase the cell proliferative rate and improve the chondrogenic
differentiation potential. The combination of TGF-β3 and BMP-6 promoted chondrogenic
induction but suppress hypertrophic gene expression. The large-scale cell number of ADSCs
with significant chondrogenic potential will benefit cartilage repair and tissue regeneration in
the future.
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FIGURE LEGENDS

Figure 3.1. The morphology and proliferative rate of ASCs grown in plastic flasks (Plastic),
AECM-coated flasks (AECM), or SECM-coated flasks (SECM). (A) Representative phase
contrast images of passage 2 ASCs; (B) the cell numbers of ASCs expanded for two
passages. Data are shown as average ± SD for n = 4. * p < 0.05 compared with ASCs
cultured in Plastic at the same passage.

#

p < 0.05 compared with ASCs at passage 1. (C)

Flow cytometry was used to measure intracellular ROS level in ASCs after expansion in
Plastic, AECM, or SECM. (D) The mean fluorescence intensity (MFI) was for the intracellular
level of ROS in ASCs. Data are shown as average ± SD for n = 4. $ p < 0.05 compared with
ASCs cultured in AECM in the same passage.

Figure 3.2. Histology and immunohistochemistry of ASC-pellets after 14-day chondrogenic
induction in a serum-free chondrogenic medium (CM) supplemented with 10 ng/mL TGF-β3
or 10 ng/mL TGF-β3 combined with 10 ng/mL BMP-6. ASCs from passage 1 in Plastic
(P1.Plastic) were expanded for two passages in Plastic (P3.Plastic), AECM (P3.AECM), or
SECM

(P3.SECM).

Safranin

O

staining

(Saf.O)

was

used

to

detect

sulfated

glycosaminoglycans (GAGs), and immunohistochemical staining (IHC) was for type I (COL I)
and type II (COL II) collagen. The scale bar is 800 µm.

Figure 3.3. Biochemical analysis for GAG (A) and DNA content (B) in ASC-pellets after a
14-day chondrogenic induction in a serum-free chondrogenic medium supplemented with 10
ng/mL TGF-β3 (T) or 10 ng/mL TGF-β3 combined with 10 ng/mL BMP-6 (T+B). ASCs from
passage 1 in Plastic (P1.Plastic) were expanded for two passages in Plastic (P3.Plastic),
AECM (P3.AECM), or SECM (P3.SECM). The rate of GAG to DNA (C) was used to represent
chondrogenic index. Data are shown as average ± SD for n = 5. * p < 0.05 compared with
ASC-pellets incubated in a medium with TGF-β3 alone. # p < 0.05 compared with ASC-pellets
from P3.Plastic incubated in the same medium.

$

p < 0.05 compared in the pellets from

expanded ASCs in AECM or SECM in the same medium.
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Figure 3.4. TaqMan real-time PCR for the evaluation of chondrogenic markers (Col I, Col II,
aggrecan, and Sox9) at mRNA levels in ASC-pellets after a 14-day chondrogenic induction in
a serum-free chondrogenic medium supplemented with 10 ng/mL TGF-β3 (T) or 10 ng/mL
TGF-β3 combined with 10 ng/mL BMP-6 (T+B). ASCs from passage 1 in Plastic (P1.Plastic)
were expanded for two passages in Plastic (P3.Plastic), AECM (P3.AECM), or SECM
(P3.SECM). 18S rRNA was used as an internal control. * p < 0.05 compared with ASC-pellets
incubated in a medium with TGF-β3 alone at the same time point. # p < 0.05 compared with
ASC-pellets incubated in the same medium.

$

p < 0.05 compared in the pellets from

expanded ASCs in AECM or SECM in the same medium.

Figure 3.5. TaqMan real-time PCR for the evaluation of hypertrophic markers (Col X and
MMP-13) at mRNA levels in ASC-pellets after 14-day chondrogenic induction in a serum-free
chondrogenic medium supplemented with 10 ng/mL TGF-β3 (T) or 10 ng/mL TGF-β3
combined with 10 ng/mL BMP-6 (T+B). ASCs from passage 1 in Plastic (P1.Plastic) were
expanded for two passages in Plastic (P3.Plastic), AECM (P3.AECM), or SECM (P3.SECM).
18S rRNA was used as an internal control. * p < 0.05 compared with ASC-pellets incubated in
a medium with TGF-β3 alone.
medium.

$

#

p < 0.05 compared with ASC-pellets incubated in the same

P < 0.05 compared in the pellets from expanded ASCs in AECM or SECM in the

same medium.

Figure 3.6. Adipogenic differentiation of ASCs was evaluated after expansion in Plastic,
AECM, or SECM for two passages and incubation in adipogenic medium for 14 days. (A) Oil
Red O staining for oil drops produced by adipocytes with hematoxylin as a counterstain. (B)
TaqMan real-time PCR for the evaluation of adipogenic genes (LPL, PPARγ and C/EBPα).
18S RNA was used as an internal control. Lower case letters (i.e. a, b, and c) indicate the
results of one-way analysis of variance (ANOVA) at p < 0.05. Groups with a letter in common
are not statistically different from one another. Error bars represent the mean ± SD for n = 4.
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Chapter 4
Extracellular Matrix Deposited by Synovium-Derived Stem Cells Delays
Chondrocyte Dedifferentiation and Enhances Redifferentiation
-- A novel ex vivo expansion system for autologous chondrocyte - based cartilage repair

Fan He, B.S., and Ming Pei, M.D., Ph.D.

Stem Cell and Tissue Engineering Laboratory, Department of Orthopaedics and Division of
Exercise Physiology, West Virginia University, Morgantown, West Virginia 26506
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ABSTRACT

Articular cartilage has a limited capacity for self heal once damaged. Autologous chondrocyte
transplantation is a promising approach for cartilage defect repair. However, in vitro
expansion can cause chondrocyte dedifferentiation. Our aim is to assess the rejuvenation
effect of extracellular matrix (ECM) deposited by synovium-derived stem cells (SDSCs) on
articular

chondrocyte

expansion

and

maintenance

of

differentiation

status

and

redifferentiation capacity. Passage 0 (P0) porcine articular chondrocytes were expanded for
six passages on plastic flasks (Plastic), SDSC-derived ECM (ECM), or substrate switching
from either Plastic to ECM (PtoE) or ECM to Plastic (EtoP). Cell morphology, gene
expression profiles and immunophenotypes at each passage were used to characterize
differentiation status of expanded cells. Expanded chondrocytes at P0, P2 and P6 were
assessed for redifferentiation capacity in a pellet culture system treated with either TGF-β1or serum-containing medium for 14 days, using histology, immunohistochemistry,
biochemistry, western blot and real time PCR. We found that ECM not only greatly enhanced
chondrocyte expansion but also delayed dedifferentiation of expanded chondrocytes.
Intriguingly, compared to a dramatic decrease in CD90+/CD105+ cells and CD90+ cells,
CD105+ cells dramatically increased when chondrocytes were plated on Plastic; on the
contrary, ECM expansion dramatically increased CD90+ cells and delayed the decrease of
CD90+/CD105+ cells. Interestingly, expanded chondrocytes on ECM also acquired a strong
redifferentiation capacity, particularly in the pellets treated with TGF-β1. In conclusion, the
ratio of CD90 to CD105 may serve as a marker indicative of proliferation and redifferentiation
capacity of dedifferentiated chondrocytes. ECM deposited by SDSCs provides a
tissue-specific 3D microenvironment for ex vivo expansion of articular chondrocytes while
retaining redifferentiation capacity, suggesting that ECM may provide a novel approach for
autologous chondrocyte - based cartilage repair.
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INTRODUCTION

Articular cartilage is a unique, hypocellular and avascular tissue, mostly made of extracellular
collagens and proteoglycans (PGs); it has a limited ability to self heal after trauma and
degenerative disease.1 Since the last century, various clinical and research approaches have
been adopted to repair articular cartilage damage, including arthroscopic abrasion,
transplantation of chondrocytes, periosteum graft, mesenchymal stem cells (MSCs), or tissue
constructs derived from MSCs. Each method, however, has disadvantages in achieving
satisfactory effects in patients or animal studies. Autologous chondrocyte transplantation
(ACT), the most current and clinically accepted method for cartilage repair, depends on the
introduction of autologous chondrocytes into the defect area.2,3 The big hurdle for this
technique is the limited expandability and dedifferentiation of chondrocytes characterized by
losing round morphology and changing to a spindle shape. Meanwhile, collagen II and
aggrecan dramatically decrease in contrast to the increase in collagen I.4,5 Dedifferentiated
chondrocytes are able to redifferentiate to express cartilage-specific genes and proteins in a
three-dimensional (3D) culture system, such as pellet,6 agarose gel,4 alginate beads,7 or
hybrid scaffold8; however, late-passage chondrocytes tend to lose their capacity to generate
cartilage tissue.9

The prevention of dedifferentiation or the preservation of chondrocyte quality during in vitro
expansion is one of the major tasks necessary for the innovation of regenerative cartilage
medicine. Traditional cell culture on two-dimensional (2D) substrate lacks a proper
microenvironment and is proposed to be responsible for the dedifferentiation of chondrocytes;
this problem can be overcome by using in vitro 3D models because of its ability to mimic the
in vivo environment.10 There is increasing evidence demonstrating that superficial zone
protein (SZP) synthesized by both chondrocytes and synovial cells bordering the joint cavity11
provides a protective microenvironment for cartilage progenitor cells at the surface of articular
cartilage.12 Our most recent study developed a novel 3D expansion system based on the
extracellular matrix (ECM) deposited by synovium-derived stem cells (SDSCs), which
dramatically enhanced SDSC proliferation and chondrogenic differentiation potential.13 In this
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study, SDSCs serve as a tissue-specific stem cell for chondrogenesis;14 we hypothesized that
SDSC-derived ECM could provide a tissue-specific microenvironment by improving articular
chondrocyte proliferation, delaying dedifferentiation, and enhancing redifferentiation potential.
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MATERIALS AND METHODS

Isolation of porcine articular chondrocytes and SDSCs
Two 3-month-old pigs were collected from a local slaughterhouse and harvested to provide
articular cartilage and synovial tissue from the knee joints. The minced cartilage was digested
in 0.2% collagenase P (Roche, Indianapolis, IN) at 37ºC overnight. The finely minced
synovial tissue was digested in 0.1% trypsin (Roche) and then placed in 0.1% collagenase P
at 37ºC for 2 h. After filtration through 70-μm nylon filter, both cells were plated in culture
medium [DMEM containing 10% fetal bovine serum (FBS), 100 U/mL penicillin, 100 µg/mL
streptomycin, and 0.25 μg/mL fungizone (Invitrogen, Carlsbad, CA)]. Synovial fibroblasts
were negatively isolated from primary culture and characterized as SDSCs according to our
previous study.14

Preparation of SDSC-derived ECM
The preparation of SDSC-derived ECM was described in our previous study (13). Briefly, cell
culture flasks were pre-coated with fibronectin (BD Biosciences, Bedford, MA) for 1 h at 37ºC.
When the plated SDSCs reached 90% confluence, 50 µM L-ascorbic acid phosphate (Wako,
Richmond, VA) was added for eight days. After washing with phosphate buffered saline (PBS),
ECM was incubated in 0.5% Triton X-100 containing 20 mM ammonium hydroxide for 5 min
followed by100 units/mL DNase (Sigma-Aldrich, St.Louis, MO) for 60 min.

Ex vivo expansion of chondrocytes
Passage 0 (P0) chondrocytes were expanded for six passages on two substrates: plastic
flasks (“Plastic”) and SDSC-derived ECM (“ECM”). To identify if the substrate switch would
affect cell expansion and redifferentiation capacity (short-term effect), P4 chondrocytes
initially expanded on Plastic were plated on ECM for two more passages (“PtoE”) or from
ECM to Plastic for two more passages (“EtoP”). Chondrocyte morphology expanded on
Plastic or ECM was assessed using phase contrast microscope and immunoflurescent
microscope. Briefly, P4 chondrocytes were stained with Vybrant DiI cell-labeling solution
(Invitrogen) and plated on Plastic or ECM for three days. The samples were fixed in 4%
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paraformaldehyde for 15 min and blocked in 1% BSA (Sigma) for 30 min, followed by
one-hour-incubation in primary antibody against collagen I (Abcam, Cambridge, MA) and
then secondary antibody of Alexa Fluor® 488 donkey anti-mouse IgG (H+L) (Invitrogen). The
samples were counterstained by mounting in Slow Fade® Gold anti-fade reagent with DAPI
(Invitrogen). Immunofluorescent images were obtained with a Nikon Eclipse E800
microscope (Japan) and processed by SPOT software (Diagnostic Instruments Inc., Sterling
Heights, MI).

Flow cytometry
The expanded chondrocytes from each passage were analyzed using the following primary
antibodies: CD14 (Abcam), CD90 (BD Biosciences Pharmingen, San Diego, CA), and CD105
(GeneTex Inc., San Antonio, TX). IgG1 and IgG2a (Beckman Coulter, Fullerton, CA) were
used as the isotype controls, and R-Phycoerythrin Conjugated Goad Anti-Mouse IgG (H+L)
was used as the secondary antibody. Samples (n = 3) of each 0.2 × 106 chondrocytes were
incubated in cold PBS containing 0.1% ChromPure Swine IgG (Jackson ImmunoResearch
Laboratories, West Grove, PA) and 1% NaN3 for 30 min. Then chondrocytes were incubated
in the primary antibodies followed by the secondary antibody for 30 min in the dark. The
labeled chondrocytes were analyzed on a BD dual laser FACS Calibur (BD Biosciences)
using FCS Express software package (De Novo Software, Los Angeles, CA).

Redifferentiation of expanded chondrocytes in a pellet culture system
The expanded chondrocytes (3 × 105) from P0, P2 and P6 were centrifuged in a 15-mL
polypropylene tube at 500 g for 5 min. After 24-hour-incubation (day 0), the pellets were
incubated in two culture mediums: one was serum-free chondrogenic medium [high-glucose
DMEM, 40 µg/mL proline (Sigma), 100 nM dexamethasone (Sigma), 100 U/mL penicillin, 100
µg/mL streptomycin, 0.1 mM ascorbic acid-2-phosphate, and ITS™ Premix (BD Biosciences)
with the supplementation of 10 ng/mL of transforming growth factor beta1 (TGF-β1, R&D
Systems, Minneapolis, MN)] (14) (“TGF-β1-containing medium”) and the other culture
medium was regular medium for chondrocyte-based tissue construct culture [high-glucose
DMEM, 10% FBS, 100 U/mL penicillin, 100 µg/mL streptomycin, 10 mM HEPES (Sigma), 0.1
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mM non-essential amino acids (Sigma), 0.4 mM proline, and 50 mg/L L-ascorbic acid] (8)
(“serum-containing medium”). The pellets were incubated at 5% CO2, 5% O2, 37ºC for 14
days.

Histology and Immunohistochemistry
The chondrocyte pellets (n = 2) were fixed in 4% paraformaldehyde at 4ºC overnight, followed
by dehydration with a gradient ethanol series, clearing with xylene, and embedding in paraffin
blocks. Sections 5 μm thick were stained with Alcian blue to detect sulfated
glycosaminoglycans (GAGs) with fast red as a counterstain. For immunohistochemical
analysis, the sections were immunolabeled with primary antibodies against collagen I
(Sigma), collagen II (II-II6B3, DSHB, Iowa City, IA), and collagen X (Sigma), respectively. A
secondary antibody of biotinylated horse anti-mouse IgG (Vector, Burlingame, CA) was
incubated on the sections for 30 min. Immunoactivity was detected using Vectastain ABC
reagent (Vector) with 3,3’-diaminobenzidine (DAB) as a substrate.

Hematoxylin (Vector)

served as a counterstain.

Biochemical analysis for DNA and GAG content
For biochemical analysis, pellets (n = 5) were digested at 60ºC for 6 h with 125 μg/mL papain
in PBE buffer (100 mM phosphate, 10 mM EDTA, pH 6.5) containing 10 mmol/L cysteine. The
amount of DNA in each pellet was measured using the QuantiTTM PicoGreen® dsDNA assay
kit (Invitrogen) with a CytoFluor® Series 4000 (Applied Biosystems, Foster City, CA). Sulfated
GAGs were measured using 16 µg/mL of dimethylmethylene blue (DMMB) dye and a
SpectronicTM BioMateTM 3 Spectrophotometer (Thermo Scientific, Milford, MA) with bovine
chondroitin sulfate (Sigma) as a standard.

TaqMan® quantitative real-time PCR
Total mRNA from pellets (n = 5) was extracted using TRIzol ® (Invitrogen) and 1 µg of mRNA
was converted to cDNA with High-Capacity cDNA Archive Kit as recommended by the
manufacturer (Applied Biosystems). Chondrogenic (aggrecan, collagen I and II) and
hypertrophy [collagen X, matrix metalloproteinase 13 (MMP13), and alkaline phosphate
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(ALP)] marker genes were customized by Applied Biosystems as part of the Custom
TaqMan® Gene Expression Assays (Table 1). Eukaryotic 18S RNA (Assay ID:
HS99999901_s1 ABI) was carried out as the endogenous control gene. Real-time PCR was
performed with the iCycler iQTM Multi Color RT-PCR Detection and calculated by computer
software (Perkin-Elmer, Waltham, MA).

Western blot
To assess non-dissolvable collagen II expression in extracellular matrix, SDSC pellets (n = 3)
were lyophilized and incubated in 4 M guanidine hydrochloride (GuHCl, Sigma) for 20 h at
4ºC, then digested with 0.6 mg/ml of pepsin (Sigma) in 0.5 M acetic acid at 4ºC for 48 h at a
ratio of 10:1 (mg/mg) dry sample to pepsin. The samples were centrifuged at 48,000 g for 1 h,
and the supernatant was lyophilized and dissolved in radioimmunoprecipitation assay (RIPA)
buffer with protease inhibitors (Pierce, Rockford, IL). To assess dissolvable collagen II
expression in cytoplasm, the pellets were homogenized and dissolved in RIPA buffer with
protease inhibitors. Total proteins were quantified using BCATM Protein Assay Kit (Pierce). 40
μg of protein from each sample was denatured and separated using NuPAGE® Novex®
Bis-Tris Mini Gels (Invitrogen) in the XCell SureLockTM Mini-Cell (Invitrogen) at 120 volts for 3
h at 4°C. Bands were transferred onto a nitrocellulose membrane (Invitrogen) using an XCell
ΙΙTM Blot module (Invitrogen) at 15 volts overnight at 4°C. The membrane was incubated with
a primary monoclonal antibody against collagen II (II-II6B3) in 1% non-fat milk in TBST for 1 h
at room temperature (β-actin served as an internal control), followed by the secondary
antibody of HRP-conjugated goat anti-mouse (Pierce) for 40 min at room temperature and
exposure using SuperSignal West Femto Maximum Sensitivity Substrate (Pierce) and
CL-XPosure Film (Pierce).

Statistical Analysis
The Kruskal-Wallis test was used to determine significant differences among all groups and
the Mann-Whitney U test was used for pairwise comparison. All statistical analysis was
performed with SPSS 13.0 statistical software (SPSS Inc., Chicago, IL). P values less than
0.05 were considered statistically significant.
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RESULTS

Expansion on ECM acquired a large number of chondrocytes with delayed dedifferentiation
To identify the effect of ECM on chondrocyte proliferation and marker gene stability, P0
chondrocytes were expanded on ECM for six passages with Plastic substrate as a control.
Compared to the original round morphology, chondrocytes expanded on Plastic exhibited
flattened and broad morphology (Figure 4.1A and 4.1Biii); in contrast, ECM-expanded
chondrocytes displayed a smaller size with a glistening surface and fibroblast-like shape that
were aligned in rows (Figure 4.1A and 4.1Bii). ECM was positively stained with collagen I
(Figure 4.1Bi). From P1 to P5, the cell number fold-change in the Plastic group continued to
decrease (on average 5-fold); surprisingly, chondrocyte expansion on ECM yielded 4 to 10
times more cells than on Plastic (Figure 4.1C). Despite a sharp decrease of collagen II mRNA
in chondrocytes from both groups, ECM expanded chondrocytes restored more collagen II
mRNA than those plated on Plastic (Figure 4.1D). In contrast, collagen I mRNA dramatically
increased in chondrocytes after isolation from cartilage despite a burst increase at P1 and P4
and a decrease at P6 in the ECM group (Figure 4.1E).

To evaluate the effect of ECM on immunophenotypic changes of articular chondrocytes
during in vitro expansion, CD14, CD90 and CD105 were chosen to identify differentiation
status of expanded chondrocytes (Figure 4.2A-C and 4.2a-c). After an instant increase at P1,
both CD14+ cells and CD90+ cells decreased with passage when chondrocytes were
expanded on Plastic; intriguingly, ECM expansion dramatically increased CD14+ cells and
CD90+ cells up to P6. On the contrary, compared to an increase in CD105+ cells after
expansion on Plastic, ECM expansion exhibited a lower expression of CD105+ cells. The
change of culture substrate from either PtoE or EtoP resulted in the same conclusion.

To identify the effect of ECM on CD90+ cells and/or CD105+ cells during in vitro expansion,
single positive (CD90+/CD105- or CD105+/CD90-), dual positive (CD90+/CD105+), and dual
negative (CD90-/CD105-) cells were measured in expanded chondrocytes at P0, P2, and P6
using flow cytometry (Figure 4.2D). Interestingly, when chondrocytes were expanded on
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Plastic, both CD90+/CD105+ cells and CD90+/CD105- cells decreased dramatically with a
sharp increase in CD105+/CD90- cells and CD90-/CD105- cells.

However, ECM expansion

delayed a decrease in CD90+/CD105+ cells but increased CD90+/CD105- cells despite a
concomitant increase in CD90-/CD105- cells.

Chondrocytes expanded on ECM acquired enhanced redifferentiation capacity
To evaluate the redifferentiation capacity of expanded chondrocytes, pellets from P0, P2
(Plastic and ECM), and P6 (Plastic, PtoE, ECM, and EtoP) were incubated in either TGF-β1or serum-containing medium for 14 days.

Redifferentiation of expanded chondrocytes in a TGF-β1-containing medium
Histology and immunostaining was performed to evaluate the density and distribution of
chondrogenic markers in pellets from expanded chondrocytes. At Day 0 (Supplemental
Figure 4.S1), there was no detectable staining for sulfated GAGs or collagen except in the
pellets from P0, P2.ECM, and P6.ECM. At day 7 (Supplemental Figure 4.S1) and day 14
(Figure 4.3A), sulfated GAGs and collagen II were distributed intensively throughout the
pellets from P0, P2.Plastic, P2.ECM and P6.ECM despite a weaker and comparable staining
of collagen I in all pellets except from P0. At P6, the pellet sizes from Plastic and EtoP were
smaller than those from ECM and PtoE. There was no detectable collagen X in any pellets
(data not shown).

To confirm our histology data, western blot was used to semi-quantify the expression of
collagen II at day 7 (Supplemental Figure 4.S2A) and day 14 (Figure 4.3B). We found that
collagen II was intensively expressed in both cytoplasm (immature) and extracellular matrix
(mature) in the pellets from P0, P2.Plastic, P2.ECM, and P6.ECM but not P6.Plastic. P6
chondrocytes expanded on either PtoE or EtoP yielded pellets with enhanced collagen II
expression compared to those from P6.Plastic. Biochemical analysis was used to quantify
GAGs in the pellets from expanded chondrocytes at day 0 (Figure 4.3C), day 7
(Supplemental Figure 4.S2B), and day 14 (Figure 4.3C). At day 0, pellets of P0 chondrocytes
contained the highest GAGs compared to other groups. After incubation in TGF-β1-containing
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medium for 14 days, pellets of P2 chondrocytes expanded on ECM exhibited a comparable
GAG amount to those plated on Plastic. In contrast, pellets of P6 chondrocytes expanded on
ECM yielded the highest level of GAGs, which was 7.9-fold greater than those from
P6.Plastic. Intriguingly, pellets of P6 chondrocytes from EtoP exhibited higher GAGs than
those from P6.Plastic but lower than those from P6.PtoE. Meanwhile, compared to a
time-dependent increase in cell number of pellets from P0 chondrocytes (“162% ± 7%” at Day
7 and “204% ± 4%” at Day 14), the cell number in the pellets from P6.Plastic dropped to 50%
even after a 7-day incubation; however, the pellets from P6 chondrocytes expanded on ECM
maintained the cell number at 124% after a 14-day incubation. The pellets of P6
chondrocytes from EtoP exhibited an increased expansion rate compared to those of
P6.Plastic. Expanded chondrocytes from P2.Plastic and P6.ECM yielded pellets with the
highest chondrogenic index whereas the pellets from P6.Plastic had the lowest chondrogenic
index after 14-day incubation with TGF-β1. The pellets of P6 chondrocytes from EtoP yielded
a higher chondrogenic index compared to those from P6.Plastic but was lower than those
from PtoE.

To assess the effect of ECM on redifferentiation capacity of expanded chondrocytes at the
mRNA level, real-time PCR was used to quantify chondrogenic marker genes (Figure 4.4A collagens I and II, and aggrecan) and hypertrophic marker genes (Figure 4.4B - collagen X,
ALP, and MMP13) at day 0 (Figure 4.4), day 7 (Supplemental Figure 4.S2C), and day 14
(Figure 4.4). Our data showed that collagen II and aggrecan presented a similar profile of
gene expression without significant variations. Despite the highest expression of both genes
in pellets from P0 chondrocytes at day 0, 14-day-incubation with TGF-β1 yielded pellets with
a higher expression of both genes in pellets from chondrocytes of P0, P2.ECM, and P6.ECM.
At P6, pellets from chondrocytes expanded on Plastic exhibited the lowest expression of both
genes. As an early marker of chondrogenic differentiation, collagen I mRNA decreased in all
pellets when incubated in a TGF-β1-containing medium. Despite the highest collagen X in
chondrocytes from P2.ECM after 14-day incubation with TGF-β1, expanded chondrocytes
from P6.ECM had comparable collagen X mRNA to those from P6.Plastic. Another two
hypertrophic markers, ALP and MMP13, both displayed a higher expression in chondrocytes
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from P6.Plastic than those from P6.ECM (6.1-fold and 9.0-fold, respectively).

Redifferentiation of expanded chondrocytes in a serum-containing medium
Although the pellets from P0 chondrocytes incubated in a serum-containing medium were
strongly stained by Alcian blue for sulfated GAGs and immunostained for collagen II as well
as non-detectable staining for collagen I as those treated with TGF-β1, the pellets from P2
chondrocytes were smaller in size and weaker in staining for both GAGs and collagen II,
especially for the pellets from P2.Plastic. More interestingly, 14-day-incubated pellets (Figure
4.5A) were weaker in chondrogenic marker staining than those from 7-day-incubated pellets
(Supplemental Figure 4.S1). At P6, only pellets from ECM maintained their size and were
positive for sulfated GAGs, collagens I and II; the pellets from other groups were tiny and less
stained.

To confirm our histology data, western blot was used to semi-quantify collagen II in pellets
incubated in a serum-containing medium (Figure 4.5B). Only three groups, the pellets from
P0, P2.ECM, and P6.ECM, could be extracted to yield sufficient proteins for immunoblotting.
The data showed that the pellets from P0 chondrocytes exhibited the highest expression of
collagen II in both cytoplasm and extracellular matrix. Despite undetectable collagen II in
those from P6.ECM, the pellets from P2.ECM exhibited detectable collagen II expression only
in extracellular matrix. Our biochemical analysis data (Figure 4.5C) showed that, compared to
those treated by TGF-β1, the pellets from P0 chondrocytes incubated in a serum-containing
medium yielded more GAG amounts and a higher DNA ratio as well as chondrogenic index.
However, the pellets from P2 chondrocytes incubated in a serum-containing medium
exhibited much less redifferentiation response despite the fact that 14-day-pellets from
P2.ECM had higher GAG amounts and maintained higher DNA ratio compared to those from
P2.Plastic.

Our mRNA data (Figure 4.6) showed that collagen II and aggrecan presented a similar profile
of gene expression without significant variation. Both genes exhibited a positive response to
serum incubation despite an initial increase at day 7 and a later decrease at day 14. The
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pellets from P2.ECM and P6.ECM displayed higher expression levels of both marker genes
not only before but also after serum incubation compared to the chondrocytes expanded on
Plastic. However, all pellets from expanded chondrocytes incubated in a serum-containing
medium displayed much less collagen II and aggrecan gene expression compared to culture
in a TGF-β1-containing medium except the pellets from P0 chondrocytes. There was no
significant difference in collagen I expression in the pellets from expanded chondrocytes,
either before or after serum treatment.
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DISCUSSION

A generally accepted opinion is that passage 3-4 is considered as a threshold for irreversible
dedifferentiation of chondrocytes.9,11 Although multiple chondrocyte passaging decreases
their redifferentiation capacity,15 our study suggested that the sequential application of ECM
(seeding substrate for cell proliferation) and TGF-β (growth factor for differentiation) affected
chondrocyte expansion and redifferentiation capacity. In our study, chondrocytes expanded
on SDSC-derived ECM showed a robust proliferation capacity in a 3D format. The expanded
cells on ECM retained more chondrocyte gene expression profiles and immunophenotypes
compared to expansion on Plastic. When incubated in a serum-free TGF-β1-containing
chondrogenic medium, chondrocytes expanded on ECM exhibited enhanced redifferentiation
for up to passage 6 compared to expansion on Plastic that retained their redifferentiation only
in the early passages.

We found that signs of dedifferentiation appeared even after one passage on Plastic,
evidenced by dramatically decreased collagen II mRNA and increased collagen I mRNA
compared with the native cartilage; this outcome is in agreement with previous studies.16,17
We also found that expansion on ECM not only increased cell number but also delayed the
decrease of a chondrocyte differentiation marker – collagen II. Consistent with a previous
study,18 our data showed that CD14+ cells decreased when chondrocytes were incubated on
Plastic. Since CD14 is normally expressed by articular chondrocytes19 instead of by MSCs18,
expansion on ECM boosted CD14+ cells, indicating that ECM was able to rescue
differentiated chondrocytes and prevent dedifferentiation during in vitro expansion. This also
can be explained by a recent report that chondrocytes cultured on collagen I–coated
substrate showed a tendency of suppressed dedifferentiation.20 Our previous study
demonstrated that ECM deposited by SDSCs, a tissue-specific stem cell for chondrogenesis,
provides a 3D microenvironment composed of collagen I–dominated nano-structure fibers;
SDSC expansion on ECM exhibited an enhanced proliferation capacity and chondrogenic
potential,13 which is in accordance with this study and indicative that ECM expanded
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chondrocytes exhibit an enhanced redifferentiation capacity.

Our data also showed that expansion on Plastic instantly increased CD90+ cells at P1
followed by a gradual decrease while continuously increasing CD105+ cells. On the contrary,
expansion on ECM increased CD90+ cells while decreasing CD105+ cells. A recent report
showed that during monolayer culture, articular chondrocytes expressed higher levels of
CD90 and lower levels of CD105 compared to MSCs.21 An interesting phenomenon was that
there was a phenotype switch in expanded chondrocytes from CD90+/CD105+ to
CD105+/CD90- when plated on Plastic or a gradual decrease in CD90+/CD105+ cells
concomitant with an increase in CD90+/CD105- when expanded on ECM. As we know, CD90
and CD105 are MSC markers;22 increased CD90+ cells are also associated with cell
proliferation capacity and chondrogenic potential23,24 as well as the induction of stress fibers
in articular chondrocytes19. CD105 (also termed endoglin or SH225) was expressed on
articular chondrocytes at a high intensity, where endoglin forms a heteromeric complex with
betaglycan.26 Endoglin-betaglycan association may be critical for achieving a balance
between the positive and negative regulation of TGF-β signaling. Compared to
overexpression of betaglycan enhanced TGF-β responses, overexpression of endoglin
resulted in an inhibition of TGF-β signaling.27 Like bone marrow MSCs, dedifferentiated
chondrocytes were positive for the CD105 marker. This suggests that, within a chondrocyte
preparation, subpopulations with higher capacity to form cartilage might correspond to those
with progenitor characteristics. Our pellet culture data suggested that ECM expanded
chondrocytes acquired not only a high proliferation capacity but also an enhanced
redifferentiation capacity, indicating that the CD90/CD105 ratio may serve as a useful index to
show the proliferation and redifferentiation capacity of dedifferentiated chondrocytes.

To stimulate chondrocyte redifferentiation after in vitro expansion, TGF-β1 was chosen to
facilitate the formation of cartilage-specific extracellular matrix28 with serum-containing
medium as a control. Culture medium supplemented with serum was proven to effectively
induce freshly isolated chondrocytes to differentiate into cartilage tissue constructs in 3D
biodegradable scaffolds.8 Under the serum treatment, however, our study showed that
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chondrocytes expanded on Plastic lose their capacity for redifferentiation as early as P2,
suggesting that serum could only maintain the redifferentiation potential of early-expanded
chondrocytes. The chondrocytes cultured on ECM were able to maintain cell viability and
generate cartilage-specific matrix up to P6, albeit much weaker than those treated by
TGF-β1-containing medium. A recent study showed that there is the existence of a certain
subpopulation of multipotent MSCs or progenitor cells in the cartilage tissue besides
terminally differentiated chondrocytes.29 In our study, chondrocytes expanded on ECM
behaved more like stem cells or progenitors rather than terminally differentiated cells in terms
of rapid proliferation rate and high level of CD90 surface marker. When culturing on ECM,
stem cells or progenitors in mixed chondrocyte populations would accelerate the expansion
rate compared with mature chondrocytes and those cells have strong chondrogenic potential,
evidenced by generating cartilage-specific matrix in response to stimulation by TGF-β1 in a
pellet culture system. A potential mechanism underlying ECM enhancing chondrocyte
proliferation and redifferentiation capacity may be explained by ECM acting through
integrin-mediated extracellular signal-activated kinase (ERK) signal transduction pathway.
Chondrocyte expansion in monolayer culture shows the expression of osteoblast cadherin
(Ob-cadherin) and abundant cell-to-cell contacts, indicative of dedifferentiation.30 On the
contrary, the 3D expanded cells exhibit lower expression of cadherins than did monolayer
expanded cells, especially that of Ob-cadherin, which was inhibited to the level of native
chondrocytes.31 Silencing of Ob-cadherin expression in monolayer cells induced
redifferentiation in dedifferentiated cells, implying that the 3D microenvironment for cell
expansion diminishes cell-to-cell contacts like native cartilage, which may result in resistance
to dedifferentiation.31 ECM would interact with chondrocytes through integrins and other
signaling receptors, in which specifically α5β1 and αVβ3 integrins were proven highly
expressed in the cells attaching on the 3D ECM.32,33 Afterwards the phosphorylation of
ERK1/2 is upregulated by the activated β1 integrin via Src/Ras/Raf signaling pathway;34 then
the high level of phosphorylated ERK1/2 would enhance TGF-β1-mediated redifferentiation of
expanded chondrocytes on ECM.35,36

Our study also investigated the short-term effect of culture substrate on chondrocyte
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expansion and redifferentiation capacity by switching either from Plastic to ECM (PtoE) or
from ECM to Plastic (EtoP). Our data suggested that expanded chondrocytes from either
PtoE or EtoP acquired higher proliferation and redifferentiation capacity compared to those
plated on Plastic but lower than those seeded on ECM. Chondrocytes expanded on PtoE
acquired a higher redifferentiation capacity than those on EtoP, suggesting that once the
chondrocytes adapt to the ECM environment, the transition from EtoP would deprive the
chondrocytes of their expandability and redifferentiation potential. Our study indicated that
dedifferentiated or aged chondrocytes would regain their redifferentiation capacity with the
help of ECM deposited by SDSCs. ECM provides an in vitro 3D expansion system that may
play an important role in autologous chondrocyte transplantation-based cartilage repair.

In summary, we found that ECM deposited by a tissue-specific stem cell was able to
efficiently expand primary chondrocytes; ECM-expanded chondrocytes retained their
significant redifferentiation capacity. These results demonstrated that SDSC-derived ECM
can function as a new ex vivo expansion system to enhance chondrocyte proliferation and
redifferentiation potential for future clinical applications. Further studies are needed to
investigate whether redifferentiated chondrocytes from expansion on ECM are capable of
forming cartilage tissue in vivo, which would ensure the stability and functionality of the
acquired chondrocyte phenotype. The mechanisms underlying the interaction between
chondrocytes and ECM also need to be further investigated.
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FIGURE LEGENDS

Figure 4.1.

In vitro expansion of articular chondrocytes on Plastic, ECM, PtoE or EtoP from

P0 to P6. (A) Representative cell morphology from expanded chondrocytes at P0, P1, P3 and
P6. (B) DiI-stained chondrocytes (red) with DAPI as a nuclear counterstain (blue) were
expanded on either ECM [immunostained with (Bi) or without (Bii) collagen I antibody (green)]
or Plastic (Biii). (C) Fold-change of expanded cell number was compared for plating on either
ECM or Plastic. (D) Fold-change of collagen II (Col II) mRNA was compared in cartilage
tissue and chondrocytes expanded on ECM or Plastic. (E) Fold-change of collagen I (Col I)
mRNA was compared in cartilage tissue and chondrocytes expanded on ECM or Plastic.
Data are shown as average ± SD for n = 4.

Figure 4.2. Immunophenotype changes of chondrocytes expanded on ECM, Plastic, PtoE,
or EtoP from P0 to P6. Flow cytometry was used to evaluate the percentage (A - C) and mean
fluorescence intensity (MFI, a - c) of CD14+, CD90+, and CD105+ chondrocytes during cell
expansion. Dual positive chondrocytes of CD90+ and CD105+ were represented at P0, P2
and P6 (D). Data are shown as average ± SD for n = 3.

Figure 4.3.

Redifferentiation capacity of expanded chondrocytes was assessed at the

protein level using chondrocyte-pellets after incubation in a TGF-β1-containing medium for 14
days. (A) Alcian blue staining was for sulfated GAGs with fast red as a counterstain, and
immunohistochemistry (IHC) was for collagens I and II (DAB substrate had a brown color
suggestive of positive staining) with hematoxylin as a counterstain. The scale bar was 800
µm. (B) Western blot was used to detect collagen II in extracellular matrix (mature) and
cytoplasm (immature) with β-actin as an internal control. (C) Biochemical analysis was used
to quantitatively measure DNA and GAG amounts in the pellets. DNA data were represented
by DNA ratio adjusted by DNA amount at day 0. Ratio of GAG to DNA was used as a
chondrogenic index. Data are shown as average ± SD for n = 5. Groups not connected by the
same letter are significantly different (p<0.05).
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Figure 4.4.

Redifferentiation capacity of expanded chondrocytes was assessed at the

mRNA level using chondrocyte-pellets after incubation in a TGF-β1-containing medium for 14
days. TaqMan® RT-PCR was used to quantitatively measure chondrogenic marker genes (A
– collagen II, aggrecan, and collagen I) and hypertrophic marker genes (B – collagen X, ALP,
and MMP13) in the pellets of expanded chondrocytes at days 0 and 14. Data are shown as
average ± SD for n = 5. Groups not connected by the same letter are significantly different
(p<0.05).

Figure 4.5.

Redifferentiation capacity of expanded chondrocytes was assessed at the

protein level using chondrocyte-pellets after incubation in a serum-containing medium for 14
days. (A) Alcian blue staining was used for sulfated GAGs with fast red as a counterstain, and
immunohistochemistry (IHC) was for collagens I and II (DAB substrate had a brown color
suggestive of positive staining) with hematoxylin as a counterstain. The scale bar was 800
µm. (B) Western blot was used to detect collagen II in extracellular matrix (mature) and
cytoplasm (immature) of pellets with β-actin as an internal control at days 7 and 14. (C)
Biochemical analysis was used to quantitatively measure DNA and GAG amounts in the 7and 14-day pellets. DNA data were represented by DNA ratio adjusted by DNA amount at day
0. Ratio of GAG to DNA was used as a chondrogenic index. Data are shown as average ± SD
for n = 5. Groups not connected by the same letter are significantly different (p<0.05).

Figure 4.6.

Redifferentiation capacity of expanded chondrocytes was assessed at the

mRNA level using chondrocyte-pellets after incubation in a serum-containing medium for 14
days. TaqMan® RT-PCR was used to quantitatively measure chondrogenic marker genes
(collagen II, aggrecan, and collagen I) in the pellets of expanded chondrocytes at days 7 and
14. Data are shown as average ± SD for n = 5. Groups not connected by the same letter are
significantly different (p<0.05).

Figure 4.S1. Redifferentiation capacity of expanded chondrocytes was assessed at the
protein and mRNA level using chondrocyte-pellets after incubation in a TGF-β1- or
serum-containing medium at Day 7.
160

Figure 4.S2. Redifferentiation capacity of expanded chondrocytes was assessed at the
protein and mRNA level using chondrocyte-pellets after incubation in a TGF-β1-containing
medium at Day 7. (A) Western blot was used to detect collagen II in extracellular matrix
(mature) and cytoplasm (immature) of pellets with β-actin as an internal control at Day 7 in
the group of TGF-β1 treatment. (B) Biochemical analysis was used to quantitatively measure
DNA and GAG amounts in the 7-day pellets treated by TGF-β1. (C) mRNA level using
chondrocyte-pellets after incubation in a TGF-β1-containing medium at Day 7.
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ABSTRACT

Study Design. After plating for six passages on either plastic flasks or extracellular matrix
(ECM) deposited by synovium-derived stem cells (SDSCs), expanded nucleus pulposus (NP)
cells were evaluated for redifferentiation capacity.
Objective. The aim was to assess the feasibility of using ECM deposited by a tissue-specific
stem cell to provide a 3D microenvironment for NP cell rejuvenation.
Summary of Background Data. Autologous disc cell-based therapy is a promising approach
for intervertebral disc (IVD) regeneration. Unfortunately, the current in vitro expansion of NP
cells in monolayer results in dedifferentiation of these cells.
Methods. Primary NP cells were plated on either plastic flasks or ECM for six consecutive
passages. At each passage, cell numbers were counted for proliferation rate, cell phenotype
was evaluated using flow cytometry and cell differentiation status was assessed using
real-time PCR. The pellets from expanded NP cells at passages 1, 4 and 6 were incubated in
a serum-free defined medium for 14 days. Redifferentiation capacity of the expanded NP
cells was evaluated using histology, biochemistry, and real-time PCR.
Results. NP cells expanded on ECM grew much faster with a smaller size and fibroblast-like
shape compared to those on plastic flasks. ECM-treated NP cells acquired an enhanced
CD90 expression and higher mRNA levels of types I, II, and X collagen and aggrecan, as well
as a robust redifferentiation capacity, evidenced by dramatically increased type II collagen,
aggrecan and Sox9 and decreased type I collagen for up to six passages.
Conclusion. SDSC-derived ECM can provide a tissue-specific microenvironment for the
rejuvenation of NP cells with a higher proliferation rate and redifferentiation capacity, which
may play a role in improving an autologous disc cell-based minimally invasive therapeutic
approach toward physiological reconstruction of a biologically functional disc in the clinical
setting.

Key words:
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Extracellular matrix, stem cell niche, proliferation, dedifferentiation, redifferentiation,
synovium, nucleus pulposus cell

Key points:
•

Monolayer culture can result in NP cell dedifferentiation, evidenced by losing cell
proliferation and gene expression profiles as well as redifferentiation capacity

•

ECM deposited by SDSCs provides a tissue-specific 3D microenvironment for NP cell
large-scale expansion

•

NP cells expanded on ECM acquire a higher expression of CD90 and differentiated
gene profiles

•

NP cells expanded on ECM also acquire a robust redifferentiation capacity

•

The expansion microenvironment switched from plastic flasks to ECM can improve
NP cell rejuvenation
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INTRODUCTION

Approximately 80% of the adult population is affected by low back pain (LBP); this has a
massive economic impact due to both health care costs and loss of productivity.1 Although the
causes of LBP are complicated and not fully understood, degeneration of the intervertebral
disc (IVD) is an important underlying cause.2;3 IVD degeneration begins in the nucleus
pulposus (NP) with a progressive decrease in proteoglycan content, leading to a loss of
hydrogel properties of the NP.4 Clinical treatments of IVD disease include various noninvasive
and invasive therapies, but are limited to symptomatic relief. Much of the recent research in
this area has focused on biological restoration of the IVD.5;6 Although human IVD cells share
matrix-producing properties with chondrocytes, studies have shown that there are indeed
phenotypic differences between NP cells and articular chondrocytes.7 Stem cells seem to be
another candidate for cell transplantation; however, the lack of a definitive cell marker to
distinguish NP cells from other cells has made clinical application more difficult and less
realistic.

Animal studies8-10 and an early clinical trial (Euro Disc Randomized Trial)11 have indicated
that autologous disc cell transplantation (ADCT) is technically feasible and biologically
relevant to repairing disc damage and retarding disc degeneration. However, one concern of
critics of ADCT is that cells isolated from degenerative discs may lack the potential of healthy
counterparts, making them poorly suited for repair in an inhospitable degenerated disc
environment.12 In addition, the preparation of NP cells for reimplantation is problematic
because autologous transplantation requires more cells than can be harvested from a small
biopsy. With low cellular yields and low proliferative activity of NP cells in monolayer culture,
further enhancement of the biological and metabolic viability of NP cells is desirable.

Our recent study has shown that synovium-derived stem cells (SDSCs) can be used to
prepare a 3D microenvironment for SDSC proliferation while maintaining and enhancing their
chondrogenic differentiation capacity.13 Since NP cells are chondrocyte-like cells, in this study,
we hypothesize that SDSC-derived ECM can serve as a tissue-specific microenvironment for
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ex vivo expansion of NP cells while maintaining NP cell differentiated phenotype and
redifferentiation capacity. Our long-term goal is to develop an autologous disc cell-based
minimally invasive therapeutic approach toward physiological reconstruction of a biologically
functional disc in the clinical setting.
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METHODS

Isolation and culture of SDSCs and NP cells
Two 3-month-old pigs were collected from a local slaughterhouse and harvested to provide
synovial tissue from both knees and NP tissue from the lumbar spine (L1-L5). The synovial
tissue was finely minced and digested at 37ºC for 30 min in 0.1% trypsin (Roche, Indianapolis,
IN) and then for 2 h in 0.1% collagenase P (Roche) to release synovial cells. The NP tissue
was digested with 0.1% collagenase A (Sigma, St. Louis, MO) and 10 U/mL hyaluronidase
(Sigma) at 37oC for 4 h. Synovial cells and NP cells were collected from the filtrate by
centrifugation and plated in complete medium [αMEM containing 10% fetal bovine serum
(FBS), 100 U/mL penicillin, 100 µg/mL streptomycin and 0.25 μg/ml fungizone]. Synovial
fibroblasts were negatively isolated from primary culture and characterized as SDSCs
according to our previous study14.

Preparation of SDSC-derived ECM
The preparation of SDSC-derived ECM was described in our previous study.13 Briefly,
fibronectin was pre-coated on plastic flasks at 37ºC for 1 h. When the plated SDSCs reached
90% confluence, 50 µM L-ascorbic acid phosphate (Wako, Richmond, VA) was added for
eight days. ECM was washed with phosphate buffered saline (PBS), and incubated with 0.5%
Triton X-100 containing 20 mM ammonium hydroxide in PBS at 37ºC for 5 min and stored in
PBS.

NP cells grown on SDSC-derived ECM
Passage one (P1) NP cells were plated at 3,000 cells/cm2 in plastic flasks with (“ECM”) or
without ECM (“Plastic”) -coating for six consecutive passages. The third group was grown on
plastic flasks for five passages and then switched on ECM for one passage (“PtoE”).
Complete medium was replaced every three days. Cell number was quantified using a
counting hemocytometer.
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FACS analysis
Triple individual samples of 0.3 × 106 cells each were incubated on ice in PBS containing
0.1% ChromPure Swine IgG (Jackson Immuno Research, West Grove, PA) and 1% NaN3 for
30 min. Primary monoclonal antibodies were applied for 30 min, including CD29 (Abcam,
Cambridge, MA), CD44 (Abcam), CD90 (BD Pharmingen, San Jose, CA), CD105 (GeneTex
Inc., San Antonio, TX) and isotype-matched IgGs (Beckman Coulter, Fullerton, CA). After
washing with cold PBS, NP cells were incubated with the secondary antibody
[FITC-conjugated goat anti-mouse Ig (Abcam)] for 30 min in the dark followed by fixation in
400 μL of 0.4% paraformaldehyde. NP cells were analyzed on a BD dual laser FACS Calibur
(BD Biosciences) using the FCS Express Version 3 (De Novo Software, Los Angeles, CA)
software package.

Redifferentiation of expanded NP cells
0.3 × 106 of NP cells from P1, P4, and P6 were centrifuged at 500 g for 5 min to form a pellet.
After 24 h incubation (day 0), the pellets were cultured in a defined medium consisting of
high-glucose DMEM, 40 µg/mL proline, 100 nM dexamethasone, 100 U/mL penicillin, 100
µg/mL streptomycin, 0.1 mM ascorbic acid-2-phosphate and 1 × ITS™ Premix (BD
Biosciences) with 10 ng/mL transforming growth factor β1 (TGF-β1) (R&D Systems,
Minneapolis, MN) for 14 days.

Histochemistry and immunohistochemistry
The pellets (n=3) were fixed in 4% paraformaldehyde, dehydrated in a gradient ethanol series,
cleared with xylene, and embedded in paraffin blocks. 5-μm sections were histochemically
stained with Safranin-O (Sigma). For immunohistochemical analysis, the sections were
immunolabeled with primary antibodies against collagen I (Sigma) and collagen II (II-II6B3,
DSHB, Iowa City, IA), respectively. A secondary antibody of biotinylated horse anti-mouse
IgG (Vector, Burlingame, CA) was incubated on the sections for 30 min. Immunoactivity was
detected using Vectastain ABC reagent (Vector) with 3,3’-diaminobenzidine (DAB) as a
substrate. Hematoxylin (Vector) served as a counterstain.
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Biochemical analysis for DNA and GAG content
The pellets (n=6) were digested for 4 h at 60ºC with 125 μg/mL papain in PBE buffer (100
mmol/L phosphate, 10 mmol/L EDTA, pH 6.5) containing 10 mmol/L cysteine using 100 μL
enzyme per sample. To quantify cell density, the amount of DNA in the papain digestion was
measured using the QuantiTTM PicoGreen® dsDNA assay kit (Invitrogen) with a CytoFluor®
Series 4000 (Applied Biosystems, Foster City, CA). GAG was measured using
dimethylmethylene blue dye and a SpectronicTM BioMateTM 3 Spectrophotometer with bovine
chondroitin sulfate as a standard.

TaqMan® Quantitative PCR
The total RNA was extracted from samples (n=5) using an RNase-free pestle in TRIzol®
(Invitrogen). 1 µg of mRNA was used for reverse transcriptase (RT) with a High-Capacity
cDNA Archive Kit at 37ºC for 120 min as recommended by the manufacturer (Applied
Biosystems). Chondrogenic marker genes (types I, II, and X collagen, Sox9, and aggrecan)
were customized by Applied Biosystems as part of the Custom Taqman® Gene Expression
Assays.13 Eukaryotic 18S RNA (Assay ID: HS99999901_s1 ABI) was carried out as the
endogenous control gene. Real-time PCR was performed with the iCycler iQTM Multi Color
RT-PCR Detection and calculated by computer software (Perkin-Elmer, Waltham, MA).
Relative transcript levels were calculated as χ=2-ΔΔCt, in which ΔΔCt=ΔE-ΔC, ΔE=Ctexp-Ct18s,
and ΔC=Ctct1-Ct18s.

Statistics
The Kruskal-Wallis test was used to test for significant differences among all groups and the
Mann-Whitney U test was used for pairwise comparison in flow cytometry data, biochemistry
analysis, and real-time PCR data. All statistical analyses were performed with SPSS 13.0
statistical software (SPSS Inc., Chicago, IL). P values less than 0.05 were considered
statistically significant.
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RESULTS
SDSC-derived ECM enhances NP cell proliferation while retaining their differentiation
phenotypes
Primary NP cells were plated in plastic flasks without or with ECM coating for six passages.
NP cells plated on plastic flasks were shown to proliferate slowly; in contrast, NP cells grown
on ECM had their cell number increased dramatically by overlapping in a 3D format after
reaching confluence (Figure 5.1A). Relative to NP cells expanded on plastic flasks,
ECM-treated NP cells yielded 7.8-fold greater cell numbers at P1. Despite a decreased
proliferation rate with passage in both groups, NP cells expanded on ECM yielded 10.8-fold at
P2, 19.1-fold at P3, 13.9-fold at P4, and 15.0-fold at P6 greater cell numbers than those
plated on plastic flasks (Figure 5.1B).

To identify if NP cells expanded on ECM acquired mesenchymal stem cell (MSC) phenotypes,
CD29, CD44 and CD90 were assessed using flow cytometry (Figure 5.2A). Despite a
comparable percentage of CD29+ cells (Figure 5.2B), NP cells expanded on ECM were lower
in mean fluorescent intensity (MFI) than those on plastic flasks (Figure 5.2C). Interestingly,
NP cells expanded on ECM acquired CD90+ cells greater than those grown on plastic flasks
in both percentage (Figure 5.2D) and MFI (Figure 5.2E), indicating that SDSC-derived ECM
provides a 3D microenvironment to enhance NP cell “stemness” toward chondrogenic
differentiation.15 For CD44, ECM-treated NP cells shared a similar expression phenotype as
those grown on plastic flasks except slightly higher at P3 and P6 in both percentage (Figure
5.2F) and MFI (Figure 5.2G). Noticeably, NP cells expanded from PtoE acquired
immunophenotypes close to those on ECM, particularly in MFI (Figure 5.2C, 5.2E, 5.2G).

To identify differentiation status of expanded NP cells, types I, II, and X collagen and
aggrecan were assessed using real-time PCR. Chondrogenic marker genes [collagen II
(Figure 5.3A) and aggrecan (Figure 5.3B)] decreased their expression with passage,
particularly in the early subculture of NP cells on plastic flasks. In contrast, ECM-treated NP
cells showed greater collagen II and aggrecan mRNA in all passages than those seeded on
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plastic flasks. Intriguingly, ECM-treated NP cells also exhibited higher collagen I mRNA
(Figure 5.3C) and collagen X mRNA (Figure 5.3D) than those grown on plastic flasks.
Collagen I mRNA was elevated in the initial passage followed by a gradual decrease until P6
in both groups.

In vitro tissue-specific microenvironment restores redifferentiation capacity of expanded NP
cells
Despite no positive staining at day 0, the pellets from expanded NP cells on either plastic
flasks or ECM at P1 were stained intensively with sulfated GAGs and types I and II collagen
at day 7 while type I collagen became weaker with the maturation of pellets.
Fourteen-day-pellets from NP cells expanded on ECM were larger in size and more
homogeneous in the distribution of sulfated GAGs and type II collagen than those on plastic
flasks. More evidently, ECM-treated NP cells at P4 yielded pellets with more sulfated GAGs
and types I and II collagen at day 7 than those grown on plastic flasks. ECM-treated NP cells
at P6 yielded pellets with more intense staining of sulfated GAGs and collagen II at days 7
and 14 than those from NP cells expanded on plastic flasks. The pellets of NP cells expanded
from PtoE exhibited more intense expression of collagen II and sulfated GAGs than those on
plastic flasks (Figure 5.4).

To evaluate redifferentiation capacity of expanded NP cells, biochemical analysis was used to
quantify GAG amount, DNA amount and ratio of GAG to DNA (chondrogenic index) in pellets.
Adjusted by those at day 0, pellets from P1 NP cells expanded on ECM exhibited a huge
increase in DNA and GAG amounts compared to a drop in those grown on plastic flasks
despite the fact that both groups had a comparable chondrogenic index at day 14 (Figure
5.5A, 5.5B, 5.5C). After six consecutive passages, NP cells expanded on either ECM or PtoE
maintained their cell numbers in pellets more than the corresponding NP cells on plastic
flasks. NP cells expanded on ECM also exhibited the highest GAG amount compared to the
other two groups, which contributed to the highest chondrogenic index in pellets of
ECM-treated NP cells at P6 (Figure 5.5D, 5.5E, 5.5F).
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Redifferentiation capacity of expanded NP cells was also evaluated at the mRNA level
(Figure 5.6). At P1, ECM-treated NP cells had a comparable collagen II but higher aggrecan
mRNA than those expanded on plastic flasks after a 14-day incubation in chondrogenic
medium. Although both collagen II and aggrecan mRNA levels decreased with passage,
ECM-treated NP cells at P6 exhibited 10.8-fold of collagen II and 10.0-fold of aggrecan
mRNA levels compared to those expanded on plastic flasks. ECM-treated NP cells also
displayed a higher expression of Sox9 mRNA, which may be responsible for the enhanced
expression of collagen II and aggrecan mRNAs. Our data also showed that ECM-treated NP
cells at P6 exhibited about half the collagen I mRNA but comparable collagen X mRNA
compared to those expanded on plastic flasks when incubated in chondrogenic medium for
14 days.
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DISSCUSSION

IVD degeneration is associated with a loss of matrix molecules resulting in altered biochemical
and biomechanical properties of the tissue.4;16;17 Since there is no risk of disease transmission
and immune rejection, autologous IVD cells are a promising cell source for disc regeneration.
However, quality and quantity of NP cells from patients are a concern.18 To make clinical
application a reality, in vitro expansion cultures are expected to yield large amounts of cells in
a short period of time. Moreover, these expanded NP cells should express or be able to
reexpress their NP cell phonotype (redifferentiation capacity) facilitating a functional
extracellular matrix. Thus, cell numbers and redifferentiation capacity are two important
parameters in disc regeneration. Our study indicated, for the first time, that ECM deposited by
SDSCs can provide such an in vitro microenvironment to rejuvenate NP cells by greatly
enhancing cell proliferation ability, differentiation status and redifferentiation capacity.

After notochordal cells disappear during childhood, lumbar discs show evidence of
degeneration with age.19 Interestingly, some species that retain their notochordal cells in
adulthood do not show age-related IVD degeneration,20 suggesting that notochordal cells can
provide a microenvironment preventing NP cells from degenerating. During in vitro expansion,
NP cells undergo a characteristic process of dedifferentiation, marked by a loss in the
expression of collagen II21;22 and aggrecan23 as well as the induction of collagen I
expression24;25. There is a discrepancy in the dedifferentiation process between articular
chondrocytes and NP cells; the former accumulates collagen I while the later loses collagen
I26. Many reports demonstrate that cells grown in a more physiological 3D environment can
differ considerably in their morphology, cell-cell and cell-matrix interactions, and
differentiation from those grown on flat 2D tissue culture substrates27;28, suggesting that there
exists a critical feature of the specialized environment (niche) in ECM that is responsible for
the maintenance of MSC “stemness” by supporting their self-renewal capability and
maintaining multipotentiality while facilitating differentiation in response to appropriate
signals.29 However, this feature is missing in standard culture systems.
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It is postulated that ECM deposited by stem cells provides a microenvironment that can
benefit adult cells in proliferation and redifferentiation capacity. Studies from our group and
other groups suggest that a tissue-specific stem cell can be used to prepare its own in vitro
niche for stem cell proliferation while maintaining and enhancing its lineage-specific
stemness.13;30 A great challenge during chondrogenesis is to generate articular cartilage-like
chondrocytes that do not undergo hypertrophy as a terminal differentiation stage.31-33
Cartilage and synovial tissue are derived from a common precursor pool34 and share similar
profiles.35-37 Recent studies demonstrate that synovial tissue can provide a superior type of
MSC for chondrogenesis compared to other sources.38-41 Since NP cells are chondrocyte-like
cells, SDSC-derived ECM may provide a tissue-specific microenvironment for the
rejuvenation of NP cells.

In our study, NP cells grown on SDSC-derived ECM yielded greater cell numbers and higher
chondrogenic marker genes than those plated on plastic flasks despite the declining trend
with passage in both groups. In contrast, NP cells grown on plastic flasks resulted in cell
dedifferentiation; our finding also demonstrated that these dedifferentiated cells were no
longer capable of redifferentiation, especially for NP cells expanded more than four passages,
which is consistent with a previous study.42 Interestingly, ECM-expanded NP cells acquired a
higher redifferentiation capacity for up to six passages. Compared to being plated on plastic
flasks, NP cells grown on SDSC-derived ECM regained a higher CD90 percentage and
median as well as a lower CD29 median, which is consistent with our previous study in which
SDSCs displayed a similar change in phenotypes when grown on SDSC-derived ECM.13
CD90 expression was reported to be positively related with MSC chondrogenic capacity43
and immunosuppressive capacity44, suggesting that ECM-treated NP cells not only acquire
enhanced redifferentiation capacity but also are able to better survive the immune reaction
after implantation.

There is a recent report indicating that the pathologically degenerate human disc contained
populations of skeletal progenitor cells.45 These stem cells or progenitor cells would be
responsible for the NP cell redifferentiation and IVD regeneration, evidenced by a higher
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proliferation capacity and multi-lineage differentiation potentials into adipogenesis,
osteogenesis and chondrogenesis.46;47 The nucleus pulposus cells expanded on our ECM
deposited by SDSCs behaved more like stem cells or progenitor cells rather than terminally
differentiated cells, suggested by the fast proliferation rate, the high expression of CD90
surface marker, and redifferentiation capacity to generate tissue-specific matrix. The
specialized microenvironment is able to up-regulate a decapentaplegic (dpp) niche signaling
pathway of incoming cells. Empty niches have the potential to alter cell fate as well as the
growth properties of already committed and maturing cells,48;49 and therefore may be able to
impose a stem cell state on more mature cells, enhancing cell proliferation and differentiation
potential.

Our study demonstrated that SDSC-derived ECM may provide a tissue-specific
microenvironment to rejuvenate NP cells for proliferation and redifferentiation. Our study also
indicated that the in vitro microenvironment from young donors may reprogram and
rejuvenate seeded cells from elderly donors that have lower proliferation and differentiation
capacity.50;51 In clinics, most patients are adults or elders. Stem cells from older patients are
not able to provide a high-quality “soil” (microenvironment) for cell rejuvenation. Stem cells
from young donors in a human tissue bank could be utilized to prepare a high-quality
microenvironment on which NP cells from patients can be greatly expanded while maintaining
their differentiation capacity.
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FIGURE LEGENDS

Figure 5.1. Effect of SDSC-derived ECM on NP cell morphology and proliferation. NP cells
were expanded on either plastic flasks or ECM for six consecutive passages. NP cell
morphology at P1 and P4 was shown at day 6 using a phase contrast microscope (A). Cell
number from both groups was compared with passage (B). Data are shown as average ± SD
for n = 3.

Figure 5.2. Flow cytometry analysis of typical MSC surface antigens (CD29, CD44, and
CD90) with isotype-specific control (A). The percentage (B, D, F) and mean fluorescent
intensity (MFI, C, E, G) of positive cells were compared for MSC phenotype changes in NP
cells grown on plastic flasks or ECM for six passages.

Figure 5.3. Quantitative real-time PCR of differentiated (A: collagen II mRNA, B: aggrecan
mRNA, and C: collagen X mRNA) and dedifferentiated (D: collagen I mRNA) phenotypes of
NP cells expanded on plastic flasks or ECM for six passages. The data were adjusted by
mRNA level of P1 NP cells expanded on plastic flasks. Data are shown as average ± SD for n
= 5.

Figure 5.4. Histological evaluation of redifferentiation capacity of NP cells expanded on
plastic flasks or ECM for six passages using safranin O staining for sulfated GAGs and
immunostaining for types I and II collagen at days 0, 7, and 14. NP cells grown on plastic
flasks for five passages and switched to ECM for one passage (PtoE) served as the third
group.

The scale bar is 800 µm.

Figure 5.5. Biochemical analyses were used to detect DNA (A,D) and GAG amounts (B,E)
per pellet at P1 (A,B,C) and P6 (D,E,F). DNA amount at days 7 and 14 was adjusted by that
at day 0 to minimize the initial difference in pellet preparation. Chondrogenic index was
presented as ratio of GAG to DNA at P1 (C) and P6 (F). Data are shown as average ± SD for
n = 6. Significant differences are indicated as *p < 0.05, **p < 0.01 and ***p < 0.001.
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Figure 5.6. TaqMan real-time PCR was used to quantitatively assess chondrogenic markers
[collagen II (A/B), aggrecan (C/D), Sox9 (E/F), collagen I (G/H), and collagen X (I/J)] at mRNA
level. All marker gene expression was presented as relative mRNA level adjusted with 18S
RNA. Data are shown as average ± SD for n = 5. Significant differences are indicated as *p <
0.05, **p < 0.01 and ***p < 0.001.
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Chapter 6
Three-dimensional extracellular matrix deposited by human bone marrow stem
cells promotes cell proliferation and chondrogenesis

ECM interacts with cells via integrin/Src/ERK signaling pathway and enhances the
sensitivity of transforming growth factor beta receptor II

Fan He, B.S. and Ming Pei, M.D., Ph.D.

Stem Cell and Tissue Engineering Laboratory, Department of Orthopaedics and Division of
Exercise Physiology, West Virginia University, Morgantown, West Virginia 26506
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ABSTRACT

The three-dimensional (3D) cell-deposited extracellular matrix (ECM) was previously
reported as a new expansion system in vitro mimicking tissue-specific mesenchymal stem
cell microenvironment, but the mechanism of the interaction between ECM and cells and the
intracellular signaling transduction pathway was not clear due to the complexity of the 3D
ECM compared with the 2D conventional monolayer culture. In this study we expanded
human bone marrow stem cells (hBMSCs) in vitro under the 3D hBMSC-deposited ECM
environment (ECM) or conventional plastic flasks (Plastic). The 3D ECM greatly improved
hBMSC proliferative rate and attenuated the intracellular reactive oxygen species but
increased the cell apoptosis. Chondrogenic differentiation was induced by transforming
growth factor - β3 (TGF-β3) and hBMSCs expanded on 3D ECM showed robust
chondrogenic potential to generate cartilage-specific genes and matrix, including sulfated
glycosaminoglycans, Sox9 and type II collagen. We compared several key signaling kinases
expression and activity in hBMSCs cultured on ECM and Plastic. The 3D ECM increased the
expression of SSEA-4, integrin α2, α4, and β5, and induced sustained activation of Src kinase,
ERK1/2 and cyclin D1. Not only the expression but also the activity of TGF-β receptor II was
enhanced by 3D ECM in hBMSCs. These observations suggested that the 3D cell-deposited
ECM promoted hBMSC proliferative capacity may through integrin/Src/ERK1/2 signaling
pathway and enhanced the chondrogenic potential by improving the responsiveness of
TGF-β receptor.
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INTRODUCTION

Mesenchymal stem cells (MSCs) are considered a promising source for cell therapy and
regenerative medicine, because not only they can be isolated from various adult tissues, but
also they have excellent self-renewal potential and multipotent differentiation capacities.1-4
The current expansion technique in vitro, however, limits the utilization of MSCs due to
inadequate cell quantity and impaired multipotent differentiation after monolayer passages.5;6
In previous studies, we developed a novel mesenchymal stem cells expansion system based
on the three-dimensional (3D) extracellular matrix (ECM) deposited by synovium-derived
stem cells (SDSCs). This system dramatically improved the proliferation and chondrogenic
potential of SDSCs7 and adipose-derived stem cells (ADSCs).

These natural ECM were first used to investigate tumor progression8;9 and provided an
excellent model to study cell behaviors in the 3D environment. The native 3D ECM is
proposed to mimic the in vivo microenvironment, thus directing MSCs in morphology, cell-cell
and cell-matrix interaction, self-renewal and differentiation.7;10;11 Compared to conventional
2D reconstructed ECM, which is usually coated with several protein monolayers, including
fibronectin,12 type I collagen13 or laminins,14 the native cell-deposited ECM not only provides
3D structure but also has multiply matrix proteins to affect the cell signaling pathway,
including type I, III and V collagens, syndecan-1, perlecan, fibronectin, laminin, biglycan and
decorin.7;10;15

Integrins are heterodimeric transmembrane receptors that are composed by an α and a β
subunit. They mediate the interaction between ECM and cells, thus affecting the cell
adhesion, survival, self-renewal, apoptosis, migration and differentiation16. Attaching to
various ECM proteins, integrins combine two different α and β subunits. β1 integrin are
proven to bind collagen and fibronectin17 and α5β1 and αVβ3 integrins were reported in the
process of cells attaching on the 3D ECM.15;18 ECM provides a structural scaffold to resist
tensile and compressive stress and functions as a tight connection to cell cytoskeleton
through cell-surface receptors enabling cells to sense and respond to the extracellular
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mechanical and chemical signals.16;19;20

However, the cell signaling pathway associated with 3D native ECM is still unclear and
different from that on 2D reconstructed ECM. It is reported that the activity of focal adhesion
kinase (FAK) which mediates integrin activation is suppressed by 3D ECM. But ECM induced
sustained phosphorylation of Src kinase, whose downstream extracellular signal regulated
kinases 1 and 2 (ERK1/2) thus is elevated.11;15;21 Integrins also play an important role in cell
proliferation through ERK1/2 dependant pathway by activating cyclin D1 to promote cell
division.19;22;23 Several integrins, including α5β1, αVβ3 and α4β1 were reported to be activated
when binding to ECM components such as fibronectin and collagens.16;20;24-27

In this study, we expanded human bone marrow stem cells (hBMSCs) under two different
conditions: (1) cells grown on conventional plastic flasks were used as the control group
(Plastic); (2) cells were cultured on 3D native hBMSC-deposited ECM (ECM). Considering
the importance of integrins and ERK1/2 in mediating cell proliferation, we tested 10 integrin
subunits immunophenotype, and the activation level of Src kinase, ERK1/2 and cyclin D1.
After separate expansion on ECM and Plastic, hBMSCs were induced to chondrogenesis and
several key proteins were examined including transforming growth factor β receptor II (TGF-β
receptor II), Sox9, type II collagen and ERK1/2. Interestingly, we found that 3D
hBMSC-deposited ECM induced sustained activation of ERK1/2 and cyclin D1 and enhanced
TGFβ receptor II activity during chondrogenesis.
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MATERIALS AND METHODS

Preparation of hBMSC-derived extracellular matrix (ECM)
Human bone marrow stem cells (hBMSCs) were purchased from Lonza (Lonza Group Ltd.,
Switzerland). The procedure of obtaining cell-free extracellular matrix was described
previously7. 75 cm2 plastic flasks were pretreated with 0.2% gelatin solution (Sigma, St. Louis,
MO) for 1 hour at 37
˚C, followed by

1% glutaraldehyde (Sigma) and 1 M ethanolamine

(Sigma) for 30 minutes separately at room temperature. Human BMSCs were seeded on
pretreated plastic flasks at the density of 3,000 cells/cm2 in culture medium [α-minimum
essential medium (Invitrogen, Carlsbad, CA) containing 10% fetal bovine serum (FBS,
Atlanta Biologicals, Lawrenceville, GA), 100 U/ml penicillin, 100 µg/ml streptomycin and 0.25
μg/ml fungizone (Invitrogen)] for 7 days. After reaching 90% confluence, 50 mg/mL of
L-ascorbic acid phosphate (Wako, Richmond, VA) was added and continued to culture for an
additional 8 days. To obtain cell-free ECM, ECM deposited by hBMSCs was incubated with
0.5% Triton X-100 (Sigma) containing 20 mM ammonium hydroxide (Sargent-Welch, Skokie,
IL) for 5 minutes at 37ºC, followed by 100 u/mL DNase I (Sigma) for 1 hour at
˚C37
and
stored at 4ºC.

In vitro culture of hBMSCs on Plastic and ECM
Passage 6 BMSCs were expanded under two different conditions: conventional plastic flasks
(Plastic) and flasks coated with hBMSC-derived ECM (ECM). Non-adherent cells were
removed by medium change every three days. At each passage, cell number was calculated
by a counting hemacytometer (Hausser Scientific, Horsham, PA) for cell number fold change.

Cell proliferation assay
Before subculturing on Plastic and ECM, passage 6 hBMSCs were labeled with CellVue®
Claret (Sigma) at 2 × 10-6 M for 5 minutes according to the manufacture protocol. After the
7-day expansion, cells were collected and measured by a BD dual laser FACS Calibur (BD
Biosciences). Cell proliferation index was analyzed using CellQuest Pro software (BD
Biosciences).
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Measurement of intracellular reactive oxygen species (ROS)
Intracellular ROS generation was measured with 2′,7′-dichlorofluorescein diacetate (DCF-DA)
(Sigma). In brief, after detachment, 2 × 105 of cells (n = 3) were incubated with 10 μM of
DCF-DA for 10 minutes at 37ºC. After washing twice with PBS, the DCF fluorescence was
measured by a BD dual laser FACS Calibur (BD Biosciences) using FCS Express software
package (De Novo Software, Los Angeles, CA) and 10000 events of each sample were
analyzed.

Apoptosis analysis of hBMSCs on Plastic and ECM
Vybrant® Apoptosis Assay Kit (Invitrogen) was used to detect hBMSCs apoptosis. By
following the manual, samples (n = 3) of each 2 × 105 cells were labeled with FITC annexin V
and propidium iodide for 15 minutes at room temperature. After washing with PBS the
fluorescence was measured by FACS Calibur (BD Biosciences) and 10000 events of each
sample were analyzed.

Flow cytometry analysis
The following primary antibodies were used in flow cytometry analysis to detect hBMSCs
surface immunophenotype profiles: CD14, CD24, integrin β1 (CD29), CD44, CD45, CD71,
CD73, CD166 were purchased from Abcam (Abcam, Cambridge, MA); CD105, SSEA-4,
integrins of α1 (CD49a), α2 (CD49b), α3 (CD49c), α4 (CD49d), α5 (CD49e), α6 (CD49f), β3
(CD61), and β4 (CD104) were from Santa Cruz (Santa Cruz Biotechnology, Santa Cruz, CA);
CD90 (BD Biosciences); Integrin β5 (Cell Signaling Technology, Danvers, MA). IgG1 and
IgG2a (Beckman Coulter, Fullerton, CA) were used as the isotype controls, and the
secondary antibody was goat anti-mouse IgG (H+L) R-phycoerythrin conjugated (Invitrogen).
Samples (n = 3) of each 0.2 × 106 chondrocytes were incubated on ice in cold PBS containing
0.1% ChromPure Human IgG whole molecule (Jackson ImmunoResearch Laboratories,
West Grove, PA) and 1% NaN3 (Sigma) for 30 minutes. After that cells were incubated in the
primary antibodies and the secondary antibodies for 30 minutes separately in the dark. The
fluorescence was analyzed by a FACS Calibur (BD Biosciences) using FCS Express software
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package (De Novo Software).

Chondrogenic differentiation of hBMSCs
3 × 105 of hBMSCs at passage 6 cultured on Plastic and ECM were centrifuged to form
pellets in a 15-ml polypropylene tube at 500 g for 5 minutes. After 24 hours the pellets were
incubated in chondrogenic medium [high-glucose DMEM, 40 µg/ml proline, 100 nM
dexamethasone (Sigma), 100 U/ml penicillin, 100 µg/ml streptomycin, 0.1 mM ascorbic
acid-2-phosphate and ITS™ Premix (BD Biosciences) with the supplementation of 10 ng/ml
of TGF-β3 (PeproTech Inc., Rocky Hill, NJ)]. Pellets at day 0, day 7 and day 15 were collected
for further analysis.

Histology and Immunohistochemistry
The chondrogenic pellets (n = 2) were fixed in 4% paraformaldehyde, embedded in paraffin
blocks and cut into 5-μm thick sections. To detect glycosaminoglycans, sections were stained
with 0.2% Alcian blue solution (Sigma). For immunohistochemistry the sections were
incubated with primary antibodies against type II collagen (II-II6B3, DSHB, Iowa City, IA),
type I collagen (Sigma) and type X collagen (Sigma), followed by the secondary antibody of
biotinylated horse anti-mouse IgG (Vector, Burlingame, CA) and detected by using Vectastain
ABC reagent (Vector) with 3,3’-diaminobenzidine (DAB) as the substrate.

Biomechanical analysis for hBMSC pellets
The pellets (n = 4) were placed into a reservoir filled with PBS and loaded onto the custom
miniature stepper motor driven compression device. This device used a 10 gram load and a
miniature displacement readout. A small preload of 10-4 Newton was applied before a 10
percent strain at a 1 second duration. From the linear portion of the load displacement curve,
the stiffness and Young’s modulus were calculated for the spherical shaped pellet.28

Biochemical analysis for DNA and glycosaminoglycan content
To exam DNA and sulfated glycosaminoglycans (GAGs) content, pellets (n = 4) were
digested for 6 hours at 60ºC with 125 μg/ml papain in PBE buffer (100 mM phosphate, 10 mM
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EDTA, pH 6.5) containing 10 mmol/L cysteine. The amount of DNA was measured by e
QuantiTTM PicoGreen® dsDNA assay kit (Invitrogen) with a CytoFluor® Series 4000 (Applied
Biosystems, Foster City, CA) followed by the protocol. Sulfated GAGs were measured by
using 16 µg/ml of dimethylmethylene blue dye and a SpectronicTM BioMateTM 3
Spectrophotometer (Thermo Scientific, Milford, MA) with bovine chondroitin sulfate (Sigma)
as the standard.

Real-time polymerase chain reaction (Real-time PCR)
The total mRNA from pellets (n = 4) was extracted by using TRIzol® (Invitrogen) and
converted to cDNA with High-Capacity cDNA Archive Kit as recommended by the
manufacturer (Applied Biosystems). Chondrogenic marker genes (aggrecan, type I and II
collagen, and Sox9) and hypertrophy marker genes (type X collagen, MMP13) are
customized by Applied Biosystems as part of the Custom Taqman® Gene. Expression Assays
Eukaryotic 18S rRNA (Assay ID HS99999901_s1 ABI) was carried out as the endogenous
control gene. Real-time PCR was performed with the iCycler iQTM Multi Color RT-PCR
Detection and calculated by computer software (Perkin-Elmer, Waltham, MA). Relative
transcript levels were calculated as χ=2-ΔΔCt, in which ΔΔCt=ΔE-ΔC, ΔE=Ctexp-Ct18s, and
ΔC=Ctct1-Ct18s.

Immunoblotting
RIPA lysis buffer (Thermo Scientific) supplemented with halt protease and phosphatase
inhibitor cocktail (Thermo Scientific) was used to extract protein from the cells. The protein
concentration was quantified using BCATM Protein Assay Kit (Thermo Scientific). The
samples was denatured and separated by NuPAGE® Novex® Bis-Tris Mini Gels (Invitrogen)
at 200V for 45 minutes at 4oC, then transferred onto a nitrocellulose membrane (Invitrogen)
using XCell IITM blot module (Invitrogen) at 30V for 1 hour at 4oC. The membranes were firstly
blocked in SuperBlock (TBS) Blocking Buffer (Thermo Scientific), then incubated with the
primary monoclonal antibodies at recommended dilution overnight at 4oC. The membranes
were incubated in the secondary antibody of Goat Anti-Mouse IgG (H+L) and Goat
Anti-Rabbit IgG (H+L) (Thermo Scientific) for 40 minutes at room temperature and exposed
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using SuperSignal® West Pico Chemiluminescent Substrate (Thermo Scientific) and
CL-XPosureTM Film (Thermo Scientific). The following primary antibodies were used in
immunoblotting: integrin α2, integrin α5, cyclin D1, transforming growth factor - β receptor II
(TGF-β RII), and phospho-TGFβ receptor II (Tyr424) were purchased from Santa Cruz; integrin
β5, phospho-cyclin D1 (Thr286), phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204), p44/42 MAPK
(Erk1/2), phospho-Src family (Tyr416), and Src were from Cell Signaling; Sox9

and β-actin

were from Abcam; type II collagen (CIIC1) was from DSHB.

Statistical Analysis
The Kruskal-Wallis test was used to determine significant differences among all groups, and
Mann-Whitney U test was used for pairwise comparison. Statistical analyses were performed
with SPSS 13.0 statistical software (SPSS Inc., Chicago, IL). P values less than 0.05 were
considered statistically significant.
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RESULTS

ECM promoted hBMSC proliferative rate and induced directional migration
Passage 6 hBMSCs were expanded on conventional plastic flasks (Plastic) and flasks coated
with extracellular matrix (ECM) at the initial density of 3,000 cells/cm 2 for 7 days. In regard to
cell morphology, hBMSCs on Plastic appeared large and flattened, consistent with our
previous study on SDSCs. In contrast, hBMSCs on ECM were smaller and spindle-like during
the whole expansion period; the cells overlapped but maintained the same morphological
appearance. It was observed that hBMSCs grown on ECM underwent directional migration
along the ECM fibrils whereas the cells grown on Plastic showed random movement (Figure
6.1A).

After 7-day expansion, hBMSCs on ECM yielded 16.8 ± 2.3 fold change of the cell number,
while Plastic group produced 6.7 ± 0.4 fold increase (Figure 6.1B). The proliferation index of
ECM group created by Proliferation Wizard Basic Model was 11.2 ± 0.2 and that of Plastic
group was 5.3 ± 0.1 (Figure 6.1C). The proliferation index is the sum of all hBMSC
generations divided by the parent cells measured at the start of expansion.

ECM attenuated the stress of intracellular reactive oxygen species but increased apoptosis
We examined the intracellular level of ROS stress in hBMSCs cultured on Plastic and ECM by
staining the cells with DCF-DA. The hBMSCs cultured on Plastic showed a markedly higher level
of DCF fluorescence compared with those cultured on ECM. At the start of passage 6 expansion,
the mean fluorescence intensity (MFI) of DCF was 184 ± 15. At day 4 the MFI of Plastic group was
202 ± 5 which was 2.1-fold that on ECM (98 ± 12). At day 7 the MFI of Plastic group reached 241
± 15 which was 1.7-fold that on ECM (139 ± 5) (Figure 6.1D). In the regard to apoptosis analysis,
however, ECM group showed higher apoptotic stress than Plastic group. The percentage of both

annexin V and propidium iodide positive cells on ECM was 14% - 144% higher than that on
Plastic (Figure 6.1E).

Immunophenotype profile of hBMSCs on Plastic and ECM
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Flow cytometry was used to identify the immunophenotype profile of hBMSCs expanded on
Plastic and ECM. Five-surface antigen expression level (Mean florescence intensity) increased in
ECM group compared to Plastic group Figure 6.2A): SSEA-4 (100 vs. 48), CD71 (12 vs. 9),
CD49b (integrin α2, 40 vs. 15), CD49d (integrin α4, 15 vs. 12) and integrin β5 (374 vs.74).
Ten-antigen expression level decreased after culturing on ECM (Figure 6.2B): CD90 (367 vs.
502), CD105 (177 vs. 273), CD166 (58 vs. 66), CD49a (integrin α1, 12 vs. 22), CD49c (integrin α3,
227 VS. 695), CD49e (integrin α5, 68 vs. 103), CD29 (integrin β1, 141 vs. 210), and CD61 (integrin
β3, 14 vs. 19). However, seven-antigen expression level showed no difference between the two
groups (Figure 6.2C): CD14, CD44, CD45, CD73, CD24, CD49f (integrin α6) and CD104 (integrin
β4).

Extracellular matrix induced changes of integrin and TGFβ receptor II expression and
promoted phosphorylation of Src, ERK1/2 and cyclin D1
Immunoblotting analysis demonstrated that the expression of integrin α2 and β5 was
up-regulated when hBMSCs were expanded on ECM, while the level of integrin α5 was
down-regulated (Figure 6.3), consistent with the immunophenotype profile. Interestingly, the

expression of TGF-β receptor II (TGF-β RII) dramatically increased after treatment with ECM
rather than Plastic, and TGF-β receptor I showed the same tendency (data not shown).
Considering the relationship between integrin and extracellular-signal regulated kinases (ERK),
we tested the activity of Src kinase and ERK1/2. The phosphorylation level of Src and ERK1/2
was dramatically enhanced after hBMSC culturing on ECM compared with the control group
(Plastic). The Src level was lower in ECM group at Day 5 but higher at Day 9, whereas ERK1/2
total protein content was continuously higher in ECM group. In order to illuminate the potential
mechanism that ECM improved hBMSC proliferative rate, we used antibodies to probe the
steady-level and phosphorylation of cyclin D1. After ECM expansion, we found a higher level of
cyclin D1 expression and phosphorylation in BMSCs during the whole expansion period. Since
the expression and activation of cyclin D1 was directly related to cell division and proliferation, the
enhanced level of cyclin D1 induced by ECM was possibly responsible for the improved
proliferative rate.
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ECM enhanced hBMSC chondrogenic differentiation potential
To compare the chondrogenic potentials of hBMSCs cultured on Plastic and ECM, cells were
induced to differentiate in the pellet culture system by 10 ng/mL of TGF-β3. After 15-day
differentiation, pellets of ECM group exhibited a larger size than those of Plastic group
(Figure 6.4A). At Day 0 no positive histology staining was detectable in either groups (data
not shown). At Day 7 Plastic group was barely positive for Alcian blue, which stained sulfated
glycosaminoglycans (GAGs). However, pellets of ECM group were strongly positive for
sulfated GAGs. The results of type II collagen immunohistochemistry were similar to those of
Alcian blue staining, in which pellets cultured with ECM treatment displayed stronger
expression than those on Plastic. Immunohistochemistry of type I collagen was nearly
negative except for positive area on the edge of the pellets of ECM group. At Day 15 pellets of
ECM group were more intensive in Alcian blue staining and type II and type I collagen
immunohistochemistry than those of Plastic. Type X collagen immunohistochemistry was
negative in all pellets (Figure 6.4B).

Pellets of ECM group yielded more sulfated GAGs than Plastic group (7.7 μg vs. 4.7 μg at
Day 7 and 34.4 μg vs. 9.9 μg at Day 15) (Figure 6.5A). With respect to DNA amount, at Day
15 hBMSC of ECM group maintained the DNA level better than Plastic group (79% vs. 61% at
Day 15) (Figure 6.5B). The chondrogenesis index, defined by the ratio of GAGs and DNA,
illustrated the grade of hBMSC chondrogenic potential. Similar to the GAG amount, hBMSCs
of ECM group showed stronger chondrogenic differentiation than the cells of Plastic group
(3.6 vs. 1.6 at Day 7 and 16.6 vs. 3.8 at Day 15) (Figure 6.5C).

To obtain mechanical properties, chondrogenic pellets were examined for stiffness and
Young’s modulus. At Day 15, pellets of ECM group were 39.9 ± 9.5 N/M in stiffness compared
with 24.9 ± 4.7 of Plastic (Figure 6.5D). In regard to Young’s modulus, ECM group was 0.6 ±
0.1 MPa and Plastic group was 0.3 ± 0.1 MPa (Figure 6.5E).

Four typical chondrogenic marker genes were detected in hBMSCs expanded on ECM and
Plastic. At the level of type II collagen mRNA expression, pellets of ECM group produced
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217-fold at Day 7 and 9-fold at Day 15 compared to Plastic group (Figure 6.6A). Aggrecan
mRNA expression showed the same tendency; ECM group yielded a 5.5-fold increase
compared with Plastic group at Day 7 (Figure 6.6B). Type I collagen was the chondrogenic
maker at the early stage, which was expressed higher in ECM group at Day 7 but lower at
Day 15 (Figure 6.6C). In regard to Sox9 mRNA level, pellets of Plastic group produced 5% at
Day 7 and 36% at Day 14 more than ECM group (Figure 6.6D).

The level of phosphorylation of TGF-β receptor II and expression of Sox9 was enhanced after
expansion on ECM in the process of chondrogenic differentiation
In the expansion period, we found that hBMSCs expressed a higher level of TGF-β RII after
culturing on ECM. To determine if the high level of TGF-β RII would improve hBMSC
chondrogenic potential, we tested the phosphorylated level of TGF-β RII during chondrogenic
induction. At Day 7 and Day 15, hBMSC pellets of ECM group showed a higher level of activation
of TGF-β RII than that of Plastic group. Sox9, as a chondrogenic-related transcription factor, had
stronger expression in ECM group. The higher level of phosphorylation of TGF-β RII and Sox9
would be responsible for the improvement of chondrogenic differentiation potential. Type II
collagen was examined by immunoblotting and hBMSCs of ECM group yielded more amount than
Plastic group, which was consistent with immunohistochemistry data. The activity of ERK1/2 was
found suppressed in ECM group rather than Plastic group (Figure 6.7).
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DISCUSSION

In this study we expanded human bone marrow stem cells in conventional plastic flasks and
on native 3D hBMSC-deposited extracellular matrix. Human BMSCs cultured on ECM had a
higher proliferative rate, attenuated stress of intracellular ROS, a different immunophenotype
profile from those expanded on Plastic, and gained an enhanced chondrogenic differentiation
potential. We also explored the activity of several key signaling molecules of hBMSCs on
Plastic and ECM during in vitro expansion and chondrogenesis. The results demonstrated
that native 3D hBMSC-deposited ECM induced an increase of integrin α2 and β5, and
enhanced the activity of tyrosine kinase Src, the downstream of ERK1/2 and cyclin D1. At the

same time, 3D ECM also elevated the expression of TGF-β receptor II in hBMSCs and
promoted the phosphorylation of TGF-β receptor in chondrogenic differentiation.

Consistent with our previous study of synovium-derived stem cells (SDSCs),7 the 3D ECM
improved hBMSC proliferative rate that was 2.5-fold that of Plastic group. Cyclin D1 is proven to
control the cell cycle progression through G1 phase and entry into S phase.22;29 The steady-state
level of activation of ERK1/2 is necessary for cyclin D1 phosphorylation and translocation, while
the inhibition of ERK1/2 and the upstream kinases results in the decreased activity of cyclin
D1.22;23 Not only the expression level of cyclin D1 but also the phosphorylation was greatly
increased in hBMSCs after expanding on 3D ECM; this could be one of the reasons for the higher
proliferative rate induced by ECM. In this study the higher activation of cyclin D1 possibly resulted
from increased Src kinase and ERK1/2.29 A similar 3D ECM deposited from NIH 3T3 cells also
induced sustained activation of Ras and ERK1/2 through Src kinase and the blockage of Src
resulted in suppression of ERK1/2.11

Intracellular ROS plays an important role in cell adhesion, migration, and proliferation and
thus is essential for cell survival.30 The low concentration of ROS has a promotional effect on
cell adhesion, whereas the high level of ROS would result in cell death.31 A high level of ROS
has an inhibitory influence on cell proliferation by arresting the cell cycle at the G1, S, and G2
phases through down-regulation of cyclin D1 and D3 signaling.32 Kim et al. showed that an
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increase of intracellular ROS generation arrested the cell cycle at G0 - G1 phase by inhibiting
the cyclin D1/CDK4 complex.33 The attenuated level of ROS by 3D ECM was reported
previously,34 and the suppression of ROS production resulted in the activation of FAK and Src
kinases to improve the cell adhesion and survival.35

The 3D ECM induced changes in the cell immunophenotype profile that was reported in our
previous and other studies.7;34 The cell surface marker expression is closely related to cell
proliferation, differentiation and immunosuppression of mesenchymal stem cells.36 SSEA-4 that
was originally discovered as an early embryonic glycolipid antigen in embryonic stem cells, was
recently reported to express in mesenchymal stem cells and indicated that SSEA-4 would be a
promising cell surface marker for cell identification and isolation37-39. In this study the increase of
SSEA-4 positive cell population induced by 3D ECM might be correlated to the improved
chondrogenic differentiation capacity, consistent with other studies.40 However, CD90
immunofluorescence intensity was attenuated in hBMSCs expanded on ECM which was
inconsistent with our previous study on SDSCs; the difference could be due to the different MSC
tissue sources.41-44

The interaction between ECM and cells is mainly dependent on integrin-induced signaling
transduction. The conventional 2D ECM was proven to induce integrin activation through focal
adhesion kinase (FAK), Src family kinase, and integrin-linked kinase (ILK) signaling
pathways.16;45-47 The FAK pathway was activated by integrin α5, αV, and β1 in the process of cell

adhesion to fibronectin and collagen substrates48 and the FAK autophosphorylation at Tyr397
to induce the activation of Src family kinase and mitogen-activated protein kinase (MAPK)
cascades.20;49-52 However Damianova et al. reported on 3D ECM the autophosphorylated
level of FAK was attenuated.11;15 The three-dimensional structure and the complex
components of the native cell-deposited ECM resulted in a distinct intracellular signaling
pathway compared to that in an 2D conventional environment.11;15;16;53 The increase of
integrin α2 and β5 and the decrease of integrin α5 and β1 was confirmed by FACS and
immunoblotting in this study. Integrin α2 and β5 contribute significantly to cell focal adhesion
and survival on fibrillar collagen substrate through Src and ERK-mediated signaling
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pathways.26;54-56 Meanwhile the activated Src increased the expression of α2 integrin to
improve cell survival.57 However, Src is also activated by other receptor kinases,27;58;59 so it is
still unclear how the sustained activation of Src and ERK1/2 was induced by 3D ECM through
certain specific integrins or other signaling receptors.

The greatly enhanced chondrogenic differentiation capacity of hBMSCs after expansion on 3D
ECM was similar to our previous study on SDSCs7, adipose-derived stem cells and articular
chondrocytes. We first demonstrated that the expression of TGF-β receptor II was increased by

the 3D ECM expansion system in hBMSCs. The high expression of TGF-β receptor II in
hBMSCs after culturing on ECM and the sustained steady-state phosphorylated level of
TGF-β receptor II induced by TGF-β1 in chondrogenesis would be responsible for the strong

expression of Sox9 and type II collagen.60 Moreover, decorin, fibronectin, laminins, and type I
and III collagens, identified in the 3D hBMSC-deposited ECM10;34, played an important role in
TGF-β receptor responsiveness and modulating TGF-β bioactivity during cell proliferation and

differentiation61-64. Decorin was also reported to promote α2β1 integrin-dependant cell
adhesion and migration65 that was related in this study to the elevated level of integrin α2. The
improved chondrogenic differentiation potential of BMSCs expanded on the 3D ECM is
possibly due to the high responsiveness and sensitivity to TGF-β. Integrins also played a
crucial role in chondrogenesis such as integrin β166 and interacted with type II collagen
through integrin α2 when differentiating to mature chondrocytes67. The mechanism of
elevated TGF-β receptor II expression is still unclear but possibly related to the crosstalk
between TGF-β receptors and integrin. Reynolds et al. reported that, in dermal fibroblasts, the
deficiency of integrin β3 caused the increased expression of both TGF-β receptor I and
receptor II.68 Myofibroblastic differentiation in dermal fibroblasts was induced by αVβ5 integrin
because of the recruitment of latent TGF-β1 and activation of TGF-β receptors.69 However the
mechanism of integrin interaction with TGF-β receptors induced by 3D ECM remains to be
established.

The role of ERK1/2 in chondrogenic differentiation is controversial. The conventional opinion
is that MAPK cascade was activated by TGF-β and the phosphorylated ERK1/2 promoted the
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expression of chondrogenic genes such as aggrecan and type II collagen.70;71 However
recent research suggested that the inhibition of ERK1/272-74 or JNK75 can improve the
chondrogenic differentiation of MSCs that were considered as two important TGF-β
non-Smad signaling pathways. We found similar decreased activity of ERK1/2 during the
chondrogenic differentiation especially in hBMSCs expanded on ECM. The possible
explanation is that the activation of ERK1/2 initiates the transcription of chondrogenic-specific
genes such as aggrecan and type II collagen but, in the long-term induction to
chondrogenesis, ERK1/2 would give way to other signaling pathways such as PI3K/Akt to
generate cartilage-specific matrix.73;75

In summary our study demonstrated that the utilization of the new 3D cell-deposited ECM on
hBMSC in vitro expansion was able to dramatically increase the cell proliferative rate,
attenuate the stress of intracellular ROS, and improve the chondrogenic differentiation
potential. We demonstrated that 3D ECM induced sustained activation of Src kinase and
ERK1/2 and phosphorylated cyclin D1 to promote the cell-cycle and proliferation. The
enhanced chondrogenic differentiation ability of hBMSCs by the 3D ECM was because of the
high expression and sensitivity of TGF-β receptor II. Due to the complexity of the 3D ECM,
the cell signaling transduction is different from that in 2D monolayer culture condition and
needs to be illuminated in the future.
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FIGURE LEDGENS

Figure 6.1 Extracellular matrix (ECM) induces changes in the human bone marrow stem cells
(hBMSCs) affacting cell morphology, proliferative rate, intracellular reactive oxygen species
(ROS) and apoptosis level in the period of monolayer expansion. (A) Representative phase
contrast images of hBMSC in the middle of expansion; (B) hBMSC cell number fold change
after 7-day monolayer expansion under Plastic and ECM culture conditions; (C) the
proliferation index of hBMSC on Plastic and ECM analyzed by flow cytometry; (D)
intracellular ROS level decreases when culturing on ECM; (E) the percentage of apoptotic
cells varies differently on Plastic and ECM. Data are shown as average ± SD.

Figure 6.2 Immunophenotype profile of hBMSCs cultured on Plastic and ECM. (A) hBMSCs
cultured on ECM showed increase in the positive-percentage and fluorescence intensity of
SSEA-4, CD71, CD49b, CD49d, and integrin β5; (B) hBMSCs cultured on Plastic have higher
expression of CD73, CD90, CD105, CD166, CD44, CD49a, CD49c, CD49e, CD29 and CD61;
(C) the expression level of CD14, CD45, CD24, CD49f and CD104 shows no difference
between Plastic and ECM groups.

Figure 6.3 Immunoblotting of hBMSCs when expanding on Plastic and ECM. Total lysates of
hBMSCs were detected to the antibodies of integrin α2, integrin β5, integrin α5, transforming
growth factor β receptor II (TGFβ receptor II). The lysates were also probed to
phospho-Cyclin D1 (Thr286), Cyclin D1, phospho-Src family (Tyr416), Src, phospho-p44/42
MAPK (Erk1/2) (Thr202/Tyr204), and p44/42 MAPK (Erk1/2). β actin was used as an internal
control for protein loading.

Figure 6.4 Phase image, histology and immunohistochemistry of hBMSC pellets under
chondrogenic stimulation. (A) typical hBMSC pellets of Plastic and ECM groups phase
images; (B) Alcian blue staining was used to detect sulfated glycosaminoglycans (GAGs),
and immunohistochemistry (IHC) was for type I (COL I), type II (COL II) and type X (COL X)
collagens.
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Figure 6.5 Biochemistry to analyze glycosaminoglycans (GAGs) and DNA content of
hBMSCs chondrogenic differentiation of Plastic and ECM groups. (A), GAGs of hBMSC
pellets were measured at day 0, day 7 and day 15; (B), DNA content of hBMSC pellets
changes during 15 days normalized by the content of pellets at day 0; (C), chondrogenesis
index (the ratio of GAGs and DNA) represented the degree of chondrogenic differentiation of
hBMSCs; mechanical testing was used to examine the stiffness (D) and Young’s modulus (E)
of hBMSC pellet after chondrogenic differentiation. Data are shown as average ± SD for n = 5
for DNA and GAGs analysis and n=4 for mechanical testing.

Figure 6.6 (A) to (D) Real-time PCR to examine the chondrogenic marker gene expression
level (type I and II collagen, aggrecan, sox-9) normalized by 18S rRNA. (E) and (F) the
hypertrophic gene expression (type X collagen and MMP13) was tested in hBMSC pellets.
Data are shown as average ± SD for n = 4.

Figure 6.7 Immunoblotting of hBMSC chondrogenic pellets was used to detect
phospho-TGFβ receptor II (Tyr 424), Sox9, type II collagen, phosphorylated ERK1/2 and
ERK1/2 expression level. β actin was used as an internal control for protein loading.
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Chapter 7
Comparison of three-dimensional extracellular matrices deposited by
synovium-derived stem cells or articular chondrocytes

Superiority of SDSC-deposited ECM as a universal novel expansion system in vitro to
promote cell self-renewal and chondrogenic potential
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ABSTRACT

Three-dimensional extracellular matrix (ECM) has been used as an in vitro expansion system
for mesenchymal stem cells. However it is unknown whether different ECMs distinctly affect
cell proliferation and differentiation. We generated two types of ECM separately from
synovium-derived stem cells (SDSCs) and articular chondrocytes. SDSC-deposited ECM
(S-ECM) contains fibrillar type I collagen whereas chondrocyte-deposited ECM (C-ECM)
composes fibrillar type I and II collagens with proteoglycans. SDSCs and chondrocytes were
separately expanded on three substrates: conventional plastic culture flasks (Plastic), S-ECM
and C-ECM. The cell proliferative rate was improved by the two ECMs compared with the
conventional plastic culture system. S-ECM promoted cell self-renewal of SDSCs and
chondrocytes but C-ECM showed strong support on chondrocytes only. SDSC and
chondrocyte pellets were induced to chondrogenic differentiation with transforming growth
factor β-1. The chondrogenic potential of SDSCs and chondrocytes after expansion on ECM
was enhanced. However SDSCs expanded on S-ECM expressed a higher level of
chondrogenic genes and generated more cartilage-specific matrix than those on C-ECM.
Chondrocytes expanded on S-ECM and C-ECM showed a similar chondrogenic
differentiation level. The enhanced chondrogenic potential by 3D ECM is partially related to
the high sensitivity of TGF-β receptor II. In conclusion, we demonstrated that
SDSC-deposited ECM was superior to chondrocyte-deposited ECM and functions as a
universal expansion system in vitro for MSCs and differentiated cells to promote proliferative
and chondrogenic potentials.
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INTRODUCTION

Articular cartilage is a unique tissue with an avascular structure.1 Due to the limited self-repair
mechanism, cartilage is vulnerable to degenerative disease after trauma or osteoarthritis.2;3
Autologous chondrocyte transplantation (ACT) has been successfully used in clinical practice
to repair cartilage defects.4;5 ACT relies on a biopsy from a non-weight bearing cartilage area,
expansion of articular chondrocytes in vitro, and transplantation into the defect site which is
sealed with a periosteal graft or collagen membrane.6;7 The disadvantages of ACT includes
the rapid dedifferentiation of chondrocytes during in vitro expansion, which is the process of
cell morphology changing to a fibroblast-like shape and an elevated expression of type I
collagen instead of type II collagen.5-7

Adult mesenchymal stem cells (MSCs) provide a promising approach for the cartilage
regeneration; these cells are derived from various tissues including bone marrow,8;9 adipose
tissue,10 synovium,11 periosteum,12 skeletal muscle13 and other connective tissues14.
Numerous researchers have reported the successful generation of hyaline cartilage-like
tissue in vitro15;16 and the use of this tissue to repair partial-thickness or full-thickness
cartilage defects in animal models.17;18 Among the various MSCs, synovium-derived stem
cells (SDSCs) are considered to have superior proliferative ability and chondrogenic
potential.19;20

MSC-based cartilage regeneration, however, faces similar challenges as ACT. The limited
self-renewal ability of MSCs is one of disadvantages compared with embryonic stem cells
(ESCs) and induced pluripotent stem (iPS) cells.21;22 The proliferative ability of MSCs usually
dramatically decreases after 10 passages and eventually disappears.23;24 To retain the
proliferative ability of MSCs, cells are required to be cultured from a relatively low seeding
density25;26 or stimulated with growth factors such as fibroblast growth factor 2 (FGF-2).27 The
conventional in vitro culture of MSCs requires weekly passage in order to maintain their
proliferative and multipotential abilities.28 However MSCs of late passages (≥15) still lose their
multipotency and only differentiate to adipocytes.29 The limitation of the current in vitro culture
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of MSCs is that, once isolated from the in vivo microenvironment, they lose their proliferation
and multipotent differentiation potentials similar to aged cells.30-32

Our previous work demonstrated that the utilization of a natural, three-dimensional (3D),
cell-deposited extracellular matrix (ECM)33 in the expansion of SDSCs can dramatically
improve SDSC self-renewal and chondrogenic potential. This native 3D ECM has also been
deployed in the culture of articular chondrocytes that successfully delayed chondrocyte
dedifferentiation and enhanced redifferentiation. However this proposed another question
whether tissue-specific generated ECM would have a similar or opposite effect on cell
proliferation and differentiation.

Type I collagen was confirmed to be one of the components in SDSC-deposited ECM33 that
has been used to promote proliferation and differentiation of MSCs and articular
chondrocytes in two-dimensional (2D) substrate34 and 3D gel format.35 Type II collagen is
another candidate to improve cell attachment and chondrogenesis; it is less commonly used
than type I collagen. Hyaline cartilage is composed of type II collagen and sulfated
proteoglycans (mainly aggrecan) that support chondrocyte morphology and gene
expressions.36 Therefore, chondrocytes or MSCs in scaffolds made by type II collagen coated
with proteoglycans have a better potential to promote cell proliferative rate and chondrogenic
differentiation potential than type I collagen gel.37;38

In the current study, we hypothesized that ECM deposited by different cells can influence cell
proliferation and differentiation potentials in distinct ways. We manufactured two distinct
ECMs deposited by SDSCs or articular chondrocytes. Porcine SDSCs and chondrocytes
were separately expanded under three conditions: the conventional plastic culture flasks
(Plastic) serving as the control group and SDSC-deposited ECM (S-ECM) and
chondrocyte-deposited ECM (C-ECM) serving as experimental groups. The data showed that,
when culturing SDSCs, S-ECM showed superiority in cell proliferation and chondrogenesis
over C-ECM and Plastic. Surprisingly, we found that chondrocytes expanded on S-ECM and
C-ECM showed similar improvement that was much greater than cells grown on Plastic.
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MATERIALS and METHODS

Isolation and culture of SDSCs and chondrocytes
Synovium and cartilage tissue were collected from two 3-month-old miniature pigs as
previously described.20;39 Briefly, chondrocytes were digested with 0.2% collagenase P
(Roche, Indianapolis, IN) at 37ºC overnight after being finely minced into pieces with a
scalpel. Synovium membrane was digested at 37ºC for 30 minutes in 0.1% trypsin (Roche)
and then for 2 hours in 0.1% collagenase P to release SDSCs. Chondrocytes and SDSCs
were resuspended and plated in culture medium [α-minimum essential medium (Invitrogen,
Carlsbad, CA) containing 10% fetal bovine serum (FBS, Atlanta Biologicals, Lawrenceville,
GA), 100 U/ml penicillin, 100 µg/ml streptomycin and 0.25 μg/ml fungizone (Invitrogen)] at
37ºC in a humidified atmosphere of 5% carbon dioxide and 95% air. Non-adherent cells were
removed by medium change every three days. For negative isolation of SDSCs from primary
cultures, cell suspension was incubated with Dynabeads® M-450 CD14 conjugated with a
monoclonal antibody specific for macrophages (Dynal Biotech, Oslo, Norway) at 4ºC for 1
hour. The conjugated cells and the unbound Dynabeads® were collected by using the Dynal
Magnetic Particle Concentrator® (Dynal Biotech) and the depleted supernatant with SDSCs
was saved for further passaging.

Preparation of SDSC-ECM (S-ECM) and Chondrocyte-ECM (C-ECM)
The procedure of obtaining cell-free extracellular matrix was described previously33. 75 cm2
plastic flasks were pretreated with 0.2% gelatin solution (Sigma, St. Louis, MO) for 1 hour at
37˚C, followed by 1% glutaraldehyde (Sigma) and 1 M ethanolamine (Sigma) for 30 minutes
separately at room temperature. SDSCs were seeded on pretreated plastic flasks at the
density of 3,000 cells/cm2 in culture medium for 7 days. After reaching 90% confluence, 50
mM of L-ascorbic acid phosphate (Wako, Richmond, VA) was added and culturing was
continued for an additional 8 days. Chondrocytes were seeded on pretreated plastic flasks at
the density of 3,000 cells/cm 2 to reach 90% confluence and changed to complete medium
[high-glucose DMEM (Cellgro, Herdon, VA), 10% FBS, 100 U/ml penicillin, 100 µg/ml
streptomycin, 10 mM HEPES (Sigma), 0.1 mM non-essential amino acids (Sigma), 0.4 mM
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proline (Sigma), and 50 mg/L l-ascorbic acid] for an additional 8 days under 5% oxygen. To
obtain cell-free ECM, S-ECM and C-ECM were incubated with 0.5% Triton X-100 (Sigma)
containing 20 mM ammonium hydroxide (Sargent-Welch, Skokie, IL) for 5 minutes at 37ºC,
followed by 100 u/mL DNase I (Sigma) for 1 hour at 37˚C and stored at 4ºC.

In vitro culture of SDSCs and chondrocytes on Plastic and ECM
SDSCs were expanded from passage 4 to passage 6 under three conditions: plastic flasks
(Plastic), flasks coated with SDSC-deposited ECM (S-ECM), and flasks coated with
chondrocyte-deposited ECM (C-ECM). Chondrocytes were cultured similarly to SDSCs for 3
further passages. The culture period of each passage was 7 days and the medium was
changed every 3 days. At each passage, cell number was calculated by a counting
hemacytometer (Hausser Scientific, Horsham, PA) for cell proliferative rate.

In vitro chondrogenic differentiation of SDSCs and chondrocytes
3 × 105 of SDSCs and chondrocytes of passage 6 cultured on Plastic, S-ECM and C-ECM
were centrifuged to form pellets in a 15-ml polypropylene tube at 500 g for 5 minutes. After 24
hours, the pellets (Day 0) were incubated in chondrogenic medium [high-glucose DMEM, 40
µg/ml proline, 100 nM dexamethasone (Sigma), 100 U/ml penicillin, 100 µg/ml streptomycin,
0.1 mM ascorbic acid-2-phosphate and ITS™ Premix (BD Biosciences, Bedford, MA) with the
supplementation of 10 ng/ml of TGF-β1 (Pepro Tech Inc., Rocky Hill, NJ)]. Pellets at Day 0,
Day 7 and Day 14 were collected for further analysis.

Histology and immunohistochemistry
The ECM deposited by SDSCs and chondrocytes and the chondrogenic pellets (n = 2) were
fixed in 4% paraformaldehyde, embedded in paraffin blocks and cut into 5-μm thick sections.
To detect glycosaminoglycans, sections were stained with 0.2% Alcian blue solution (Sigma).
For immunohistochemistry, the sections were incubated with primary antibodies against type
II collagen (II-II6B3, Developmental Studies Hybridoma Bank DSHB, Iowa City, IA), type I
collagen (Sigma) and type X collagen (Sigma), followed by the secondary antibody of
biotinylated horse anti-mouse IgG (Vector, Burlingame, CA) and detected by using Vectastain
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ABC reagent (Vector) with 3,3’-diaminobenzidine (DAB) as a substrate.

Biochemical analysis for DNA and glycosaminoglycan (GAG) content
To examine DNA and glycosaminoglycan content in pellets, samples (n = 4) were digested for
6 hours at 60ºC by 125 μg/ml papain in PBE buffer (100 mM phosphate, 10 mM EDTA, pH 6.5)
containing 10 mmol/L cysteine. The amount of DNA was measured by QuantiTTM PicoGreen®
dsDNA assay kit (Invitrogen) and CytoFluor® Series 4000 (Applied Biosystems, Foster City,
CA) following by the protocol. The GAG content was measured by using 16 µg/ml of
dimethylmethylene blue dye and a SpectronicTM BioMateTM 3 Spectrophotometer (Thermo
Scientific, Milford, MA) with bovine chondroitin sulfate (Sigma) as the standard.

Real-time polymerase chain reaction (Real-time PCR)
The total mRNA from pellets (n = 4) was extracted using TRIzol® (Invitrogen) and converted to
cDNA with High-Capacity cDNA Archive Kit as recommended by the manufacturer (Applied
Biosystems). Chondrogenic marker genes (aggrecan, type I and II collagen, and Sox9) and
hypertrophy marker genes (type X collagen, MMP13) were customized by Applied Biosystem
as part of the Custom Taqman® Gene. Expression Assays Eukaryotic 18S rRNA (Assay ID
HS99999901_s1 ABI) was carried out as the endogenous control gene. Real-time PCR was
performed with the iCycler iQTM Mutil Color RT-PCR Detection and calculated by computer
software (Perkin-Elmer, Waltham, MA). Relative transcript levels were calculated as χ=2-ΔΔCt,
in which ΔΔCt=ΔE-ΔC, ΔE=Ctexp-Ct18s, and ΔC=Ctct1-Ct18s.

Immunoblotting
The cytoplasm protein of pellets was extracted by using RIPA lysis buffer (Thermo Scientific)
supplemented with halt protease and phosphatase inhibitor cocktail (Thermo Scientific). The
protein concentration was quantified using the BCATM Protein Assay Kit (Thermo Scientific).
The samples was denatured and separated by NuPAGE® Novex® Bis-Tris Mini Gels
(Invitrogen) at 200V for 45 minutes at 4oC, then transferred onto a nitrocellulose membrane
(Invitrogen) using XCell IITM blot module (Invitrogen) at 30V for 1 hour at 4oC. The
membranes were first blocked in SuperBlock (TBS) Blocking Buffer (Thermo Scientific), then
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incubated with the primary monoclonal antibodies of phospho-TGFβ RII (Tyr 424) (Santa
Cruz Biotechnology, Santa Cruz, CA), Sox9 (Abcam, Cambridge, MA), type II collagen
(II-II6B3), phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204) (Cell Signaling Technology,
Danvers, MA), p44/42 MAPK (Erk1/2) (Cell Signaling) and β-actin (Abcam) at the
recommended dilution overnight at 4oC. The membranes were incubated in the secondary
antibody of Goat Anti-Mouse IgG (H+L) or Goat Anti-Rabbit IgG (H+L) (Thermo Scientific) for
40 minutes at room temperature and exposured using SuperSignal® West Pico
Chemiluminescent Substrate (Thermo Scientific) and CL-XPosureTM Film (Thermo Scientific).

Statistical Analysis
The Kruskal-Wallis test was used to test for significant differences among all groups and the
Mann-Whitney U test was used for pairwise comparison. All statistical analyses were
performed with SPSS 13.0 statistical software (SPSS Inc., Chicago, IL). P values less than
0.05 were considered statistically significant.
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RESULTS

Immunohistochemistry of SDSC-deposited ECM and chondrocyte-deposited ECM
S-ECM showed strong expression of type I collagen but absence of sulfated GAGs or type II
collagen. The composition of S-ECM was consistent with previous studies on ECM derived
from bone marrow stem cells and fibroblasts.33;40 The components of C-ECM were revealed
to be more complex than S-ECM, which contained sulfated GAGs, type I and II
collagen.(Figure 7.1).

In vitro expansion of SDSCs and chondrocytes on Plastic, S-ECM and C-ECM
The cell morphology of SDSCs and chondrocytes on Plastic is flat and large, but when cells
were cultured on S-ECM and C-ECM, they appeared spindle-like and small. The morphologic
appearance of S-ECM and C-ECM was unchanged within 3 passages. Moreover, cell
migration was directional on S-ECM and C-ECM compared to the random movement on
Plastic (Figure 7.1B).

The proliferative rate of SDSCs on S-ECM had a 2.4- to 7.2- fold increase compared to cells
on Plastic and average 2-fold higher than cells on C-ECM (Figure 7.1C). At passage 4
chondrocytes on S-ECM and C-ECM yielded a similar cell number that was 6-fold that of
Plastic. At passage 5 and 6, chondrocytes on S-ECM exhibited 20%-40% higher proliferative
ability than that on C-ECM, and maintained 4- to 12-fold that on Plastic (Figure 7.1D). Cells
on S-ECM regained the highest proliferative rate; the proliferation ability was improved on
C-ECM but still lower than S-ECM and both S-ECM and C-ECM were higher than Plastic.

S-ECM mostly improved chondrogenic differentiation potential of SDSCs
Passage 6 SDSCs expanded on Plastic, S-ECM and C-ECM were centrifuged to form pellets
and induced to chondrogenic differentiation by TGF-β1. SDSCs of S-ECM group showed
strong expression of sulfated GAGs stained by Alcian blue, and extensive expression of type
I and II collagen. SDSCs of C-ECM group were positive for Alcian blue staining;
immunohistochemistry showed type I and II collagens at Day 14 but the results were weaker
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than S-ECM group. SDSCs of Plastic group had the worst chondrogenic differentiation
potential as proven by the partial positive staining at Day 14 (Figure 7.2).

At Day 14 pellets of S-ECM group generated 23.5 ± 1.6 μg of sulfated GAGs compared to
11.1 ± 1.6 μg in C-ECM group and 2.5 ± 0.8 μg in Plastic group (Figure 7.3A). The DNA
content was maintained in S-ECM group; it was 81% at Day 14 which is higher than that of
C-ECM (45%) and Plastic groups (21%) (Figure 7.3B). The chondrogenic index, defined by
the ratio of sulfated GAGs to DNA, had the highest level in S-ECM group (39.3 ± 3.1 at Day
14), with lower level in C-ECM (27.8 ± 4.4) and Plastic groups (7.6 ± 2.2) (Figure 7.3C).

The expression of chondrogenic and hypertrophic genes was quantified by real-time PCR.
The level of type II collagen mRNA in S-ECM was 464-fold and 4-fold that of Plastic group
and C-ECM group at Day 7, respectively (Figure 7.3D). The expression of aggrecan mRNA
was highest in S-ECM; it was 11-fold and 2-fold that of Plastic and C-ECM at Day 7,
respectively (Figure 7.3E). The expression of type I collagen mRNA was similar in S-ECM
and C-ECM groups and was at least 30% higher than that of Plastic group (Figure 7.3F).
Sox-9, the transcription factor in chondrogenesis, mRNA expression was highest in S-ECM
group (Figure 7.3G). During chondrogenesis the level of type X collagen mRNA was not
significantly different between the three groups (Figure 7.3H), but the level of MMP13 mRNA
was highest in S-ECM group at Day 7 and higher in S-ECM and C-ECM than Plastic group
(Figure 7.3I).

S-ECM and C-ECM elevated the activity of receptors of TGF-β in SDSCs
During the induction of chondrogenesis, immunoblotting showed that the TGF-β receptor II
(TGF-β RII) in the three groups was activated but the activity of TGF-β RII was higher in
S-ECM and C-ECM groups than that in Plastic group. Correspondingly, the expressions of
Sox9 and type II collagen were stronger in S-ECM and C-ECM groups than in Plastic group.
However, ERK1/2 activity was suppressed during chondrogenesis except the high
phosphorylation level of C-ECM group at Day 14 (Figure 7.4).
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The chondrogenic potential of chondrocytes was improved by S-ECM and C-ECM
After expansion on Plastic, S-ECM and C-ECM, chondrocytes of passage 6 were induced to
chondrogenesis in the pellet culture system. At Day 7 and 14, chondrocyte pellets of S-ECM
and C-ECM groups showed stronger expression of sulfated GAGs, type I and II collagens
than those of Plastic group. The chondrogenic differentiation potential was improved in
chondrocytes after S-ECM and C-ECM expansion (Figure 7.5).

To compare the chondrogenic differentiation effect, biochemistry was used to quantify the
content of sulfated GAGs and DNA in each group. At Day 14 chondrocyte pellets generated
high amount of sulfated GAGs in S-ECM and C-ECM groups at the similar level (58.1 ± 2.5
μg vs. 56.1 ± 3.0 μg), but the level of GAGs in Plastic group was only 47% of that in ECM
groups (27.2 ± 1.6 μg) (Figure 7.6A). At Day 14 the DNA content of chondrocyte pellets in
Plastic group dropped to 35% but increased to 111% in S-ECM group and 119% in C-ECM
group (Figure 7.6B). The chondrogenic index in the three groups at Day 14 was relatively
high and that of Plastic group reached 92.7 ± 3.0. The chondrogenic index of C-ECM group
was 8.3% higher than that of S-ECM (105.5 ± 4.9 vs. 97.5 ± 5.2) and both were higher than
Plastic group (Figure 7.6C).

At the level of mRNA expression chondrocyte pellets of S-ECM and C-ECM groups had a
higher level than those of Plastic group in chondrogenic and hypertrophic genes (Figure 7.6
D-I). But the difference between S-ECM and C-ECM was not significant. At the level of type II
collagen and aggrecan mRNA, pellets of S-ECM and C-ECM groups expressed 5-fold and
7-fold, respectively, as that of Plastic group (Figure 7.7 D&E). At Day 7 the expression of type
X collagen in S-ECM and C-ECM groups was 80% higher than that of Plastic group (Figure
7.6H). At Day 14 the level of MMP13 mRNA in S-ECM and C-ECM groups was 6.2-fold that of
Plastic group (Figure 7.6I).

S-ECM and C-ECM improved the activity of receptors of TGF-β in chondrocytes
Before treatment with TGF-β1, the level of phosphorylated TGF-β RII in Plastic group was
much higher than that in ECM groups. After the chondrogenic induction the activity of TGF-β
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RII in S-ECM and C-ECM groups was higher than that of Plastic group. The expression of
Sox9 and type II collagen in S-ECM and C-ECM groups was stronger than that of Plastic
group. The phosphorylation of ERK1/2 was decreased after expansion on S-ECM and
C-ECM and the activity was suppressed during chondrogenic differentiation (Figure 7.7).

247

DISCUSSION

In this study we used porcine SDSCs to deposit S-ECM composed of a fibrillar type I collagen
network and articular chondrocytes to generate C-ECM that contained a type I and II collagen
network with proteoglycans. Though the two types of ECMs had three-dimensional structure
and were deprived of the original feeder cells, they showed a distinct influence on cell
proliferative rate and chondrogenic potential. SDSC-deposited ECM improved the
proliferation rate and chondrogenic differentiation of both SDSCs and chondrocytes, while
chondrocyte-deposited ECM only significantly affected chondrocyte expansion rate and
chondrogenesis. However both S-ECM and C-ECM promoted cell self-renewal and
chondrogenic potential compared to the conventional plastic culture system.

The traditional 2D reconstructed ECM uses monomeric proteins to coat substrates such as
fibronectin, laminin, gelatin, and denatured collagens, to improve MSC proliferation and
differentiation. However, the 3D culture system has been proven more efficient than 2D
culture substrates in cell expansion and preserving the multipotent capability for MSCs in vitro.
The 3D natural cell-deposited ECM used in this study has been adopted to study the
signaling pathway in cell adhesion41 and cell invasion.42;43 Recent studies showed that the
utilization of 3D ECM in expansion of MSCs in vitro can greatly improved cell proliferation and
enhanced multipotential differentiation.33;40;44 Not only MSCs but also terminally differentiated
cells such as adult articular chondrocytes and nucleus pulposus cells exhibited enhanced
self-renewal and redifferentiation potential after expansion on 3D ECM. However it is
important to establish a tissue-specific microenvironment in vitro to direct MSC differentiation.
Due to the similar properties shared by MSCs from many sources and the same procedure to
generate ECM, MSC-deposited ECMs are identical in structure and composition.33;40;41;45 We
chose articular chondrocytes to reconstruct the native 3D ECM that mimics hyaline cartilage
tissue. The component of fibrillar type II collagen associated with proteoglycans in
chondrocyte-deposited ECM was one of the major differences from SDSC-deposited ECM.
The presence of type I collagen in C-ECM was partially due to the dedifferentiation of articular
chondrocytes in the in vitro culture.5;7
248

Type I collagen was used as a substrate and gel to facilitate cell expandability and
differentiation and achieved better results than other ECM proteins. Compared to type I
collagen, type II collagen was less commonly used for cell expansion but was proven to
induce chondrocyte redifferentiation more effectively. Bosnakovski et al. provided evidence
that bone marrow stem cells seeded in type II collagen hydrogel generated more
cartilage-specific genes and matrix than cells in type I collagen gel.46 Moreover, Buma et al.
reported that using type II collagen scaffold to repair full-thickness articular cartilage defects
generated hyaline cartilage-like tissue instead of fibro-cartilaginous tissue by type I
collagen.47 Moreover, proteoglycans were found in C-ECM rather than S-ECM. Previous
studies showed that type II collagen-GAG scaffolds were able to enhance cell
chondrogenesis48 and had more stiffness than a type I collagen scaffold.49 Besides the
different composition, the rigidity of the two ECMs caused distinct proliferation and
differentiation potentials in SDSCs and chondrocytes. Winer et al. compared the effect of
substrates with different rigidity on human BMSCs and demonstrated that cells became
quiescent on the soft matrix (250 Pa) but resumed the proliferation when transferred to a stiff
substrate.50

The great improvement on cell proliferative rate after culturing on the two types of ECM was
partially induced by the activation of the integrin/Src/ERK1/2 signaling pathway and the
activation of cyclin D1.51-53 However, the different proliferation rates of SDSCs on the two
ECMs suggested that the signaling pathway may not be exactly the same. Cells recognize
fibrillar collagens mainly through integrin α2β1 and α5β154-57 but recently it was reported that
Rock 2 expression was suppressed in type II collagen-rich gel instead of type I collage gel.58
Besides the increased proliferative rate, SDSCs and chondrocytes showed directional
migration along the fibrils of ECM rather than the random migration found on Plastic. One
possible explanation is that ECM can effectively reduce the activity of Rac that is responsible
for the random cell migration.59-61

Induced by TGF-β, SDSCs showed higher chondrogenic differentiation potential after
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expansion on S-ECM and chondrocytes cultured on S-ECM and C-ECM showed a similar
level of chondrogenic genes and matrix. The enhanced chondrogenic potential caused by
ECM is explained by the high activity of TGF-β RII when induced with TGF-β. More
interestingly, chondrocytes cultured on Plastic had a highly phosphorylated level of TGF-β RII
before chondrogenesis that was possibly autophosphorylation and induced spontaneous
differentiation in the monolayer culture period.40;62;63 The spontaneous differentiation was
reported by Chen et al. and it suppressed the later growth factor-induced specific
differentiation.40 ECM significantly reduced the degree of autophosphorylation, increased the
sensitivity of TGF-β RII and enhanced the effectiveness of TGF-β induction to
chondrogenesis. Among the various ECM proteins, decorin may play an important role in
preventing TGF-β receptor autophosphorylation that was proven to exist in BMSC-deposited
ECM.40 Decorin, often found in type I collagen-rich matrices and composed of a leucine
repeated core protein attached with a glycosaminoglycan chain of varying length and
composition, is considered as the antagonist of TGF-β, masks the binding site of TGF-β
receptors64;65 and contributes to the low level of autophosphorylation of TGF-β receptor.

The MAPK signaling pathway was previously considered to promote chondrogenic
transcription factors and induce the expression of chondrogenic genes.66;67 Recently several
studies suggested that the inhibition of the MAPK signaling pathway can improve MSC
chondrogenic differentiation.68-70 Consistent with our immunoblotting data, ERK1/2 activity
was suppressed during chondrogenesis and was significantly lower in SDSCs and
chondrocytes expanded on ECM than those expanded on Plastic. The robust elevation of
phosphorylated ERK1/2 at Day 14 in SDSCs of C-ECM and chondrocytes in S-ECM is
possibly related to the increased expression of hypertrophic genes.71 Type X collagen is the
well-accepted hypertrophic marker and in late chondrogenesis MMP13 and ALP are
proposed as other markers for hypertrophy.72;73 The increase of hypertrophic genes after
ECM expansion is not consistent with our previous study33 and due to the complex
mechanism of chondrocyte hypertrophic differentiation, future studies will be conducted on
the hypertrophic issue by applying different growth factors in vitro and conducting
transplantation in vivo.
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In summary, we compared the influence of two natural 3D extracellular matrices, deposited
by

SDSCs

and

chondrocytes,

on

cell

proliferation

and

chondrogenic

potential.

SDSC-deposited ECM can improve the proliferative and chondrogenic capacities of SDSCs
and chondrocytes. Chondrocyte-deposited ECM can only promote chondrocyte proliferation
and chondrogenesis. The enhanced chondrogenic potential of cells expanded on 3D ECM is
related to the high sensitivity of TGF-β receptor II. Together with previous studies, we
demonstrate that SDSC-deposited extracellular matrix functions as a universal expansion
system in vitro for MSCs and differentiated cells to promote proliferative and chondrogenic
potentials.
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FIGURE LEGENDS

Figure 7.1 (A) Histology and immunohistochemistry of SDSC-derived ECM (S-ECM) and
chondrocyte-derived ECM (C-ECM). Alcian blue and alcian blue staining was used to detect
sulfated glycosaminoglycans (GAGs), and immunohistochemistry staining (IHC) was for type
I (COL I) and type II (COL II) collagen; (B) S-ECM and C-ECM induces a cell morphology
change in SDSCs and chondrocytes in monolayer expansion; (C) the mean cell number of
SDSCs harvested from passage 4 to passage 6 on the three different substrates (Plastic,
S-ECM and C-ECM); (D) the mean cell number of chondrocytes harvested on Plastic, S-ECM
and C-ECM. Data are shown as average ± SD for n = 4.

Figure 7.2 Histology and immunohistochemistry of SDSC pellets of Plastic, S-ECM and
C-ECM groups induced chondrogenic differentiation. Alcian blue (blue) staining was used to
detect sulfated glycosaminoglycans (GAGs), and immunohistochemistry was for type I (COL
I), II (COL II) and X collagens (COL X).

Figure 7.3 (A) Biochemistry analysis for GAGs of SDSC pellets were measured at day 0, day
7 and day 14. (B), DNA content of SDSC pellets changes during 14 days normalized by the
content of pellets at day 0. (C), chondrogenic index (the ratio of GAGs and DNA) showed the
degree of chondrogenic differentiation of SDSCs. (D) to (G) Real-time PCR to examine the
chondrogenic marker gene expression level (type I and II collagen, aggrecan, sox-9)
normalized by 18S rRNA. (H) and (I) the hypertrophic gene expression (type X collagen and
MMP13) was tested in the SDSC pellets. Data are shown as average ± SD for n = 4.

Figure 7.4 Immunoblotting of the SDSC chondrogenic pellet was used to detect
phospho-TGFβ RII (Tyr 424), Sox9 and type II collagen expression level. β actin was used as
an internal control for protein loading.

Figure 7.5 (A) Histology and immunohistochemistry of chondrocyte pellets of Plastic, S-ECM
and C-ECM groups that underwent induced chondrogenic differentiation. Alcian blue (blue)
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staining was used to detect GAGs, and immunohistochemistry determined type I (COL I), II
(COL II) and X collagen (COL X).

Figure 7.6 (A) Biochemistry analysis for GAGs of SDSC pellets were measured at day 0, day
7 and day 14. (B), DNA content of chondrocyte pellets changes during 14 days normalized by
the content of pellets at day 0. (C), chondrogenic index (the ratio of GAGs and DNA) showed
the degree of chondrogenic differentiation of chondrocytes. (D) to (G) Real-time PCR to exam
the chondrogenic marker gene expression level (type I and II collagen, aggrecan, sox-9)
normalized by 18S rRNA. (H) and (I) the hypertrophic gene expression (type X collagen and
MMP13) was tested in the chondrocyte pellets. Data are shown as average ± SD for n = 4.

Figure 7.7 Immunoblotting of chondrocyte chondrogenic pellet was used to detect
phospho-TGFβ RII (Tyr 424), Sox9 and type II collagen expression level. β actin was used as
an internal control for protein loading.
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The objective of this dissertation is to develop a novel strategy for cell-based cartilage
regeneration (including mesenchymal stem cells and autologous differentiated cells) that can
promote cell expandability, enhance chondrogenic differentiation, and improve the repair
effect for cartilage defects in animal studies and clinical trials. A native cell-deposited
three-dimensional (3D) extracellular matrix (ECM) provides a promising approach to improve
current in vitro MSC expansion system not only increasing cell proliferative ability but also
enhancing chondrogenic differentiation potential. The central hypothesis of this dissertation is
that the natural three-dimensional cell-deposited extracellular matrix can provide a proper
microenvironment to improve MSC self-renewal and multipotent differentiation. This natural
3D ECM can also improve the current procedures of autologous cell transplantation for
cartilage defects and intervertebral disc degeneration.

8.1 Extracellular matrix improves MSC self-renewal

Mesenchymal stem cells are attractive for tissue repair and regeneration, because of their
multipotential differentiation to various lineages, including chondrocytes for cartilage repair,1;2
osteoblasts for bone reconstitution,3 adipocytes for adipose tissue regeneration,4 cardiac
myoblasts for cardiovascular repair,5;6 myoblasts for skeletal muscle regeneration7 and
neuronal cell for neurological system repair.8 It is extremely important for MSC to obtain
sufficient cell numbers and to maintain their stemness in the in vitro culture process.9
Sufficiency of MSCs is a basic requirement for MSC-based tissue regeneration. Typically the
intracellular injection therapy to repair partial-thickness cartilage defects requires minimal 10
million cells for a single injection.10 For infracted heart repair 4 million cells are necessary for
a single injection.11 Moreover, in cartilage repair the loss of regenerative cells will occur due to
leakage or cell apoptosis.12 In autologous chondrocyte transplantation, the leakage of
injected chondrocytes from repaired sites usually results in the failure of implantation, multiple
complications and extra cost of patients. In clinical practice, cartilage repair using autologous
chondrocyte transplantation usually requires several injections instead of a single injection to
enhance the repair effect.12-14 Besides, apoptosis or cell death are also induced by
inflammatory cytokines, metalloproteinase, intracellular oxygen species or mechanical
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forces.9 Osteoarthritis, which was considered a degenerative disease, now is more realized
as an immune disorder. It is evident that several inflammatory factors, including interleukin Iβ (IL-Iβ), IL-I7, IL-I8, TNF-α and oncostatin M (OSM), are responsible mediators for cartilage
degeneration and osteoarthritis. These inflammatory factors not only stimulate the turnover of
cartilage extracellular matrix but also increase chondrocyte apoptosis.15 Overall, to obtain
adequate cell number is one of the most important issues in cell-based tissue regeneration.

The current in vitro culture condition limits the use of MSC-based tissue regeneration. Once
isolated from the in vivo microenvironment, MSCs rapidly lost the ability of proliferation and
multipotent differentiation like aged cells.16-18 In this dissertation, we tried to use a native 3D
cell-deposited ECM to replace conventional MSC expansion process, not only shortening
expansion time but also increasing yielded cell numbers. Starting at a relatively high seeding
density (3,000 cells/cm 2), it only took 5 - 6 days to reach 90% confluence, while at low
seeding density (1,000 cells/cm 2) the expansion period extented to 7 to 10 days depending
on specific cell types. More importantly, the complete confluence did not inhibit cell
proliferation, since cells continued to grow overlaply in 3D format.19;20 The adequate cell
number produced by ECM expansion system provided sufficient cells for transplantation.

The high proliferative rate on ECM is related to activated cyclin D1 and reduced intracellular
reactive oxygen species (Chapter 3 and Chapter 6). Cyclin D1 is proven to control cell cycle
progression through G1 phase into S phase. The steady-state level of phosphorylated ERK1/2 is
essential for cyclin D1 phosphorylation and translocation to promote cell cycle from G1 to S phase,
while inhibition of ERK1/2 or upstream kinases such as MAPK results in decreased activity of
cyclin D1.21 Except MAPK cascade, Rac1 is another distinct mediator to activate cyclin D1 and
promote cell-cycle.22;23 Page et al. showed that overexpression of activated Rac increased the
activity of cyclin D1, but the transcription of mutant Rac attenuated cyclin D1 activity. The Rac1
signaling pathway is completely independent of ERK activation. Westwick et al. showed that Rac1
regulated the activity of at least four protein kinases including PAK, JNK, p38 and serum response
factor (SRF), among which Rac1 stimulated the transcription of cyclin D1 promoter associated
with PAK binding.22 Besides, they also showed that low level of intracellular ROS induced
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activation of cyclin D1 and antioxidant treatment attenuated Rac1-induced cyclin D1 promotor
activity.24 In this dissertation, human BMSCs expanded on ECM showed a sustained activation of
ERK1/2 and cyclin D1. Besides, phosphatidylinositol 3-kinase (PI3-kinase) signaling pathway also
modulates the activity of cyclin D1 and the progression from G1 to S phase of cell cycle.
Jirmanova et al. showed the evidence that activated PI3-kinase induced an increased
steady-state level of cyclin D1 and the decrease of GSK3β-dependent rate of cyclin D1
degradation.25 Considering the regulatory effect of PI3-kinase/Akt signaling pathway in TGF-β

induced chondrogenesis, it is possible that PI3-kinase influences cell proliferation and
chondrogenic potential when expanding on ECM; this particular signaling pathway will be
examined in the future studies. One of the limitations in this dissertation is that the assay to
study the effect of inhibition of Src or ERK1/2 on cell proliferation is not available due to
serious apoptotic response in a short time.

Intracellular reactive oxygen species (ROS) are proven to play an important role in cell
adhesion, migration, proliferation and cell survival.26-29 The low concentration of ROS had a
promotional effect on cell adhesion and the threshold, demonstrated by Lamari et al., was
between 5 to 7 nanmoles / mL of superoxide anions, whereas the high level of ROS resulted
in cell death.30 High level of ROS had an inhibitory influence on cell proliferation by arresting
cell cycle at G1, S, and G2 phases through down-regulation of cyclin D1 and D3.31 The high
level of ROS or treatment of hydrogen peroxide resulted in cyclin D1 degradation, which was
reversed in the presence of antioxidants or overexpression of hypoxia-inducible factor (HIF) 1α.32 Kim et al. also showed that the increase of intracellular ROS generation arrested cell
cycle at G0 - G1 phase by inhibition of cyclin D1/CDK4 complex.33 Besides, Lai et al. reported
an elevated activity of telomerase in human BMSCs expanded on a similar natural 3D ECM
that might also promote cell proliferation.20

8.2 3D cell-deposited ECM is different from 2D reconstructed ECM

Traditional 2D reconstructed ECM uses monomeric proteins such as fibronectin and
laminin-1 to coat substrates and showed little effect on cell morphology or proliferation.34 Tsai
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et al. provided evidence that type I collagen achieved better result in promoting human MSC
proliferation and osteogenesis than fibronectin, laminins or gelatin. The improved osteogenic
differentiation was related to activated ERK and Akt pathways instead of FAK; the inhibition of
ERK attenuated osteogenic process.35 More importantly, the 3D environment can result in
different cell responses and behaviors from the 2D ones. Fassett et al. showed that
hepatocytes in type I collagen gel remained round and arrested growth, whereas on the
monomeric type I collagen coating film the cells spreaded and proliferated. The different
activity of cAMP-dependent protein kinase (PKA) was responsible for the distinct cell
proliferation responses, because inhibition of PAK restored ERK activation and cyclin D1 to
promote cell cycle from G1 to S phase.36 However, 2D ECM containing multiple proteins was
able to induce stem cell self-renewal and to promote chondrogenic differentiation.34 3D
culture system has been proven more efficient in cell expansion and preserving multipotent
characters of MSCs in vitro. Majd et al. recently developed a new 3D dynamic culture for
MSCs that yielded 10-fold cells more than conventional plastic culture in nine weeks; it also
maintained MSC multipotential to differentiate into osteoblasts, adipocytes, chondrocytes and
myoblasts that was lost in the conventional culture.37

The compositions of MSC-deposited ECM included type I collagen, fibronectin, laminins and
decorin detected by immunohistochemistry.19;20;38;39 Proteomics provides a novel method to
analyze the components in ECM. A detailed analysis of the compositions in ECM can help us
understand the interactions between cells and ECM. Overall, the improved proliferative and
chondrogenic potential of MSCs induced by ECM is related to the integration of multiple
matrix molecules and the unique three-dimensional structure.

MSCs on 3D ECM exhibited distinct behaviors compared to conventional plastic flasks or
constructed 2D ECM. Cells migrated along the fibrils of ECM instead of random movement on
plastic flasks. The directional migration was closely related to decreased activity of Rac1 that
was demonstrated to control cell migration.40 Moreover, the uneven distribution of matrix
components resulted in different rigidity of ECM. Cells liked to move from an area with higher
flexibility to a region with more rigidity.41 On conventional plastic flasks or reconstructed 2D
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ECM the well-distribution of molecules leaded to random cell migration. Also the elasticity of
ECM affected cell shape and proliferation. For example, fibroblasts appeared round shape on
soft substrates but changed to stressed shape when they were cultured on matrix with high
rigidity. Winer et al. compared the effect of substrates with different rigidity on human BMSCs
and demonstrated that cells became quiescent on soft matrix (250 Pa) but resumed
proliferation when transferring to a stiff substrate.42

During cell adhesion, 3D ECM induced decreased FAK related to focal adhesion and formed
new contacts with cells. The MAPK cascade and ERK1/2 in cell adhesion, migration and
proliferation has been studied in depth. Sustained activation of ERK1/2 was necessary for
cell cycle progession by induction of cyclin D1; the inhibition of ERK1/2 resulted in reduction
of cyclin D1 and arrest at G1 phase.43 The attachment of cells onto ECM, including fibronectin,
vitronectin, laminins and collagens, induced the activation of integrin α1, α2, α5, αV, β1, β3 and
β5. Integrin system transduced extracellular signals into intracellular pathways by activating
FAK, Src, MAPK cascade, ERK1/2 and cyclin proteins to control cell cycles.44;45 Park et al.
cultured embryonic stem cells on fibronectin-coated surfaces and showed an upregulation of
integrin β1, FAK, Src, ERK1/2, Akt and caveolin-1. The intracellular signaling pathways
induced by fibronectin increased cell cycle regulatory proteins such as cyclin D1 and cyclin E.
The inhibition of integrin β1 or blockage of kinases such as Src, FAK, caveolin-1, Akt or
ERK1/2 resulted in significantly decreased [3H]-thymidine incorporation and attenuated cell
cycle regulatory proteins.46 Roovers et al. showed that integrin α5β1 controlled cyclin D1
expression through sustained activation of ERK1/2 on fibronectin to promote cell cycle.47
Cukierman et al. used a similar 3D ECM deposited by fibroblasts to study cell adhesion and
demonstrated that integrin α5β1 translocated to the region of fibronectin and induced
intracellular signaling transduction.39 On fibronectin-coated surface, integrin α5β1 mediated
epithelial cell proliferation through epithelial growth factor (EGF) receptor. Kuwada et al.
showed that, in the presence of EGF receptor antagonistic antibody, epithelia cells
overexpressed with integrin α5 grew at a normal rate, while control group was inhibited in cell
proliferation.48 Meanwhile, integrin αV activation in 3D collage gel contributed cell survival
through phosphorylation of MAPK and ERK1/2, while the inhibition of ERK1/2 induced
273

serious cell apoptosis.49

8.3 The interaction between integrin system and 3D ECM

In Chapter 6, integrin α2 and β5, receptors for fibrillar collagens, showed an elevated level.
The elevated level of integrin α2 was closely related to focal adhesion and cell motility.
Sawhney et al. identified the role of integrin α2 in cell adhesion that activated FAK, ERK1/2
and μ-calpain pathways on type IV collagen. Inhibition of integrin α2 by a specific antibody
suppressed FAK activation and ERK1/2 phosphorylation.50 Integrin α2β1 was proven to induce
cyclin expression and promote cell cycle on type IV collagen. This process involved activation
of the ERK1/2 signaling pathway and the production of ROS by NADPH oxidase.51 In this
dissertation, increased integrin α2 may result in activation of ERK1/2. Meanwhile, integrin
α2-regulated cell adhesion and migration were modulated through activation of Src and were
completely inhibited in the presence of Src inhibitor PP2.52 Overall, Integrin α2 plays an
important role in cell adhesion and migration involving FAK, Src, p38 and MAPK cascade
signaling transduction and contributes to cell-cycle progression. Besides, Priestley et al.
demonstrated the role of integrin α4 in stem cell self-renewal by knocking-out of integrin α4
that seriously restricted cell proliferation.53 In this dissertation, we found an increased level of
integrin α4 in human BMSCs expanded on ECM that was possibly related to the high rate of
cell self-renewal (Chapter 6).

Integrin β5 plays an important role in cell migration and proliferation proven by previous
studies. Zhang et al. showed that in human breast carcinoma cells p21-activated kinase 4
(PAK4) contributed to cell migration; PAK4 attached to integrin β5 cytoplasmic domain. Cell
migration involved the engagement of integrin αVβ5 and extracellular matrix such as
vitronectin; it induced a redistribution of PAK from cytosol to dynamic lamellipodial
structures.54 Braam et al. also provided evidence that vitronectin-coated surface promoted
human embryonic stem cell attachment and self-renewal through integrin αVβ5.55 Cukierman
and his colleagues used a similar ECM deposited by human fibroblast and showed that ECM
induced activation of PI3K and Akt/PKB through the integrin β1 dependent signaling
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pathway.56 In this dissertation, we found other integrin receptors at a decreased or
unchanged level. However, in future it is important to establish a full analysis of integrin and
other ECM receptors, not only by flowcytometry but also using immunofluorescence.

Intracellular reactive oxygen species affect cell adhesion, survival and proliferation. The
increase of ROS inhibited cell adhesion and migration by decreasing the activity of focal
adhesion-related and integrin-related molecules.57 Song et al. provided evidence that
hydrogen peroxide treatment induced detachment of MSCs and significantly decreased cell
adhesion and migration. The cell detachment was caused by decreased integrin αVβ1 and
focal adhesion-related molecules such as FAK and Src in the presence of high level of
intracellular ROS.57 Moreover, ROS-induced cell adhesion was related to the modification of
integrin system by altering the exposure of integrin outside cell surface or their clustering.
Low level of ROS decreased the expression of integrin α5 but increased αV that was related to
cell adhesion.30;58-60 In this dissertation, we found human BMSCs expanded on ECM showed
decrease of integrin α5 that was possibly induced by the low level of ROS. Meanwhile,
integrin β4 had a negatively regulatory effect on the production of ROS. Lv et al. showed that
inhibition of integrin β4 in primary mouse neuron cells elevated significant apoptosis and
declined cell viability; the process was associated with increased activity of NADPH oxidase
and production of intracellular ROS.61 In this dissertation we found that integrin β4 slightly
increased when human BMSCs were cultured on ECM that possibly was related to the
declined level of ROS.

In this dissertation, flowcytometry showed that the expression of integrin α1, α3, α5, β1 and β3
decreased compared to those expanded on plastic culture (Chapter 6). Hayashi et al.
cultured embryonic stem cells on ECM to promote cell self-renewal and showed that the
expression of fibronectin- and laminin-binding integrin subunits increased while some
collagen-binding integrins down-regulated. The overexpression of collagen-binding integrin
subunits induced stem cell differentiation instead of self-renewal.62 Considering the
down-regulated expression of certain integrins after expansion on ECM (Chapter 6), it was
possible that inactivation of certain integrins was essential to promote stem cell self-renewal,
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and it will be studied in future.

The central role of Src in focal adhesion has been well studied. In FAK-dysfunctional cells,
overexpression of activated Src can rescue cell apoptotic response. The inhibition of Src
significantly increased adhesion-dependent apoptosis.63 Activated Src can enhance the
expression of integrin α2 through protein kinase C-ζ in fibroblasts.63 Xu et al. demonstrated
that a three-dimensional collagen substrate increased integrin α2 and it was mediated by
protein kinase C-ζ.64;65 Moreover, Eliceiri et al. reported that Src was indispensible during the
formation of FAK/integrin αVβ5 complex, when endothelial cells attached to ECM or were
activated by vascular endothelial growth factor (VEGF). The complex of FAK/αVβ5 and the
activity of Src were critical to VEGF-induced angiogenesis.66

In Chapter 6 human BMSCs cultured on ECM responded a higher level of apoptosis than
those on conventional plastic flasks, suggested by an increased immunofluorescence
intensity of annexin V. In endothelial cells and terminally differentiated chondrocytes, annexin
V binded to integrin β5 and activated protein kinase C α (PKCα). Activated PKCα induced an
increase of caspase-3 activity and leaded to ultimate apoptosis.67-69 Integrin β5 showed an
increase in BMSCs expanded on ECM that might correlate to the elevated level of annexin V,
but the detail mechanism and the potential effects on MSCs are still unclear. One possible
explanation is that in the human BMSCs there were mixture cell populations containing
healthy and aged cells. The healthy BMSCs had a higher proliferative rate that acquired most
of the nutrients, and had a faster migration to occupy most of the space on ECM. The
insufficiency of nutrients and space induced apoptosis in aged cells. So the overall increase
of proliferation was due to the self-renewal in healthy BMSCs and the increase of apoptosis
was because of the cell death in aged BMSCs.

The robust proliferative rate of MSCs or differentiated cells expanded on ECM aroused
another potential issue: were ECM-expanded cells uncontrollable or likely to form tumor? In
this dissertation, cells expanded on ECM were reversible when culture environment changed.
In Chapter 4, chondrocytes were first cultured on ECM for four passages and then transferred
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to conventional plastic culture for two passages; cells showed significant decrease in
proliferation ability. The reduced proliferation after disengagement from ECM suggested that
the robust proliferative rate was temporary and there was low risk of tumor formation if using
for cartilage repair and regeneration in vivo. Similarly, late-passaged cells in conventional
plastic culture system exhibited a decreased proliferative rate, but once contacting with ECM
they showed stronger proliferation. The native 3D ECM has the potential to expand aged cells
and can be used in some degenerative diseases.

On the other hand, strong chondrogenic differentiation potential is important to MSC-based
cartilage repair. In vivo MSCs often stay in a quiescent state but have the potential to
self-renew or differentiate rapidly once stimulated by intrinsic or extrinsic factors from the
microenvironment.70 However, conventional in vitro culture system for MSCs impairs their
multipotential. When reaching 70% - 90% confluence, MSCs contact with neighbor cells and
inhibit their proliferation, so weekly passaging is required in MSCs expansion.18 To improve
MSC proliferative rate, low seeding density is used to increase the yielded cell number at the
cost of long expansion period (usually two to three weeks).16 Another method to improve
MSC self-renewal is stimulating cells with growth factors such as fibroblast growth factor 2
(FGF-2). However, some studies suggested that the supplement of FGF-2 inhibited MSC
chondrogenic potential.71 In spite of various means to promote MSC proliferative rate, the
intrinsic self-renewal ability of MSCs limits their usage in tissue regeneration. The proliferative
rate of MSCs usually significantly decreases after 10 passages and eventually disappears.72
Repeated passaging is able to extent the proliferative ability of MSCs for a longer time but
seriously impairs the multipotent differentiation. Vacanti et al. compared early-passaged and
late-passaged porcine MSCs. The late-passaged MSCs lost their multipotential and only
differentiated to adipocytes. Besides, cell aging symptoms appeared in the late-passaged
MSCs such as actin accumulation, reduced cell adhesion and high activity of lysosomal acid
beta-galactosidase.73 The impaired multipotential of MSCs is possibly related to the exposure
to enzyme detachment such as trypsin which can degrade cell surface receptors or
proteins.73-75
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8.4 3D ECM is a potential positive-isolation model for MSCs

We chose SDSCs for cartilage regeneration due to their superior chondrogenic differentiation
potential to other MSCs such as ADSCs or muscle satellite cells.76 To purify SDSCs we used
a negative isolation method using Dynabeads conjugated with CD14 antibody to remove type
A cells (macrophages);77;78 however, this method still failed to separate SDSCs from synovial
fibroblasts. Karystinou et al. demonstrated that there were multiple MSC sub-populations in
synovium tissue. They obtained 50 colonies from single cell-derived clonal populations and
these colonies varied in proliferative doubling time, mean telomere lengths from 5.2 to 10.9
kb and variable differentiation potency only 30% of which were adipogenic.79 To isolate pure
adult stem cells, some new cell surface markers were proposed but they were not popularly
accepted such as CD271, CD140b, CD340 and CD349.80

In this dissertation, 3D SDSC-deposited ECM is a potential positive-isolation model to isolate
or purify MSCs from multiple cell populations. SDSCs or chondrocytes expanded by
conventional plastic culture showed diverse expression of cell surface markers, even
completely positive but with different fluorescence intensity, suggesting that the conventional
expanded cells were a mixed population. But cells expanded on SDSC-deposited ECM
exhibited a centralized expression of surface markers and this implied that the cells were
composed of one or two major populations (Chapter 2). More importantly, after several
passages on ECM this centralization phenomenon appeared more obvious, suggesting that
the percentage of the major cell population increased and the yielded cells were likely a
unique population instead of a mixture. This phenomenon of centralization expression
surface marker in SDSCs was CD90 (Chapter 2) and in articular chondrocyte was CD29
(Chapter 4). However, due to the lack of a unique surface marker for MSCs we can’t provide
direct evidences for the positive isolation function of ECM.

CD90, originally a marker for thymus-derived lymphocytes, is considered an indicator of
chondrogenic potential in SDSCs. Consistent with our study (Chapter 2), Nagase et al.
analyzed the ratio of CD90-positive SDSCs and suggested that the ratio decreased with
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passaging accompanied by a reduced chondrogenic potential.81 In this dissertation, we found
that the ratio of CD90-positive SDSCs increased dramatically when expanding on ECM and it
decreased on the conventional plastic culture (Chapter 2). In the expansion of articular
chondrocytes (Chapter 4) and nucleus pulpous cells (Chapter 5), the percentage of
CD90-positive cells increased and stayed at a high level on ECM, similar to SDSCs, due to
the existence of undifferentiated progenitor cells in articular cartilage and nucleus pulpous
tissue. However, this tendency did not appear in the expansion of human BMSCs, in which
the ratio of CD90-positive cells decreased on ECM (Chapter 6). Overall, CD90 is a potential
indicator for chondrogenic differentiation in certain MSCs or progenitor cells and future
studies are needed to compare the differences between CD90-positive and CD90-negative
cells not only in chondrogenesis but also in multipotent differentiation.

SSEA-4, a stage-specific embryonic antigen, was recently used to identify mesenchymal
stem cells and made it as a prospective isolation marker. In human BMSCs, SSEA-4 positive
cells had a better colony forming ability and stronger multipotential to chondrogenesis,
osteogenesis and adipogenesis.82 Interestingly, Lai et al. found human BMSCs after
expansion on ECM showed an increased tendency of SSEA-4 positive cells.20 We also
showed that not only the percentage of SSEA-4 positive cells but also the fluorescence
intensity in human BMSCs expanded on ECM was significantly higher than those cultured on
conventional plastic flasks (Chapter 6). Overall, SSEA-4 provided a potential way for MSC
purification and an indicator for MSC multipotential differentiation ability.

8.5 MSCs expanded on ECM may have higher potential of integration

The integration of neo-cartilage tissue into articular cartilage defect sites determined the
success of cartilage repair; however, several factors impeded cell-based cartilage
regeneration.9;83 Physical trauma significantly increased cell death in lesion edges and
resulted in a hindering area for neo-cartilage integration.84 Due to the absent ability of
migration, chondrocytes in neo-cartilage or host cartilage failed to move into lesion edges that
hindered the full integration of repaired tissue and defect sites.13;85 Archer et al. suggested
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that the intactness of lesion edges was essential to the integration of cartilage defect repair.84
The failure of full integration was also related to chondrocyte cell death caused by
differentiation-related apoptosis or inflammatory factors.9 In vitro chondrogenesis induced by
TGF-β1 decreased cell viability proven by reduced DNA content.2 Using intracellular injection
of MSCs or chondrocytes to repair cartilage defect, it required a high cell viability during
chondrogenesis.86 Conventional expanded cells on plastic culture dramatically lost their cell
number but ECM-expanded cells maintained their viability during in vitro chondrogenesis.1;87
The high viability of ECM-expanded cells will improve the integration in cartilage repair in vivo
and resist the effect of inflammatory factors. In autologous chondrocyte transplantation,
dedifferentiated chondrocytes leaded to the failure of cartilage repair because the matrix
generated by dedifferentiated chondrocytes was mostly type I collagen that formed fibrous
cartilage and degraded eventually.12 However, chondrocytes expanded on ECM delayed
dedifferentiation and maintained a strong chondrogenic differentiation potential (Chapter 4).
The usage of chondrocytes expanded on ECM to repair cartilage defects will be conducted in
future. Similarly, nucleus pulpous cells expanded on ECM preserved their original cell
phenotype and properties (Chapter 5) and can be used in IVD regeneration.88

8.6 3D ECM reduces chondrogenic hypertrophic risk in MSCs

Chondrocyte hypertrophy is an important stage in cartilage and bone development,
accompanied by vascularization and calcification.89;90 From the initiation of MSC transition
toward chondrogenic differentiation, MSCs proceed from type I collagen-positive cells to type
II collagen-positive chondrocytes, and changed to type X collagen-positive hypertrophic
chondrocytes, terminally became fully differentiated cells expressed MMP13 associated with
calcification and ossification. In endochondral bone formation, cartilage was formed first, then
chondrocytes underwent a proliferative stage following hypertrophy, change in gene
expression and matrix calcification.91 In chondrogenic induction in vitro and in vivo, MSCs
proceeded hypertrophic transition that changed cell morphology from chondrocyte-like to
osteoblasts with the expression of type X collagen, alkaline phosphatase, MMP-13, vascular
endothelial growth factor (VEGF) and parathyroid hormone–related protein receptor
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(PTHrPR).92-95 The importance of studying chondrocyte hypertrophic mechanism is not only
to understand bone development but also to prevent ossification in MSC-based cartilage
repair and regeneration.

Pelttari et al. reported that after transplantation of pre-chondrogenic differentiated MSC
aggregates into the ectopic sites in SCID mice, they underwent a change to endochondral
ossification instead of continuous chondrogenesis, whereas the control group of chondrocyte
pellets resisted calcification and vascular invasion.96 Moreover, TGF-β97 and high
concentration of dexamethasone98 exhibited an inhibitory effect on hypertrophy during MSC
chondrogenesis. Meanwhile, during MSC chondrogenic differentiation induced by TGF-β, the
expression of type X collagen and MMP13 increased in the early stage but decreased in the
late stage, indicating an intermediate role that was still unclear.94 The use of type X collagen
as a marker of chondrocyte hypertrophy may have some limits due to the elevated level in the
early chondrogenic stage.93

The mechanism of chondrocyte hypertrophy is not fully understood, but the MAPK cascade
including ERK1/2 and p38 was suggested to modulate the process of hypertrophy. In the
process of BMP-2 induced chondrocyte hypertrophy, characterized by elevated type X
collagen, ERK1/2 might have an inhibitory influence. The inhibition of ERK1/2 induced
activation of type X collagen promotor but had little effect on alkaline phosphatase activity.91
Stanton et al. provided evidence that p38 MAP kinase was indispensible in chondrocyte
hypertrophic differentiation and the inhibition of p38 resulted in decreased expression of
hypertrophic marker genes such as type X collagen, MMP13 and bone sialoprotein.99
However, Prasadam et al. showed the opposite evidence that subchondral bone osteoblasts
induced hypertrophic change in articular chondrocytes through ERK1/2 phosphorylation and
deactivation of p38 phosphorylation. The inhibition of ERK1/2 significantly suppressed the
hypertrophic change.100 Different from chondrogenesis, ERK1/2 was continuously activated
during osteogenesis. Phosphorylated ERK1/2 activated other transcription factors such as
Runx2 and cbfa-1 and induced osteocalcin and mineralization.101-103 Considering the elevated
level of type X collagen in human BMSCs expanded on ECM (Chapter 6) and the decreased
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activity of ERK1/2, hypertrophic transition was possibly related to the ERK1/2 signaling
pathway.

In this dissertation, SDSCs and ADSCs after expansion on ECM showed a suppressed level
of hypertrophy-related gene expression and negative immunohistochemistry of type X
collagen (Chapter 2 and Chapter 3), suggesting that there was no evidence at protein level to
prove the hypertrophic transition of MSCs during in vitro chondrogenesis. With regard to
chondrocytes and nucleus pulposus cells expanded on ECM or conventional plastic flasks,
there were not positive data for hypertrophic genes or proteins (Chapter 4 and Chapter 5).
MSCs from different tissue sources may have distinct potentials of hypertrophy that will be
taken into account in future. Furthermore, considering the intrinsic differences between
chondrocytes and MSCs in the resistance to hypertrophy, future studies are needed to
evaluate MSC chondrogenesis and hypertrophy in native cartilage joints in vivo.

8.7 ECM Improves chondrogenic potential of MSCs and the underlying mechanism

The enhanced chondrogenic potential after ECM expansion was proven by different cell
types including SDSCs (Chapter 2 and Chapter 7), ADSCs (Chapter 3), BMSCs (Chapter 6),
chondrocytes (Chapter 4 and Chapter 7) and nucleus pulposus cells (Chapter 5). The
obvious mechanism was the increased expression and responsiveness of TGF-β type II
receptor (Chapter 6). However, the reason of elevated expression of TGF-β type II receptor in
human BMSCs after expansion on ECM is quite unclear. The cross-talk between integrin
system and TGF-β receptors may be involved in this mechanism. Garamszegi et al. recently
demonstrated that soluble extracellular matrix proteins can induce Smad signaling that was
considered to be activated by TGF-β ligand. They showed that soluble collagens and
laminins induced Smad activation initially from integrin α2β1, then recruited TGF-β receptors,
formed a complex membrane signaling receptor and activated several kinases including FAK
and Src. The ECM induced activation of Smads was independent of the activation induced by
TGF-β ligand. However, they didn’t provide the information of the expression or
responsiveness of TGF-β receptors in the presence of soluble matrix proteins.104
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Decorin is an important component in the cell-deposited ECM, confirmed by Chen et al. using
human BMSCs to generate ECM.38 Decorin is often found in type I collagen-rich matrices and
is composed of a leucine repeated core protein attached with a glycosaminoglycan chain with
varied length and composition. Conventionally, decorin was considered an antagonist to
TGF-β by masking the binding site of TGF-β receptors.105;106 Before chondrogenic
differentiation, the low level of autophosphorylation of TGF-β type II receptor in human
BMSCs expanded on ECM was contributed by the presence of decorin in ECM (Chapter 6),
even though this needs to be confirmed in future. Moreover, decorin can influence
integrin-dependent cell adhesion and migration. Fiedler et al. provided evidence that decorin
promoted endothelial cell adhesion on fibrillar type I collagen by modulating the activity of
integrin α2β1 instead of α1β1 and activating insulin-like growth factor-I receptor.107 In
accordance to our data of an increased expression of integrin α2β1 after ECM expansion,
decorin possibly promoted mesenchymal stem cell adhesion and proliferation through
integrin and Rac signaling pathway that is also needed to be explored in future.

In the process of chondrogenic differentiation induced by TGF-β, non-Smad intracellular
signaling pathways shared several kinases of integrin-induced signaling pathways. ERK1/2
were important kinases that could be phosphorylated by integrin activation or TGF-β
induction.108;109 The role of ERK1/2 in chondrogenesis is not completely understood.
Watanabe et al. demonstrated that TGF-β induced the phosphorylation of ERK1/2 to activate
chondrogenic-specific genes expression associated with other transcription factors.110 Bobick
also provided evidence that the level of phosphorylated ERK1/2 paralleled the progress of
human BMSC chondrogenesis; the inhibition of MEK1 or ERK1 significantly attenuated the
expression of chondrogenic marker genes.111 However, several recent studies suggested that
ERK1/2 played an inhibitory role in MSC chondrogenic differentiation.112;113 Lee et al. showed
the phosphorylated level of ERK1/2 during chondrogenesis in BMSC that reached the peak at
10 hours to 1 day after the induction of TGF-β3, but from then until day 14 the activity of
ERK1/2 showed a decreased tendency. They suggested that ERK1/2 might play an inhibitory
role in MSC chondrogenesis.114 Zhao et al. demonstrated that TGF-β induced a rapid and
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transient phosphorylation of ERK1/2, whereas activated p38 was in a slow and sustained
way.115 In this dissertation, we also found a suppressed activity of ERK1/2 in human BMSCs
expanded on ECM during chondrogenesis. One possible explanation was that the activation
of ERK1/2 initiated the transcription of chondrogenic-specific genes such as aggrecan and
type II collagen, but in a long-term induction of chondrogenesis ERK1/2 may give way to
other signaling pathways such as PI3K/Akt to generate cartilage-specific matrix.

JNK is another important non-Smad TGF-β signaling molecule that was proven to promote
cartilage-specific gene expression.108 However, Caerteling et al. recently published their work
to demonstrate that inhibition of JNK increased chondrogenic gene expression and matrix
generation.116 The involvement of PI3K-Akt pathway in chondrogenesis was reported.
Induced by TGF-β, Akt was phosphorylated at T308 and S473 by PI3K and translocated to the
nucleus to mediate the differentiation process.117-120 However, the lack of PI3K-Atk analysis is
one of the limitations in this dissertation that will be investigated in future. Different from
ERK1/2, p38 is considered a positive regulatory protein in chondrogenesis. Oh et al. showed
that the activity of p38 increased during chondrogenesis while ERK1/2 decreased. Inhibition
of p38 significantly decreased the expression of chondrogenic-specific genes, whereas the
blockage of ERK1/2 did not affect.121 Meanwhile, Chang et al. provided evidence that PKC
promoted MSC chondrogenic differentiation and inhibition of PKC reduced the expression of
chondrogenic marker genes. More importantly, the inhibition or depletion of PKC induced
sustained activation of ERK1/2 and suppressed chondrogenesis, while inhibition of ERK1/2
enhanced chondrogenesis but it had no effect on PKC. The authors concluded that PKC
regulated chondrogenesis through down-regulating the activity of ERK.122 However,
TGF-β-induced signaling pathways need to be more investigated in future not only in the in
vitro chondrogenesis but also in the microenvironment of in vivo.

Hayashida et al. recently published their work about integrin β1 and TGF-β. They showed that
in epithelia cells knock-down of integrin β1 enhanced type I collagen expression via integrin
αVβ3 and ERK1/2 signaling pathway stimulated by TGF-β.123 In this dissertation, MSCs
(Chapter 2 and 6) and terminally differentiated cell (Chapter 4 and 5) expanded on ECM
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showed declined expression of integrin β1 and enhanced chondrogenic potential with high
level of type II collagen expression, indicating there possibly was relationship between
integrin β1 and TGF-β response. Moreover, Bianchi et al. reported that TGF-β upregulated the
expression of integrin β5 in carcinoma cells; the knock-down of integrin β5 inhibited
epithelial-mesenchymal-transition but it did not affect TGF-β target genes.124 The interaction
of integrin β1 and TGF-β induced chondrogenesis needs to be explored in future work.

In Chapter 4 and 5, ECM showed the effect to increase proliferative rate and delayed
dedifferentiation in terminally differentiated cells such as chondrocytes and nucleus pulposus
cells. For articular chondrocytes, dedifferentiation underwent during serial monolayer culture
with declined expression of type II collagen and aggrecan but increased level of type I
collagen. The delayed dedifferentiation process in chondrocytes expanded on ECM was
possibly related to PKC and ERK. Yoon et al. showed that the expression of PKCα decreased
during chondrocyte dedifferentiation but the overexpression of PKC did not affect the
dedifferentiation process. Meanwhile, ERK activity increased during dedifferentiation and
inhibition of ERK1/2 successfully retarded chondrocyte dedifferentiation with the elevated
expression of type II collagen and proteoglycans. They concluded that PKC and ERK
independently regulated chondrocyte dedifferentiation.125 Moreover, Barbero et
demonstrated

that

dedifferentiated

human

articular

chondrocytes

had

al.

multipotent

differentiation capacity toward chondrogenic, osteogenic and osteogenic lineages; that was
believed to be the evidence of progenitor cells or MSCs in articular cartilage.126 Future work
will be conducted in the interaction between chondrocytes and ECM and mechanism of
delaying chondrocyte dedifferentiation.

In this dissertation, we did not observe the improvement in osteogenesis and adipogenesis of
SDSCs or ADSCs after ECM expansion. However, Chen et al. demonstrated that human
BMSCs expanded on a similar 3D ECM gained stronger osteogenic potential.38 The
inconsistence of osteogenic potential was possibly because we induced MSCs to
osteogenesis or adipogenesis in vitro and they implanted cells subcutaneously into mice after
8-week in vitro osteogenic culture. The in vivo environment could induce cells further
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differentiation with stimulation of certain growth factors and nutrients.

SDSC-deposited ECM not only was able to expand MSCs but also culture differentiated cells
including chondrocytes and nucleus pulposus cells. ADSC-deposited ECM showed similar
functions to promote MSC self-renewal and chondrogenic potential. Chondrocyte-deposited
ECM only improved articular chondrocyte proliferation and redifferentiation. The three types
of ECMs had three-dimensional structures but they contained different components. The
different compositions in ECM affected cell adhesion, proliferation and differentiation through
distinct intracellular signaling pathways. However, SDSC-deposited ECM exhibited a
universal compatibility to MSCs and terminally differentiated cells that may have a wide
application in tissue regenerative medicine and establish an in vitro model to study cell and
matrix interaction.

In conclusion, we demonstrated that 3D cell-deposited ECM provides a proper
microenvironment for in vitro expansion of MSCs and terminally differentiated cells, not only
promoting self-renewal ability but also improving chondrogenic potential, and the novel 3D
expansion system greatly improves cell-based cartilage and intervertebral disc regeneration.
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